Abbott Laboratories (ABT)

Company ID: 39 | CIK: 0000001800
10-Q view:
No 10-K data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-K data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-K data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-K data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-K data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
Segments are charted by their disclosed metrics (revenue, segment profit, etc.). Each line is a single segment. Reconciliation/corporate items are excluded. Major customers are shown as a percentage of revenue. Operational KPIs are grouped by metric concept; sub-metrics appear as separate lines.

Geographic Segments

No 10-Q data
No 10-Q data
No 10-Q data

Business Unit / Product Segments

Major Customers (% of Revenue)

No 10-Q data

Operational KPIs

Contract liabilities (backlog)

No 10-K data

Common Shareholders (customers)

No 10-Q data

Employees (headcount)

Antitrust suits pending (other)

No 10-K data

Biaxin sales (other)

No 10-K data

Boehringer Ingelheim product sales (other)

No 10-K data

Boston Scientific shares held (other)

No 10-K data

CGM Systems Sales (other)

No 10-K data

CGM sales (other)

No 10-Q data

CGM systems sales (other)

CGM systems sales growth (other)

No 10-K data

COVID-19 Testing Sales (other)

No 10-K data

COVID-19 diagnostic tests launched (other)

No 10-K data

COVID-19 rapid testing sales (other)

No 10-K data

COVID-19 testing related sales (other)

No 10-K data

COVID-19 testing sales (other)

COVID-19 testing-related sales (other)

COVID-19 tests launched (other)

No 10-K data

Capital expenditures for pollution control (other)

No 10-Q data

Cash and short-term investments (other)

No 10-K data

Common Shares Outstanding (other)

Common shareholders (other)

No 10-Q data

Common shares outstanding (other)

Common shares purchased and retired (other)

No 10-K data

Common shares repurchased (other)

No 10-K data

Consent decree sales impact (other)

Contract liabilities (other)

No 10-K data

Core Lab COVID antibody sales (other)

No 10-K data

Core Lab antibody sales (other)

No 10-K data

Core Lab antibody testing sales (other)

No 10-K data

Core Laboratory IgG Antibody Testing Sales (other)

No 10-K data

Core Laboratory antibody testing sales (other)

No 10-K data

Countries marketed (other)

Countries of operation (other)

No 10-Q data

Countries served (other)

No 10-Q data

Countries with marketed products (other)

No 10-Q data

Countries with properties (other)

No 10-Q data

Currency impact on sales (other)

No 10-K data

Depakote U.S. sales (other)

No 10-K data

Depakote sales (other)

No 10-K data

Diabetes Care sales (other)

No 10-K data

Diagnostic sales (other)

No 10-K data

Dividend per share (other)

No 10-K data

Dividends declared per share (other)

No 10-K data

Effective income tax rate (other)

No 10-K data

Effective tax rate (other)

No 10-K data

Emerging markets revenue share (other)

No 10-Q data

Emerging markets sales mix (other)

No 10-Q data

Emerging markets sales share (other)

No 10-Q data

Emerging markets share of sales (other)

No 10-Q data

Employees covered by restructuring (other)

No 10-Q data

Environmental capital expenditures (other)

No 10-Q data

Environmental operating expenditures (other)

No 10-Q data

Equity securities portfolio value (other)

No 10-Q data

Exclusive WIC states (other)

No 10-Q data

Exercisable stock options (other)

No 10-K data

FX impact on international sales (other)

No 10-K data

FX impact on intl sales (other)

No 10-K data

FX impact on net sales (other)

No 10-K data

Favorable exchange effect on sales (other)

No 10-K data

Foreign currency sales impact (other)

No 10-K data

FreeStyle Libre Sales (other)

No 10-K data

FreeStyle Libre sales (other)

Government receivables over one year past due (other)

No 10-K data

Government receivables past due (other)

No 10-K data

Governmental receivables (other)

No 10-K data

Governmental receivables past due (other)

Gross margin excluding charges (other)

No 10-K data

Gross profit margin (other)

HUMIRA U.S. sales (other)

No 10-K data

HUMIRA international sales (other)

No 10-K data

HUMIRA sales (other)

No 10-K data

HUMIRA sales growth forecast (other)

No 10-K data

HYTRIN U.S. sales (other)

HYTRIN US sales (other)

No 10-K data

Hospira operations transferred (other)

No 10-K data

Humira product sales (other)

No 10-K data

Humira sales (other)

No 10-K data

Humira worldwide sales (other)

No 10-K data

Hytrin U.S. sales (other)

No 10-K data

Hytrin US sales (other)

No 10-K data

Infant formula antitrust suits pending (other)

No 10-K data

Infant formula brand sales (other)

No 10-K data

Infant formula investigations pending (other)

No 10-K data

Infant formula sales (other)

No 10-K data

International sales currency headwind (other)

No 10-K data

International sales mix (other)

No 10-Q data

International sales share (other)

No 10-Q data

International share of sales (other)

No 10-Q data

International share of worldwide sales (other)

No 10-Q data

Key emerging markets (other)

No 10-Q data

Key emerging markets sales growth (other)

No 10-K data

Lupron sales (other)

No 10-K data

Molecular COVID sales (other)

No 10-K data

Molecular COVID-19 sales (other)

No 10-K data

Molecular Diagnostics COVID-19 Testing Sales (other)

No 10-K data

Molecular Diagnostics COVID-19 sales (other)

No 10-K data

Molecular Diagnostics COVID-19 testing sales (other)

No 10-K data

Mylan N.V. shares held (other)

No 10-K data

Net cash from operating activities (other)

No 10-K data

Net monetary assets subject to revaluation (other)

No 10-K data

Net sales growth (other)

No 10-K data

Net sales growth ex-COVID and ex-FX (other)

No 10-K data

Net sales growth ex-FX (other)

No 10-K data

Net sales growth ex-acquisitions/FX (other)

No 10-K data

Net sales growth ex-exchange (other)

No 10-K data

Net sales growth excl. COVID and FX (other)

No 10-K data

Net sales growth excl. FX (other)

No 10-K data

Net sales growth excluding FX (other)

No 10-K data

Net sales growth excluding exchange (other)

No 10-K data

New diagnostic products launched (other)

No 10-Q data

New product sales (other)

No 10-Q data

New products launched (other)

No 10-Q data

Norvir product sales (other)

No 10-K data

Norvir sales (other)

No 10-K data

Number of Reportable Segments (other)

Nutritional sales (other)

No 10-K data

Omnicef sales (other)

No 10-K data

Operating expenditures for pollution control (other)

No 10-Q data

Organic net sales growth (other)

No 10-K data

Organic sales growth (other)

No 10-K data

Pending Meridia lawsuits (other)

No 10-K data

Pending OxyContin lawsuits (other)

No 10-K data

Pending antitrust suits (other)

No 10-K data

Pending lawsuits (other)

No 10-K data

Pharmaceutical sales (other)

No 10-K data

Pollution Control Capital Expenditures (other)

No 10-Q data

Pollution Control Operating Expenditures (other)

No 10-Q data

Pollution control capex (other)

No 10-Q data

Pollution control capital expenditures (other)

No 10-Q data

Pollution control expenditures (other)

No 10-Q data

Pollution control operating expenditures (other)

No 10-Q data

Pollution control opex (other)

No 10-Q data

Prescription drug antitrust cases (other)

No 10-K data

Product group sales (other)

No 10-K data

Product net sales (other)

No 10-K data

Product sales (other)

No 10-K data

R&D as percent of net sales (other)

No 10-K data

R&D expenditures (other)

No 10-K data

R&D expense (other)

R&D expense ratio (other)

No 10-K data

R&D intensity (other)

No 10-Q data

R&D percent of net sales (other)

No 10-K data

R&D percent of sales (other)

No 10-K data

RPO recognition timing (other)

No 10-K data

Rapid Diagnostics COVID sales (other)

No 10-K data

Rapid Diagnostics COVID-19 Testing Sales (other)

No 10-K data

Rapid Diagnostics COVID-19 sales (other)

No 10-K data

Rapid Diagnostics COVID-19 testing sales (other)

No 10-K data

Ratio of earnings to fixed charges (other)

No 10-K data

Rebate rate on gross sales (other)

No 10-Q data

Rebates and chargebacks (other)

No 10-Q data

Rebates and chargebacks rate (other)

No 10-Q data

Rebates as percent of gross sales (other)

No 10-Q data

Recall infant formula sales (other)

No 10-K data

Recall-related formula sales (other)

No 10-K data

Receivables over one year past due (other)

No 10-K data

Remaining buyback authorization (other)

No 10-K data

Remaining repurchase authorization (other)

No 10-K data

Remaining share repurchase authorization (other)

No 10-K data

Research and Development Spending (other)

No 10-Q data

Research and development (other)

No 10-K data

Research and development expenditures (other)

No 10-K data

Research and development expense (other)

Research and development expense growth (other)

No 10-K data

Research and development ratio (other)

No 10-Q data

Research and development spend (other)

No 10-Q data

Research and development spending (other)

No 10-Q data

Restricted funds in escrow (other)

No 10-Q data

Restricted stock awards and units outstanding (other)

No 10-K data

Restructuring accrual balance (other)

No 10-K data

Restructuring additions (other)

No 10-Q data

Restructuring charges (other)

No 10-K data

Restructuring departures (other)

No 10-Q data

Restructuring eliminations (other)

No 10-Q data

Restructuring employees covered (other)

No 10-Q data

SYNTHROID net sales (other)

No 10-K data

Sales growth excluding FX (other)

No 10-K data

Sales growth excluding currency (other)

No 10-K data

Sales per employee (other)

No 10-Q data

Selling, general and administrative expense growth (other)

No 10-K data

Sevoflurane sales (other)

No 10-K data

Share repurchase authorization remaining (other)

No 10-K data

Share repurchase cost (other)

No 10-K data

Share repurchases (other)

No 10-K data

Shareholders of record (other)

No 10-Q data

Shares available for repurchase (other)

No 10-K data

Shares outstanding (other)

No 10-K data

Shares remaining under buyback (other)

No 10-K data

Shares remaining under repurchase authorization (other)

No 10-K data

Shares repurchase authorization remaining (other)

No 10-K data

Shares repurchased (other)

No 10-K data

Shares repurchased and retired (other)

No 10-K data

Shares reserved for future grants (other)

No 10-K data

Shares reserved for grants (other)

No 10-K data

Sites under environmental review (other)

No 10-Q data

Solvay acquired net sales (other)

No 10-K data

State court pricing cases pending (other)

No 10-K data

States with WIC business (other)

No 10-Q data

States with WIC contracts (other)

No 10-Q data

States with exclusive WIC business (other)

No 10-Q data

Stock options exercisable (other)

No 10-K data

Stock options outstanding (other)

No 10-K data

Superfund remediation sites (other)

No 10-Q data

Superfund sites (other)

No 10-Q data

Supplier Y2K action plan rate (other)

No 10-K data

Supplier Y2K certification (other)

No 10-K data

Supplier Y2K compliance rate (other)

No 10-K data

Supplier Y2K response rate (other)

No 10-K data

Synagis promotion revenue (other)

No 10-K data

Synthroid U.S. sales (other)

No 10-K data

Synthroid net sales (other)

No 10-K data

Synthroid sales (other)

No 10-K data

TAP Holdings equity earnings (other)

No 10-K data

TAP net sales (other)

No 10-K data

Treasury shares (other)

No 10-K data

US distribution centers (other)

No 10-Q data

US research and development facilities (other)

No 10-Q data

Unfavorable exchange effect (other)

No 10-K data

Unfavorable exchange impact (other)

No 10-K data

Unfavorable exchange impact on sales (other)

No 10-K data

Unrecognized share-based compensation (other)

No 10-K data

Unused domestic lines of credit (other)

No 10-K data

Unused lines of credit (other)

Unused share repurchase authorization (other)

No 10-K data

Voluntary contamination investigations (other)

No 10-Q data

WIC business states (other)

No 10-Q data

WIC contract states (other)

No 10-Q data

WIC exclusive business states (other)

No 10-Q data

WIC exclusive states (other)

No 10-Q data

WIC program states (other)

No 10-Q data

WIC state contracts (other)

No 10-Q data

Women in workforce (other)

No 10-Q data

Women representation (other)

No 10-Q data

Working Capital (other)

No 10-K data

Working capital (other)

No 10-K data

Worldwide sales growth (other)

No 10-K data

Y2K certified suppliers (other)

No 10-K data

Y2K remediation costs (other)

No 10-K data

Y2K remediation progress (other)

No 10-K data

Y2K supplier action plan rate (other)

No 10-K data

Y2K supplier action plans (other)

No 10-K data

Y2K supplier certification rate (other)

No 10-K data

Y2K supplier response (other)

No 10-K data

Y2K supplier response rate (other)

No 10-K data

Y2K testing completed (other)

No 10-K data

Manufacturing facilities (properties)

No 10-Q data

Remaining performance obligations (rpo)

Common shares outstanding (shares)

No 10-Q data

Property square footage (square_footage)

No 10-Q data
Human capital disclosures. Workforce totals and demographics are point-in-time. Flow metrics use the year-to-date period for 10-Q and full year for 10-K. Workforce actions (RIFs, restructurings, acquisition-related changes) are listed in the table at the bottom.

Workforce Totals

Demographics

No 10-Q data
No 10-Q data
No 10-Q data
No 10-Q data
No 10-Q data
No 10-Q data

Workforce Breakdowns

No 10-Q data

HCM Metrics — Point-in-Time

No point-in-time HCM metrics found.

HCM Metrics — Flow (Annual / YTD)

No flow HCM metrics found.

Workforce Actions

Period EndTypeStatusAffected% WorkforceAnnouncedExpected CompletionGeographySegment / FunctionChargeSourceNote
2026-06-30restructuringin_progress2025Diagnostics and Medical Devices businessesrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2025-approved plans to streamline operations and reduce costs. No employee counts disclosed. Accrued balance declined from $180 million at December 31, 2025 to $104 million at June 30, 2026 after $76 million of payments and other adjustments; no new charges recorded in the first six months of 2026.
2026-06-30restructuringin_progressDiagnostics and Medical DevicesUSD 104 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plans approved in 2025 to streamline operations and reduce costs in diagnostics and medical devices; accrual was $180M at 2025-12-31, reduced by $76M of payments/adjustments to $104M at 2026-06-30. No employee counts, announcement date, or completion date disclosed in this filing.
2026-06-30acquisition_additioncompleted2026-03-23Diagnostic Products (Cancer Diagnostics)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Exact Sciences completed 2026-03-23 for approximately $20.6 billion; headcount added through the acquisition is not disclosed in this filing.
2026-06-30restructuringin_progress2025Diagnostics and Medical DevicesUSD 104 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Accrued balance at June 30, 2026, is $104 million. Plans approved in 2025 to streamline operations. Employee count not disclosed.
2026-06-30acquisition_additioncompleted2026-03-232026-03-23Diagnostic ProductsUSD 20,600 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Exact Sciences completed March 23, 2026, for approx. $20.6 billion. Headcount added not explicitly disclosed.
2026-03-31restructuringin_progress2025-01-01Diagnostics and Medical DevicesUSD 132 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2025-approved plans to streamline diagnostics and medical devices operations; accrued liability of $132 million at March 31, 2026 after $48 million of payments in the quarter. No employee counts disclosed. Prior-year period included $12 million of asset impairment charges.
2026-03-31acquisition_additioncompleted2026-03-232026-03-23Diagnostic Products (Cancer Diagnostics)USD 21 (billions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Exact Sciences acquisition completed March 23, 2026 for approximately $20.6 billion; unvested restricted stock units (1,476,916) converted to Abbott units and equity awards cashed out ($321 million stock compensation expense). Headcount added not disclosed.
2026-03-31acquisition_additioncompleted2026-03-232026-03-23United StatesDiagnostic Products (Cancer Diagnostics)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Exact Sciences for ~$20.6B completed 2026-03-23; headcount added not disclosed. Includes conversion of 1,476,916 unvested Exact Sciences RSUs into Abbott RSUs.
2026-03-31restructuringin_progressNot specifiedDiagnostic Products; Medical Devicesrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plans approved in 2025 to streamline operations in diagnostics and medical devices. Accrual rolled from $180M (2025-12-31) to $132M (2026-03-31) after $48M of payments/adjustments. No employee counts or new charges disclosed this quarter.
2026-03-31restructuringin_progressDiagnostics and Medical DevicesUSD 132 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Accrued balance for restructuring plans approved in 2025 to streamline operations. Employee count not disclosed.
2026-03-31acquisition_additioncompleted2026-03-23Diagnostic Productsbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Exact Sciences completed. Headcount added not explicitly disclosed.
2025-12-31restructuringin_progress2025Not specifiedDiagnostics, Nutritionals, Established Pharmaceuticals, and Medical DevicesUSD 274 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		2025 streamlining plans to reduce costs and improve efficiencies; severance and other charges of $274M recorded ($109M in cost of products sold, $53M in R&D, $112M in SG&A). Employee count affected not disclosed. Additionally $28M of fixed asset impairment charges recognized; $94M paid during 2025 and $180M liability remained at December 31, 2025.
2025-12-31acquisition_additionannounced2025-11-19Not specifiedDiagnostic Products (entry into cancer diagnostics market)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Definitive agreement to acquire Exact Sciences Corporation at $105 per share in cash (~$21B equity value, ~$23B enterprise value, including ~$1.8B net debt); pending Exact Sciences shareholder approval and regulatory clearances. Workforce/headcount impact not disclosed. Backed by a $20.0B 364-day senior unsecured bridge facility commitment.
2025-12-31restructuringin_progressGlobalDiagnostics, Nutritionals, Established Pharmaceuticals, and Medical DevicesUSD 274 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2025 program: employee-related severance and other charges of $274M ($109M in cost of products sold, $53M in R&D, $112M in SG&A); payments of $94M during 2025; $180M liability remaining at year-end. Separately, $28M of fixed asset impairment charges recognized in 2025. Number of employees affected not disclosed; no announcement date given.
2025-12-31acquisition_additionannounced2025-11-19United StatesCancer diagnostics (pending new market entry)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire Exact Sciences Corporation at $105 per share in cash (~$21B equity value, ~$23B enterprise value); subject to Exact Sciences shareholder approval and regulatory clearances. Headcount to be added not disclosed.
2025-12-31restructuringin_progress2025GlobalDiagnostics, Nutritionals, Established Pharmaceuticals, Medical DevicesUSD 274 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Abbott recorded employee related severance and other charges of $274 million in 2025 to streamline operations. Remaining liabilities totaled $180 million at December 31, 2025. Specific headcount affected not disclosed.
2025-12-31restructuringcompleted2024GlobalDiagnostics, Medical Devices, Established Pharmaceuticals, NutritionalsUSD 129 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2024 restructuring actions included discontinuation of ZonePerfect product line. Accrued balance at Dec 31, 2025 was $27 million.
2025-12-31restructuringcompleted2023GlobalMedical Devices, Diagnostics, Established PharmaceuticalsUSD 144 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2023 restructuring actions. Accrued balance at Dec 31, 2025 was $6 million.
2025-12-31restructuringin_progress2025GlobalDiagnostics, Nutritionals, Established Pharmaceuticals, and Medical DevicesUSD 274 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Abbott recorded employee related severance and other charges of $274 million. Payments totaled $94 million in 2025 and remaining liabilities totaled $180 million at December 31, 2025. Specific headcount affected was not disclosed.
2025-12-31restructuringin_progressSegment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member]USD 287,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-09-30restructuringin_progress2025-01-01Diagnostic Products and Medical DevicesUSD 197 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2025 plans to streamline operations and improve efficiencies; severance charges recorded $100M in cost of products sold, $38M in R&D, $59M in SG&A; payments of $57M made in first nine months, remaining liability $140M at quarter-end; plus $25M asset impairment charges
2025-09-30restructuringin_progress2024-01-01Medical Devices, Diagnostics, Nutritionals, Established PharmaceuticalsUSD 22 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2024 and 2023 plans to restructure or streamline various operations, including discontinuation of the ZonePerfect product line in 2024; $22M asset impairment charges recognized in first nine months of 2024; accrued balance $49M at September 30, 2025
2025-09-30restructuringin_progressDiagnostic Products; Medical DevicesUSD 197 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2025 plans to streamline operations in diagnostics and medical devices; $197M employee-related severance and other charges YTD (split $100M COGS, $38M R&D, $59M SG&A), plus $25M asset impairment charges. $57M paid YTD; $140M remaining liability at 2025-09-30. No employee count or completion date disclosed.
2025-09-30restructuringin_progress2025-01-01GlobalDiagnostic and Medical DevicesUSD 197 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Management approved plans to streamline operations in diagnostic and medical devices businesses. Employee-related severance and other charges of $197 million recorded in the first nine months of 2025. Remaining liabilities of $140 million at September 30, 2025. Employee count not disclosed.
2025-09-30restructuringin_progress2024-01-01GlobalMedical Devices, Diagnostic, Nutritional, and Established Pharmaceuticalrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plans approved in 2024 and 2023 to restructure or streamline various operations. Accrued balance of $49 million at September 30, 2025. Employee count not disclosed.
2025-06-30restructuringin_progress2025-01-01Diagnostic Products and Medical DevicesUSD 104 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2025 plans to streamline diagnostics and medical devices operations; severance charges of $104M in H1 2025 ($69M cost of products sold, $20M R&D, $15M SG&A); $21M paid, $83M liability remaining at June 30, 2025; plus $12M asset impairment charges. Employee count not disclosed.
2025-06-30restructuringin_progressDiagnostic Products and Medical DevicesUSD 104 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2025 plans approved to streamline operations and improve efficiencies in the diagnostics and medical devices businesses. Severance and other charges of $104M recorded in 1H 2025 ($69M in cost of products sold, $20M in R&D, $15M in SG&A), plus $12M of related asset impairment charges. Payments of $21M made in 1H 2025; remaining liabilities stated as $83M at 2025-06-30. Number of employees affected, announcement date, and completion timing not disclosed. Note: the restructuring accrual roll-forward table shows a total accrued balance of $62M at 2025-06-30 (from $118M at 2024-12-31 after $56M of payments/adjustments), which includes prior-year (2023/2024) plans.
2025-06-30restructuringin_progress2025-01-01GlobalDiagnostic and Medical DevicesUSD 104 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Management approved plans to streamline operations in diagnostic and medical devices businesses. Recorded $104M in employee-related severance and other charges in the first six months of 2025. Remaining liabilities totaled $83M at June 30, 2025. Employee count not disclosed.
2025-03-31restructuringin_progress2025-01-01Diagnostic Products and Medical DevicesUSD 34 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2025 plan to streamline operations and reduce costs; severance split $13M cost of products sold, $13M R&D, $8M SG&A; $4M paid in Q1, $30M accrued at quarter-end; no employee counts disclosed
2025-03-31restructuringin_progress2025-01-01Diagnostic Products and Medical DevicesUSD 12 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Asset impairment charges related to the 2025 streamlining plans
2025-03-31restructuringin_progress2025-01-01Diagnostic Products; Medical DevicesUSD 34 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2025 plans to streamline operations in diagnostics and medical devices; $34M severance charges recorded in Q1 2025 ($13M COGS, $13M R&D, $8M SG&A), plus $12M asset impairment charges. $4M paid in Q1; $30M remaining liability at 2025-03-31. No employee count disclosed.
2025-03-31restructuringin_progress2025-01-01Diagnostic and Medical DevicesUSD 46 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Management approved plans to streamline operations in diagnostic and medical devices businesses. Charges include $34M in employee-related severance and other charges, and $12M in asset impairment charges. Employee count not disclosed.
2024-12-31restructuringin_progress2024Diagnostics, Medical Devices, Established Pharmaceutical Products, and Nutritional Products businesses; includes discontinuation of ZonePerfect product lineUSD 129 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Employee severance and other charges of $129 million ($62M in cost of products sold, $21M in R&D, $46M in SG&A); $32 million paid in 2024 and $97 million liability remaining at year-end, indicating actions still winding down. Related inventory charges of $34 million and fixed asset impairments of $12 million also recognized. Headcount affected not disclosed. Same plan also described in MD&A.
2024-12-31divestiture_reductioncompleted2024Established Pharmaceutical ProductsUSD 143 (millions)other
f5-10k / GLM-5.3-flash-HTML		Sale of a non-core business completed in Q2 2024; $143 million loss recorded in Other (income) expense, including $116 million of cumulative currency translation reclassified from Accumulated other comprehensive income (loss). Net assets sold had a $28 million carrying value. Employee headcount transferred not disclosed.
2024-12-31restructuringin_progressGlobalDiagnostic, Medical Devices, Established Pharmaceutical and Nutritional businessesUSD 129 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2024 plans approved during the year to streamline operations and improve efficiencies, including discontinuation of the ZonePerfect product line. Severance split $62M cost of products sold, $21M R&D, $46M SG&A; plus $34M inventory and $12M fixed asset impairment charges. $32M paid in 2024; $97M liability remained at 2024-12-31. Employees affected not disclosed.
2024-12-31divestiture_reductioncompleted2024-062024-06Not disclosedEstablished Pharmaceutical ProductsUSD 143 (millions)other
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of a non-core business in Q2 2024; $143M loss recorded in Other (income) expense, net. Announcement date disclosed only as the second quarter of 2024. Headcount removed through the disposition not disclosed.
2024-12-31restructuringin_progress2024-01-01GlobalDiagnostic, Medical Devices, Established Pharmaceutical, NutritionalUSD 129 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Abbott recorded employee-related severance and other charges of $129 million in 2024. Payments totaled $32 million in 2024, with a remaining liability of $97 million at year-end. Specific headcount affected was not disclosed.
2024-12-31restructuringcompleted2023-01-01GlobalMedical Devices, Diagnostic, Established PharmaceuticalUSD 144 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2023 restructuring charges of $144 million. Accrued balance at Dec 31, 2024 was $21 million, indicating ongoing payments from prior year actions.
2024-12-31restructuringcompleted2022-01-01GlobalMedical Devices, Nutritional, Diagnostic, Established PharmaceuticalUSD 234 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2022 restructuring charges of $234 million. Accrued balance at Dec 31, 2024 was $9 million, indicating near completion.
2024-12-31restructuringin_progress2024GlobalDiagnostic, Medical Devices, Established Pharmaceutical, NutritionalUSD 129 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Plans approved in 2024 to streamline operations. Employee-related severance and other charges of $129 million recorded. Remaining liability of $97 million at year-end. Headcount not disclosed.
2024-12-31restructuringin_progressSegment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member]USD 185,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-09-30restructuringin_progress2024-01-01Diagnostic, Medical Devices and Nutritional businesses, including discontinuation of ZonePerfect product lineUSD 60 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Nine-month severance and other charges of $60M ($39M in cost of products sold, $2M in R&D, $19M in SG&A); payments of $25M made, $35M accrued at September 30, 2024; plus $22M of asset impairment charges. Announcement date inferred as within 2024.
2024-09-30divestiture_reductioncompletedEstablished Pharmaceutical ProductsUSD 143 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Sale of a non-core EPD business in Q2 2024; $143M loss recorded in Other (income) expense, net, including $116M of cumulative foreign currency translation adjustment; net assets sold had carrying value of $28M. No headcount figures disclosed.
2024-09-30restructuringin_progressNot specifiedDiagnostic Products; Medical Devices; Nutritional ProductsUSD 60 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2024 plans to streamline operations and improve efficiencies, including discontinuing the ZonePerfect product line. Severance charges split $39M COGS, $2M R&D, $19M SG&A. $25M paid YTD; $35M liability remaining at 2024-09-30. No employee count disclosed.
2024-09-30restructuringin_progressNot specifiedMedical Devices; Diagnostic Products; Nutritional Products; Established Pharmaceutical Productsrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Prior-year (2023/2022) restructuring programs: accrual rolled from $137M at 2023-12-31 to $55M at 2024-09-30 after $82M of payments/adjustments. No employee counts disclosed for these legacy programs.
2024-09-30restructuringin_progress2024-01-01GlobalDiagnostic, Medical Devices, NutritionalUSD 60 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plans approved in 2024 to streamline operations and improve efficiencies, including discontinuation of ZonePerfect product line. Employee-related severance and other charges of $60 million recorded in first nine months of 2024. Remaining liabilities of $35 million at Sept 30, 2024. Employee count not disclosed.
2024-09-30restructuringin_progress2024-01-01GlobalDiagnostic, Medical Devices, NutritionalUSD 22 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Asset impairment charges of $22 million related to 2024 restructuring plans. Employee count not disclosed.
2024-09-30restructuringin_progress2022-01-01GlobalMedical Devices, Diagnostic, Nutritional, Established Pharmaceuticalrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plans approved in 2023 and 2022 to restructure or streamline various operations. Accrued balance of $55 million at Sept 30, 2024. Employee count not disclosed.
2024-06-30restructuringin_progress2024-01-01Diagnostic Products, Medical Devices, Nutritional ProductsUSD 59 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2024 streamlining plans to reduce costs and improve efficiencies, including discontinuation of the ZonePerfect product line. Severance charges of $59 million recorded in the six months ended June 30, 2024 ($38M in cost of products sold, $2M in R&D, $19M in SG&A); $8 million paid, $51 million accrued at June 30, 2024. No employee counts disclosed.
2024-06-30restructuringin_progress2024-01-01Diagnostic Products, Medical Devices, Nutritional ProductsUSD 28 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Asset impairment charges of $28 million recognized in the six months ended June 30, 2024 related to the 2024 restructuring plans.
2024-06-30divestiture_reductioncompleted2024-06-30Established Pharmaceutical ProductsUSD 143 (millions)other
f5-10q / GLM-5.3-flash-fp4-HTML		Abbott sold a non-core business in the Established Pharmaceutical Products segment in Q2 2024; net assets sold had a carrying value of $28 million. Loss of approximately $143 million recorded in Other (income) expense, net, including $116 million of cumulative foreign currency translation adjustments. No headcount figures disclosed.
2024-06-30restructuringin_progressGlobalDiagnostic Products, Medical Devices, Nutritional ProductsUSD 59 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2024 plans to streamline operations across diagnostics, medical devices and nutrition, including discontinuing ZonePerfect. Severance charges: $38M in COGS, $2M in R&D, $19M in SG&A. Payments of $8M in H1 2024; $51M liability remaining at 2024-06-30. Number of employees affected not disclosed.
2024-06-30restructuringin_progressGlobalDiagnostic Products, Medical Devices, Nutritional Products, Established Pharmaceutical Productsrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Prior-year (2023/2022) restructuring programs: accrual balance $137M at 2023-12-31, reduced by $69M of payments/adjustments to $68M at 2024-06-30. Employee counts not disclosed.
2024-06-30divestiture_reductioncompletedInternationalEstablished Pharmaceutical ProductsUSD 143 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of a non-core EPP business in Q2 2024; $143M loss recorded in Other (income) expense, net. Net assets of $28M (primarily inventory and PP&E) included in sale. Headcount removed not disclosed.
2024-06-30restructuringin_progress2024-01-01GlobalDiagnostic, Medical Devices, NutritionalUSD 87 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Management approved plans to streamline operations in diagnostic, medical devices, and nutritional businesses, including discontinuation of ZonePerfect product line. YTD charges include $59M in employee-related severance/other and $28M in asset impairments. Employee count not disclosed.
2024-03-31restructuringin_progress2024-01-01Nutritional Products; Medical DevicesUSD 17 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2024 plans to streamline operations, including discontinuation of ZonePerfect product line; severance split roughly $11M cost of products sold, $1M R&D, $5M SG&A; plus ~$30M asset impairment charges; $3M paid in Q1, $14M liability remaining at 2024-03-31. Employee count not disclosed.
2024-03-31restructuringin_progress2023-01-01Medical Devices; Diagnostics; Nutrition; Established Pharmaceuticalsrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2023 and 2022 plans to restructure or streamline operations to reduce costs; accrual of $137M at 2023-12-31 reduced to $96M at 2024-03-31 after $41M of payments and other adjustments. Employee count not disclosed.
2024-03-31restructuringin_progress2024-01-01Nutritional Products; Medical DevicesUSD 17 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2024 plans to streamline nutritional business (including ZonePerfect discontinuation) and medical devices segment; severance charges split $11M COGS, $1M R&D, $5M SG&A; $3M paid in Q1; $14M liability at quarter-end; separate $30M asset impairment also recognized; no employee count disclosed.
2024-03-31restructuringin_progress2024-01-01GlobalNutritional Products, Medical DevicesUSD 47 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Management approved plans to streamline operations in nutritional business (including discontinuation of ZonePerfect product line) and medical devices segment. Recorded $17M in employee-related severance/other charges and $30M in asset impairment charges in Q1 2024. Employee count affected not disclosed.
2023-12-31restructuringin_progress2023Medical Devices; Diagnostic Products; Established Pharmaceutical ProductsUSD 144 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		2023 cost-reduction plans; severance allocated $56M to COGS, $22M to R&D, $66M to SG&A; additional $31M fixed-asset impairment and inventory charges; $65M paid in 2023 with $79M liability remaining at year-end; affected headcount not disclosed.
2023-12-31acquisition_additioncompleted2023-04-272023-04-27Medical Devices (Vascular)USD 851 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquisition of Cardiovascular Systems, Inc. at $20/share (purchase price $851 million, charged value shown is purchase price, not severance); adds atherectomy technology to vascular portfolio; headcount added through the combination not disclosed.
2023-12-31acquisition_additioncompleted2023-09-222023-09-22Medical Devices (Diabetes Care)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquisition of Bigfoot Biomedical, Inc. completed; purchase price described as not material to consolidated financial statements; headcount added not disclosed.
2023-12-31restructuringin_progressGlobalMedical Devices, Diagnostic Products, Established Pharmaceutical ProductsUSD 144 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2023 program: employee-related severance and other charges of approximately $144 million (split across cost of products sold, R&D and SG&A), plus approximately $31 million of fixed asset impairment and inventory charges. Payments of $65 million made in 2023; $79 million liability remained at 2023-12-31. Employees affected not disclosed.
2023-12-31acquisition_additioncompleted2023-04-272023-04-27United StatesMedical Devices (Vascular)USD 851 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Purchase price of $851 million ($20 per share), funded with cash on hand. Headcount added through the acquisition not disclosed; associated value is the purchase price, not a charge.
2023-12-31acquisition_additioncompleted2023-09-222023-09-22United StatesMedical Devices (Diabetes Care)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Purchase price and headcount contribution stated as not material to the consolidated financial statements.
2023-12-31restructuringcompleted2023-01-012023-12-31GlobalMedical Devices, Diagnostic, Established PharmaceuticalUSD 175 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Total charges of $175 million ($144 million employee-related severance and other; $31 million fixed asset impairment and inventory). Employee-related charges allocated: $56M Cost of products sold, $22M R&D, $66M SG&A. Payments of $65 million made in 2023; remaining liability of $79 million at year-end.
2023-12-31restructuringin_progress2023GlobalMedical Devices, Diagnostic, Established PharmaceuticalUSD 175 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Approximately $144 million in employee-related severance and other charges, plus $31 million in fixed asset impairment and inventory charges. Employee count not disclosed.
2023-12-31restructuringin_progressSegment Reconciling Items [Member]USD 122,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-09-30restructuringin_progressMedical devices, nutritional, diagnostic, and established pharmaceutical businessesUSD 102 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Employee severance and other charges of approximately $102 million recorded in the nine months ended September 30, 2023 under plans approved in 2022 and 2023 to streamline operations and reduce costs; charges split across Cost of products sold (~$31M), R&D (~$16M), and SG&A (~$55M). Additionally, fixed asset impairment charges of approximately $29 million were recognized. Accrued restructuring balance was $149 million at September 30, 2023 (from $228 million at December 31, 2022, plus $102 million charges, less $181 million payments). No employee counts disclosed.
2023-09-30restructuringin_progressMedical Devices, Nutritional Products, Diagnostic Products, Established Pharmaceutical ProductsUSD 102 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Approved in 2022 and 2023 to streamline operations; severance charges split across COGS ($31M), R&D ($16M), SG&A ($55M). Employee headcount affected not disclosed. Separate fixed asset impairment charges of $29M also recognized. Accrual roll-forward: $228M at 2022-12-31, +$102M charges, -$181M payments, $149M at 2023-09-30.
2023-09-30acquisition_additioncompleted2023-04-272023-04-27Medical Devices (Vascular)USD 851 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Cardiovascular Systems, Inc. (CSI) at $20 per share; purchase price $851M funded with cash. Headcount added not disclosed; revenue and earnings contribution described as not material.
2023-09-30acquisition_additioncompleted2023-09-222023-09-22Medical Devices (Diabetes Care)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Bigfoot Biomedical, Inc.; purchase price, asset allocation, and contribution described as not material to the condensed consolidated financial statements. Headcount added not disclosed.
2023-09-30restructuringin_progressMedical Devices, Nutritional, Diagnostic, and Established PharmaceuticalUSD 102 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Nine months ended Sept 30, 2023: recorded employee-related severance and other charges of approx $102M. No employee count disclosed.
2023-09-30acquisition_additioncompleted2023-09-22Medical Devices (Diabetes Care)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Bigfoot Biomedical completed Sept 22, 2023. Headcount not disclosed.
2023-09-30acquisition_additioncompleted2023-04-27Medical Devices (Vascular)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Cardiovascular Systems, Inc. completed April 27, 2023. Headcount not disclosed.
2023-06-30restructuringin_progressMedical Devices, Nutritional Products, Diagnostic Products, Established Pharmaceutical ProductsUSD 49 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Employee severance and other charges of ~$49 million in H1 2023 under plans approved in 2022 and 2023 to streamline operations and reduce costs; ~$17M in cost of products sold, ~$5M in R&D, ~$27M in SG&A. Plus ~$17M fixed asset impairment charges. Accrued balance $157M at June 30, 2023 (from $228M at Dec 31, 2022, less $120M payments). No employee counts disclosed.
2023-06-30restructuringin_progressGlobalMedical Devices, Nutritional Products, Diagnostic Products, Established Pharmaceutical ProductsUSD 49 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Employee-related severance and other charges of ~$49M recorded in first six months of 2023 (approx. $17M in cost of products sold, $5M in R&D, $27M in SG&A), plus ~$17M fixed asset impairment charges. Accrued restructuring balance: $228M at Dec 31, 2022; $49M charged in 2023; $120M paid; $157M balance at Jun 30, 2023. No employee counts, announcement date, or completion date disclosed.
2023-06-30restructuringin_progressMedical Devices, Nutritional, Diagnostic, and Established PharmaceuticalUSD 49 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Recorded employee-related severance and other charges of approx. $49 million in the six months ended June 30, 2023. Employee count affected is not disclosed.
2023-06-30acquisition_additioncompleted2023-04-27Medical DevicesUSD 851 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired Cardiovascular Systems, Inc. (CSI) for $851 million. Headcount added is not disclosed.
2023-03-31restructuringin_progressMedical devices, nutritional, diagnostic, and established pharmaceutical businessesUSD 17 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plans approved in 2022 and 2023 to streamline operations and reduce costs; Q1 2023 charges of ~$17M for employee severance and other costs, with ~$6M in cost of products sold and ~$11M in SG&A. Accrued balance decreased from $228M at year-end 2022 to $184M after $61M of payments. No employee counts disclosed.
2023-03-31restructuringin_progressGlobalMedical Devices, Nutritional, Diagnostic, Established PharmaceuticalUSD 17 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Approved in 2022 and 2023 to streamline operations; Q1 2023 charges of $17M ($6M in cost of products sold, $11M in SG&A). Accrued balance fell from $228M to $184M after $61M of payments. No employee count, announcement date, or completion date disclosed.
2023-03-31acquisition_additionannounced2023-04-272023-04-27United StatesMedical Devices (Vascular)USD 850 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Completed acquisition of Cardiovascular Systems, Inc. at $20 per share (~$850M), funded with cash on hand; adds atherectomy systems for peripheral and coronary artery disease. No headcount added disclosed.
2023-03-31restructuringin_progressMedical Devices, Nutritional, Diagnostic, and Established PharmaceuticalUSD 17 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Abbott recorded employee related severance and other charges of approximately $17 million in the first three months of 2023 to streamline operations. Employee count affected not disclosed.
2022-12-31restructuringin_progress2022Medical Devices; Nutritional Products; Diagnostic Products; Established Pharmaceutical ProductsUSD 234 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Plans approved in 2022 to streamline operations and reduce costs. Employee severance and other charges of ~$234M recorded in 2022 ($59M in cost of products sold, $36M in R&D, $139M in SG&A); the program also included $23M inventory-related charges and $4M fixed-asset impairment charges not included in the $234M. Accrued balance of $228M remained at December 31, 2022 with only $6M paid, indicating execution still in progress. Number of employees affected not disclosed.
2022-12-31restructuringin_progressGlobalMedical Devices, Nutritional Products, Diagnostic Products, Established Pharmaceutical ProductsUSD 234 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2022 approved plans to streamline operations; $234M employee-related severance and other charges ($59M in cost of products sold, $36M in R&D, $139M in SG&A), plus $23M inventory-related and $4M fixed-asset impairment charges. Accrued balance of $228M remained at 2022-12-31. Employees affected not disclosed.
2022-12-31plant_closurein_progress2022-02United States (Sturgis, Michigan)Nutritional Products — U.S. Pediatric NutritionalsUSD 176 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Voluntary recall of certain infant powder formula products and production stoppage at Sturgis; consent decree entered 2022-05-16, partial production restarted 2022-07-01. Segment footnote reports $176M of charges related to the recall. Employees affected not disclosed.
2022-12-31divestiture_reductionannounced2022-12ChinaNutritional Products — Pediatric NutritionalsMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		In December 2022 Abbott initiated steps to exit its pediatric nutrition business in China. Employees affected and completion timeline not disclosed.
2022-12-31acquisition_additionannounced2023-02-08United StatesMedical Devices — VascularUSD 890 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire Cardiovascular Systems, Inc. at $20 per share, approximately $890M total expected equity value, to be funded with cash on hand. Subject to CSI shareholder approval and regulatory approvals. Headcount to be added not disclosed.
2022-12-31restructuringcompleted2022GlobalMedical Devices, Nutritional, Diagnostic, Established PharmaceuticalUSD 234 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Abbott recorded employee-related severance and other charges of approximately $234 million in 2022 to streamline operations.
2022-12-31acquisition_additioncompleted2021-09GlobalMedical DevicesNotes to Consolidated Financial Statements
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Abbott acquired Walk Vascular, LLC in September 2021. Headcount not disclosed.
2022-12-31restructuringin_progress2022GlobalMedical Devices, Nutritional, Diagnostic, Established PharmaceuticalUSD 234 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Abbott recorded employee-related severance and other charges of approximately $234 million. Specific headcount affected was not disclosed.
2022-12-31restructuringcompleted2021-05-27GlobalDiagnostic ProductsUSD 499 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Plan approved in 2021 to align manufacturing network for COVID-19 tests. Charges of $499 million recorded in 2021. Accrual balance of $13 million remained at Dec 31, 2022. Specific headcount affected was not disclosed.
2022-12-31restructuringin_progressSegment Reconciling Items [Member]USD 265,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-09-30restructuringin_progress2021-05-27Diagnostic ProductsUSD 499 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2021 plan to align COVID-19 test manufacturing network with reduced testing demand; charges recorded in Q2 2021 in Cost of products sold. Accrued balance of $13 million for other exit costs remained at September 30, 2022.
2022-09-30restructuringin_progress2022-01-01Medical DevicesUSD 12 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2022 streamlining plan in medical devices segment; employee-related severance and other charges of approximately $12 million in first nine months of 2022, split roughly $5M cost of products sold, $2M R&D, $5M SG&A. Accrued balance $34 million at September 30, 2022 across all streamlining plans.
2022-09-30restructuringin_progressNot specifiedMedical DevicesUSD 12 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Streamlining plan approved in 2022 (and 2021) for the medical devices segment; severance and other charges of approximately $12 million recorded in the first nine months of 2022, split across cost of products sold (~$5M), R&D (~$2M), and SG&A (~$5M). No employee count disclosed. Accrued balance was $34 million at 2022-09-30 after $39 million of payments and adjustments.
2022-09-30restructuringin_progress2021-05-27Not specifiedDiagnostic Productsrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		COVID-19 diagnostic manufacturing network alignment plan approved 2021-05-27; original 2021 charges of $441 million (after $58M favorable revision). No 2022 charges; remaining other-exit-cost accrual of $13 million at 2022-09-30 after $10 million of payments/adjustments during the first nine months of 2022. No employee count disclosed.
2022-09-30restructuringin_progressNot specifiedDiagnostic Products, Established Pharmaceutical Products, Nutritional Productsrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Streamlining plans approved in 2021 across diagnostic, established pharmaceutical, and nutritional businesses; no 2022 charges disclosed for these plans. Accrued balance at 2022-09-30 not separately disclosed from the medical devices restructuring accrual of $34 million. No employee count disclosed.
2022-09-30restructuringin_progress2021-05-27Diagnostic ProductsUSD 12 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges recorded in first nine months of 2022 for streamlining operations in diagnostic, established pharmaceutical, nutritional, and medical devices businesses. Employee count not disclosed for current period charges.
2022-09-30restructuringin_progressRestructuring Plan 2021, Streamline of Operations and Improve Efficiencies [Member]USD 12,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-06-30restructuringin_progress2021-05-27Diagnostic ProductsUSD 499 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2021 plan to align COVID-19 test manufacturing network with reduced testing demand; charges included $80M fixed asset write-downs, $248M inventory charges, and $171M other exit costs including contract cancellations and employee-related costs. Accrued other exit cost balance of $13M remained at June 30, 2022. No employee count disclosed.
2022-06-30restructuringin_progress2021Diagnostics, Established Pharmaceuticals, Nutritionals, Medical DevicesUSD 68 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2021 plans to streamline operations and reduce costs across four businesses; employee-related severance and other charges of ~$68M recorded in 2021. Accrued balance of $31M at June 30, 2022. No employee count disclosed.
2022-06-30plant_closurein_progress2022-02-01United StatesNutritional Products — U.S. Pediatric NutritionalsUSD 162 (millions)MD&A
f5-10q / GLM-5.3-flash-fp4-HTML		Voluntary recall of infant powder formula made at Sturgis, Michigan facility with production stopped; consent decree with FDA signed May 16, 2022; partial production restarted July 1, 2022 beginning with EleCare and metabolic formulas, then Similac. Charges of $162M YTD related to the recall recorded in Other, net. No employee count disclosed.
2022-06-30restructuringin_progress2021-05-27GlobalDiagnostic ProductsUSD 499 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan to align COVID-19 test manufacturing network with reduced projected testing demand; charge recorded in Q2 2021 (prior year), comprising $248M inventory, $80M fixed-asset write-downs, $113M other exit costs. Accrued balance $13M at June 30, 2022 after $10M of payments/adjustments in H1 2022. No employee headcount affected disclosed.
2022-06-30restructuringin_progress2021GlobalDiagnostic Products; Established Pharmaceutical Products; Nutritional Products; Medical DevicesUSD 68 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Employee-related severance and other charges approved in 2021 to streamline operations; $16M in cost of products sold, $4M in R&D, $48M in SG&A. Accrued balance $31M at June 30, 2022 after $30M of payments/adjustments in H1 2022. No employee headcount affected disclosed.
2022-06-30plant_closurein_progress2022-022022-07-01United States (Sturgis, Michigan)Nutritional ProductsMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Voluntary recall of infant powder formula products and production stoppage at Sturgis facility; consent decree with FDA entered May 16, 2022; partial production restarted July 1, 2022 (subsequent to quarter end). Recall-related charges of $162M in H1 2022 recorded in Other, net (segment note). No workforce reduction count disclosed.
2022-06-30restructuringin_progress2021-05-27Diagnostic ProductsUSD 13 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Accrued balance at June 30, 2022 for 2021 COVID-19 diagnostic manufacturing network alignment plan. Employee count not disclosed in current period.
2022-06-30restructuringin_progress2021Diagnostic, Established Pharmaceutical, Nutritional, and Medical DevicesUSD 31 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Accrued balance at June 30, 2022 for 2021 operational streamlining plans. Employee count not disclosed in current period.
2022-03-31restructuringin_progress2021-05-27Diagnostic ProductsUSD 499 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2021 plan to align COVID-19 test manufacturing network with changing demand; charges included $80M fixed asset write-downs, $248M inventory charges, and $171M other exit costs. Accrued other exit cost balance of $20M at March 31, 2022. No employee count disclosed.
2022-03-31restructuringin_progress2021-01-01Diagnostics, Established Pharmaceuticals, Nutrition, Medical DevicesUSD 68 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2021 plans to streamline operations and reduce costs; employee-related severance and other charges of ~$68M recorded in 2021 ($16M cost of products sold, $4M R&D, $48M SG&A). Accrued balance of $45M at March 31, 2022. No employee count disclosed.
2022-03-31restructuringin_progress2021-05-27GlobalDiagnostic ProductsUSD 441 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan to align COVID-19 test manufacturing network with projected demand; $441M accrued in 2021 (inventory $248M, fixed assets $80M, other exit costs $113M); $20M accrual remained at 2022-03-31. No employee count disclosed.
2022-03-31restructuringin_progress2021-01-01GlobalDiagnostics, Established Pharmaceuticals, Nutritional, Medical DevicesUSD 68 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Streamlining plans approved during 2021; $68M of employee-related severance and other charges recorded in 2021 ($16M in cost of products sold, $4M in R&D, $48M in SG&A); $45M accrual remained at 2022-03-31. No employee count disclosed.
2022-03-31restructuringin_progress2021-05-27Diagnostic ProductsUSD 20 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Accrued balance for other exit costs (contract cancellations and employee-related costs) as of March 31, 2022. Original plan approved May 27, 2021.
2022-03-31restructuringin_progress2021Diagnostics, Established Pharmaceuticals, Nutritional, Medical DevicesUSD 45 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Accrued balance for employee-related severance and other charges as of March 31, 2022. Plans approved in 2021 to streamline operations.
2021-12-31restructuringin_progress2021-05-27Diagnostic ProductsUSD 441 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Plan approved May 27, 2021 to align COVID-19 test manufacturing network with reduced projected demand. Net FY2021 charges of $441M ($248M inventory, $80M fixed asset write-downs, $113M other exit costs); initial Q2 charge was $499M, reduced by a net $58M of exit-cost adjustments, and ~$181M of previously written-down inventory was sold in H2. Year-end accrual of $23M, primarily severance. Employee headcount affected not disclosed.
2021-12-31restructuringin_progressMedical Devices; Diagnostic ProductsUSD 10 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year St. Jude Medical and Alere integration program (2017-2021); only FY2021 activity captured. Employee-related severance and other charges of ~$10M in 2021 (cumulative ~$95M since 2019); $9M accrued at December 31, 2021.
2021-12-31restructuringin_progressDiagnostics; Established Pharmaceuticals; Nutritionals; Medical DevicesUSD 68 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		2021-approved plans to streamline operations and improve efficiencies. Employee-related severance and other charges of ~$68M ($16M in cost of products sold, $4M in R&D, $48M in SG&A); $61M accrued at December 31, 2021, primarily severance. Employee headcount affected not disclosed.
2021-12-31restructuringin_progress2021-05-27GlobalDiagnostic ProductsUSD 441 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Plan to align COVID-19 test manufacturing network with reduced projected demand. Q2 2021 gross charge of $499M (incl. $80M fixed asset write-downs, $248M inventory charges, $171M other exit costs); footnote reports $441M net charges recorded in 2021 after H2 reversals ($181M inventory sold that had been written down, $58M net reduction in exit cost estimates). $23M accrued at year-end, primarily severance. Employees affected not disclosed.
2021-12-31restructuringin_progress2021-01-01GlobalDiagnostics, Established Pharmaceuticals, Nutritional, and Medical DevicesUSD 68 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2021 streamlining plan to reduce costs and improve efficiencies; employee-related severance and other charges of approximately $68M ($16M in cost of products sold, $4M in R&D, $48M in SG&A). $61M accrued at year-end. Announcement date not specified; attributed to fiscal year 2021.
2021-12-31restructuringin_progress2021-01-01GlobalMedical Devices and Diagnostic Products (St. Jude Medical and Alere integration)USD 10 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Multi-year integration program (2017–2021); only the $10M of employee-related severance and other charges recorded in fiscal 2021 is captured here. $9M accrued at year-end. Employees affected not disclosed.
2021-12-31acquisition_additioncompleted2021-09-012021-09-30United StatesMedical Devices (endovascular portfolio)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Abbott acquired 100% of Walk Vascular, LLC in September 2021; purchase price and acquired headcount not material to consolidated statements and not disclosed. Announcement date approximate (month only).
2021-12-31restructuringcompleted2021-05-272021-12-31GlobalDiagnostic ProductsUSD 499 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Abbott recorded charges of $499 million in Q2 2021 related to aligning manufacturing network for COVID-19 diagnostic tests. Employee count not explicitly disclosed.
2021-12-31restructuringcompleted2017-01-012021-12-31GlobalMedical Devices, Diagnostic ProductsUSD 10 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Integration of St. Jude Medical and Alere. $10 million recorded in 2021. Employee count not explicitly disclosed.
2021-12-31restructuringcompleted2017-01-012021-12-31GlobalNutritional, Established Pharmaceuticals, Vascularrestructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Streamlining operations. No new charges recorded in 2021; prior year accruals remain. Employee count not explicitly disclosed.
2021-12-31restructuringcompleted2021-01-012021-12-31GlobalDiagnostics, Established Pharmaceuticals, Nutritional, Medical DevicesUSD 68 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Plans approved in 2021 to streamline operations. $68 million recorded. Employee count not explicitly disclosed.
2021-12-31restructuringcompleted2021-05-27GlobalDiagnostic ProductsUSD 499 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Plan to align manufacturing network for COVID-19 diagnostic tests. Charges included fixed asset write-downs, inventory-related charges, and other exit costs. Employee count not explicitly disclosed.
2021-12-31restructuringcompleted2021-01-01GlobalVarious (Diagnostics, Established Pharmaceuticals, Nutritional, Medical Devices)USD 68 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Plans to streamline operations to reduce costs and improve efficiencies. Charges primarily represent severance obligations. Employee count not explicitly disclosed.
2021-12-31restructuringcompleted2017-01-01GlobalMedical Devices, Diagnostic ProductsUSD 10 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Integration of St. Jude Medical and Alere acquisitions. $10 million in charges recorded in 2021. Employee count not explicitly disclosed for 2021 activity.
2021-12-31restructuringin_progressInventory-related charges / COVID-19 Test Manufacturing Network Restructuring PlanUSD 248,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-12-31restructuringin_progressFixed asset write-downs / COVID-19 Test Manufacturing Network Restructuring PlanUSD 80,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-12-31restructuringin_progressOther exit costs / COVID-19 Test Manufacturing Network Restructuring PlanUSD 113,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-12-31restructuringin_progressCOVID-19 Test Manufacturing Network Restructuring PlanUSD 441,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-12-31restructuringin_progressRestructuring Plan 2021 [Member]USD 68,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-09-30restructuringin_progress2021-05-27Diagnostic ProductsUSD 480 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plan to align COVID-19 test manufacturing network with reduced projected testing demand; charges include $248M inventory-related, $80M fixed asset write-downs, and $152M other exit costs. Third-quarter favorable revisions: ~$120M of previously written-down inventory sold and $19M reduction in exit cost estimates. No employee counts disclosed.
2021-09-30restructuringin_progressMedical Devices / Diagnostic ProductsUSD 5 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Integration restructuring plans for St. Jude Medical and Alere acquisitions (2017-2021); nine-month 2021 charges of $5M; $10M accrued at September 30, 2021, primarily severance obligations.
2021-09-30restructuringin_progressNutritional, Established Pharmaceuticals and Vascular businessesUSD 17 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plans to streamline operations and improve efficiencies; nine-month 2021 charges of $17M; $57M accrued at September 30, 2021. No employee counts disclosed.
2021-09-30restructuringin_progress2021-05-27Diagnostic ProductsUSD 480 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan to realign the COVID-19 diagnostic test manufacturing network after Q2 demand projections fell. Q2 charge was $499M (incl. $171M other exit costs covering contract cancellations and employee-related costs); footnote table shows net 2021 charges of $480M after Q3 reductions. No employee count disclosed. In Q3, ~$120M of previously written-down inventory was sold and other exit costs were cut by a net $19M; $98M accrual remained at 2021-09-30.
2021-09-30restructuringin_progressMedical Devices; Diagnostic ProductsUSD 5 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ongoing 2017-2021 integration restructuring for St. Jude Medical and Alere acquisitions; $5M of charges recognized in the nine months ended 2021-09-30 ($1M in cost of products sold, $4M in SG&A); $10M accrued at quarter-end, primarily severance. No employee count disclosed; charge is nine-month, not quarterly.
2021-09-30restructuringin_progressNutrition, Established Pharmaceuticals, Vascular and other businessesUSD 17 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ongoing 2017-2021 operational streamlining/cost-reduction plans; $17M of charges in the nine months ended 2021-09-30 ($1M cost of products sold, $16M SG&A); accrual of $57M at 2021-09-30 after $30M payments/adjustments. No employee count disclosed; charge is nine-month, not quarterly.
2021-09-30acquisition_additioncompletedMedical Devices (endovascular)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Abbott acquired 100% of Walk Vascular, LLC in September 2021; purchase price, purchase accounting and contributed revenue/net income stated as immaterial. Headcount added not disclosed.
2021-09-30restructuringin_progress2021-05-27Diagnostic ProductsUSD 499 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan approved May 27, 2021 to align manufacturing network for COVID-19 tests. Q2 charges included $80M fixed asset write-downs, $248M inventory charges, and $171M other exit costs (contract cancellations and employee-related costs). Q3 saw $120M inventory sold and $19M reduction in exit cost estimates. Accrued balance at Sept 30, 2021 was $98M.
2021-09-30restructuringin_progressMedical Devices, Diagnostic ProductsUSD 5 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Integration of St. Jude Medical and Alere Inc. acquisitions. Q9 2021 charges of $5M ($1M COGS, $4M SG&A). Accrued balance at Sept 30, 2021 was $10M, primarily severance.
2021-09-30restructuringin_progressNutritional, Established Pharmaceuticals, VascularUSD 17 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plans to streamline operations to reduce costs. Q9 2021 charges of $17M ($1M COGS, $16M SG&A). Accrued balance at Sept 30, 2021 was $57M.
2021-09-30restructuringin_progressInventory-related charges / COVID-19 Test Manufacturing Network Restructuring PlanUSD 248,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-09-30restructuringin_progressFixed asset write-downs / COVID-19 Test Manufacturing Network Restructuring PlanUSD 80,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-09-30restructuringin_progressOther exit costs / COVID-19 Test Manufacturing Network Restructuring PlanUSD 152,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-09-30restructuringin_progressCOVID-19 Test Manufacturing Network Restructuring PlanUSD 480,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-09-30restructuringin_progressSt Jude and Alere IntegrationsUSD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-09-30restructuringin_progressCost of products sold / St Jude and Alere IntegrationsUSD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-09-30restructuringin_progressSelling, general and administrative expense / St Jude and Alere IntegrationsUSD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-09-30restructuringin_progressStreamline of Operations and Improve EfficienciesUSD 17,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-09-30restructuringin_progressCost of products sold / Streamline of Operations and Improve EfficienciesUSD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-09-30restructuringin_progressSelling, general and administrative expense / Streamline of Operations and Improve EfficienciesUSD 16,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-06-30restructuringin_progress2021-05-272021-12-31Diagnostic ProductsUSD 499 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plan to align COVID-19 diagnostic test manufacturing network with reduced projected testing demand; Q2 2021 charge includes fixed asset write-downs of $80M, inventory-related charges of $248M, and other exit costs of $171M. Total estimated pre-tax cost $500M-$625M. Employee headcount affected not disclosed; accrued other exit costs of $152M at June 30, 2021, with cash outlays expected primarily over the next six months.
2021-06-30restructuringin_progress2021-05-272021-12-31GlobalDiagnostic ProductsUSD 499 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan aligns COVID-19 diagnostic test manufacturing network with lower projected testing demand; estimated total pre-tax cost $500M-$625M (fixed asset write-downs $80M-$115M, inventory charges $250M-$260M, other exit costs $170M-$250M). Q2 2021 charge of $499M comprises $80M fixed asset write-downs, $248M inventory charges, $171M other exit costs; $152M accrued at June 30, 2021. No number of employees affected disclosed.
2021-06-30restructuringin_progressGlobalMedical Devices; Diagnostic ProductsUSD 4 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ongoing 2017-2021 integration restructuring for St. Jude Medical and Alere acquisitions; $4M charged in first six months of 2021 ($1M in cost of products sold, $3M in SG&A); $15M accrued at June 30, 2021, primarily severance. No employee counts disclosed; programs predate the quarter.
2021-06-30restructuringin_progressGlobalNutritional; Established Pharmaceutical Products; VascularUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ongoing 2017-2020 operational streamlining plans; $1M charged in first six months of 2021 in cost of products sold; $47M accrued at June 30, 2021. No employee counts disclosed; programs predate the quarter.
2021-06-30restructuringin_progress2021-05-272021-12-31GlobalDiagnostic ProductsUSD 499 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan to align manufacturing network for COVID-19 diagnostic tests. Total estimated cost $500M-$625M. Q2 charges included $80M fixed asset write-downs, $248M inventory charges, and $171M other exit costs (contract cancellation and employee-related). Employee count not disclosed.
2021-06-30restructuringin_progressCovid19 Test Manufacturing Network Restructuring Plan [Member]USD 499,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-06-30restructuringin_progressFixed Asset Write Downs [Member] / Covid19 Test Manufacturing Network Restructuring Plan [Member]USD 80,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-06-30restructuringin_progressInventory Related Charges [Member] / Covid19 Test Manufacturing Network Restructuring Plan [Member]USD 248,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-06-30restructuringin_progressOther Exit Costs [Member] / Covid19 Test Manufacturing Network Restructuring Plan [Member]USD 171,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-06-30restructuringin_progressRestructuring Plan Business Acquisition St. Jude And Alere Inc. [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-06-30restructuringin_progressCost Of Sales [Member] / Restructuring Plan Business Acquisition St. Jude And Alere Inc. [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-06-30restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan Business Acquisition St. Jude And Alere Inc. [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-06-30restructuringin_progressCost Of Sales [Member] / Restructuring Plan Streamline Operations [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-06-30restructuringin_progressRestructuring Plan Streamline Operations [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-03-31restructuringin_progressNutritionals, Established Pharmaceuticals, VascularUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Streamlining plans approved 2017-2020; $1M charge in Q1 2021 recorded in cost of products sold; accrual fell from $70M to $58M. No employee counts disclosed.
2021-03-31restructuringin_progressMedical Devices; Diagnostic Productsrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		St. Jude Medical and Alere integration actions; no new charges in Q1 2021; remaining accrual of $13M primarily severance. No employee counts disclosed.
2021-03-31restructuringin_progressNutritional, Established Pharmaceuticals, VascularUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges of $1 million recognized in Cost of products sold for plans to streamline operations. Accrued balance decreased from $70 million to $58 million due to payments and adjustments. No employee count disclosed.
2021-03-31restructuringin_progressRestructuring Plan Business Acquisition St. Jude And Alere Inc. [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-03-31restructuringin_progressRestructuring Plan Streamline Operations [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-03-31restructuringin_progressUSD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-12-31restructuringin_progressMedical Devices and Diagnostic Products segments (St. Jude Medical and Alere integration)USD 13 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year integration program approved 2017-2020; fiscal 2020 employee severance and other charges of approximately $13 million; remaining accrual of $25 million (primarily severance) at December 31, 2020. Charges split across cost of products sold, R&D and SG&A over the three-year period 2018-2020.
2020-12-31restructuringin_progressNutritional, Established Pharmaceuticals and Vascular businesses (operations streamlining)USD 36 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year streamlining program approved 2016-2020; fiscal 2020 employee severance and other charges of approximately $36 million; accrued balance of $70 million at December 31, 2020. 2020 charges: ~$6M cost of products sold, ~$2M R&D, ~$28M SG&A. Activity disclosed as cumulative program roll-forward.
2020-12-31restructuringin_progressGlobalMedical Devices and Diagnostic Products (St. Jude Medical and Alere integration)USD 13 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Multi-year program approved 2017-2020; $13M employee-related severance and other charges recorded in 2020 (program charges 2018-2020 total ~$137M). Accrued liability remaining at 2020-12-31 for these actions was $25M. Employees affected in 2020 not disclosed.
2020-12-31restructuringin_progressGlobalNutritional, Established Pharmaceutical and Vascular businessesUSD 36 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Multi-year program approved 2016-2020 to streamline operations; $36M employee-related severance and other charges recorded in 2020. Employees affected in 2020 not disclosed.
2020-12-31restructuringcompletedGlobalMedical Devices, Diagnostic Products, Nutritional, Established Pharma, VascularUSD 13 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Employee-related severance and other charges of $13 million recorded in 2020 for integration of St. Jude Medical and Alere acquisitions.
2020-12-31restructuringcompletedGlobalNutritional, Established Pharma, VascularUSD 36 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Employee-related severance and other charges of $36 million recorded in 2020 for streamlining operations.
2020-12-31restructuringcompleted2017-01-012020-12-31GlobalMedical Devices, Diagnostic ProductsUSD 13 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Integration of St. Jude Medical and Alere Inc. acquisitions. $13M recorded in 2020 as part of multi-year program.
2020-12-31restructuringcompleted2016-01-012020-12-31GlobalNutritional, Established Pharmaceuticals, VascularUSD 36 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Streamline operations to reduce costs. $36M recorded in 2020 as part of multi-year program.
2020-12-31restructuringin_progressUSD 36,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2020-09-30restructuringin_progressSt. Jude Medical and Alere integrationUSD 13 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Charges for first nine months of 2020 under plans approved 2017-2020 to integrate St. Jude Medical and Alere; $6M in cost of products sold, $1M in R&D, $6M in SG&A. Accrual balance $35M at September 30, 2020. No employee counts disclosed.
2020-09-30restructuringin_progressNutritional, established pharmaceuticals and vascular businessesUSD 29 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Charges for first nine months of 2020 under plans to streamline operations and reduce costs; $1M in cost of products sold, $1M in R&D, $27M in SG&A. Accrual balance $84M at September 30, 2020. No employee counts disclosed.
2020-09-30restructuringin_progressGlobalMedical Devices; Diagnostic ProductsUSD 13 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Nine-month 2020 charges for St. Jude Medical and Alere integration; no employee count disclosed. Accrued balance $35M at 2020-09-30.
2020-09-30restructuringin_progressGlobalNutritional Products; Established Pharmaceutical Products; VascularUSD 29 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Nine-month 2020 charges for streamlining operations; no employee count disclosed. Accrued balance $84M at 2020-09-30.
2020-09-30restructuringin_progressMedical Devices, Diagnostic ProductsUSD 13 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges related to integration of St. Jude Medical and Alere Inc. acquisitions. No employee count disclosed.
2020-09-30restructuringin_progressNutritional, Established Pharmaceuticals, VascularUSD 29 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges to streamline operations and reduce costs. No employee count disclosed.
2020-09-30restructuringin_progressRestructuring Plan Business Acquisition St. Jude And Alere Inc. [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-09-30restructuringin_progressCost Of Sales [Member] / Restructuring Plan Business Acquisition St. Jude And Alere Inc. [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-09-30restructuringin_progressResearch And Development Expense [Member] / Restructuring Plan Business Acquisition St. Jude And Alere Inc. [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-09-30restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan Business Acquisition St. Jude And Alere Inc. [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-09-30restructuringin_progressRestructuring Plan Streamline Operations [Member]USD 29,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-09-30restructuringin_progressCost Of Sales [Member] / Restructuring Plan Streamline Operations [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-09-30restructuringin_progressResearch And Development Expense [Member] / Restructuring Plan Streamline Operations [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-09-30restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan Streamline Operations [Member]USD 27,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-30restructuringin_progressSt. Jude Medical and Alere integrationUSD 10 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Charges of $10 million in first six months of 2020 under approved restructuring plans for acquisition integrations; $4 million in cost of products sold, $2 million in R&D, and $6 million in SG&A. Accrued balance of $46 million at December 31, 2019 moved to $36 million after payments and adjustments. No employee counts disclosed.
2020-06-30restructuringin_progressVarious businesses (nutritional, established pharmaceuticals, vascular)USD 10 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Charges of $10 million in first six months of 2020 under cost-reduction streamlining plans across various businesses; $1 million in cost of products sold, $1 million in R&D, and $8 million in SG&A. Accrued balance of $84 million at December 31, 2019 moved to $77 million after payments and adjustments. No employee counts disclosed.
2020-06-30restructuringin_progressGlobalMedical Devices; Diagnostic ProductsUSD 10 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Programs from 2017-2020 covering St. Jude Medical and Alere integration; first six months of 2020 charges of $10M ($3M cost of products sold, $1M R&D, $6M SG&A). Accrued balance $36M at June 30, 2020. No employee count disclosed.
2020-06-30restructuringin_progressGlobalNutritional Products; Established Pharmaceutical Products; VascularUSD 23 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Streamlining programs from 2017-2020; first six months of 2020 charges of $23M ($1M cost of products sold, $1M R&D, $21M SG&A). Accrued balance $84M at June 30, 2020. No employee count disclosed.
2020-06-30restructuringin_progressMedical Devices, Diagnostic ProductsUSD 10 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges related to integration of St. Jude Medical and Alere Inc. acquisitions. Employee count not disclosed.
2020-06-30restructuringin_progressNutritional, Established Pharmaceuticals, VascularUSD 23 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges to streamline operations and reduce costs. Employee count not disclosed.
2020-06-30restructuringin_progressRestructuring Plan Business Acquisition St. Jude And Alere Inc. [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-30restructuringin_progressCost Of Sales [Member] / Restructuring Plan Business Acquisition St. Jude And Alere Inc. [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-30restructuringin_progressResearch And Development Expense [Member] / Restructuring Plan Business Acquisition St. Jude And Alere Inc. [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-30restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan Business Acquisition St. Jude And Alere Inc. [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-30restructuringin_progressRestructuring Plan Streamline Operations [Member]USD 23,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-30restructuringin_progressCost Of Sales [Member] / Restructuring Plan Streamline Operations [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-30restructuringin_progressResearch And Development Expense [Member] / Restructuring Plan Streamline Operations [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-30restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan Streamline Operations [Member]USD 21,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-31restructuringin_progressMedical Devices and Diagnostic Products (St. Jude Medical and Alere integration)USD 9 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Charges from 2017-2020 integration plans; $3M in cost of products sold, $1M in R&D, $5M in SG&A. Accrued balance $37M at March 31, 2020. No employee counts disclosed.
2020-03-31restructuringin_progressNutritional, Established Pharmaceuticals and Vascular businessesUSD 23 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Streamlining plans approved 2017-2020 to reduce costs; $1M in cost of products sold, $1M in R&D, $21M in SG&A. Accrued balance $94M at March 31, 2020. No employee counts disclosed.
2020-03-31restructuringin_progressGlobalMedical Devices; Diagnostic ProductsUSD 9 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2020 charges of $9M ($3M cost of products sold, $1M R&D, $5M SG&A) under 2017-2020 plans integrating St. Jude Medical and Alere acquisitions; accrual $37M at 2020-03-31. No employee count disclosed.
2020-03-31restructuringin_progressGlobalNutritional Products; Established Pharmaceutical Products; VascularUSD 23 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2020 charges of $23M ($1M cost of products sold, $1M R&D, $21M SG&A) under 2017-2020 cost-reduction and streamlining plans; accrual $94M at 2020-03-31. No employee count disclosed.
2020-03-31restructuringin_progressMedical Devices, Diagnostic ProductsUSD 9 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges related to integration of St. Jude Medical and Alere Inc. acquisitions.
2020-03-31restructuringin_progressNutritional, Established Pharmaceuticals, VascularUSD 23 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges related to streamlining operations to reduce costs and improve efficiencies.
2020-03-31restructuringin_progressRestructuring Plan Business Acquisition St. Jude And Alere Inc. [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-31restructuringin_progressCost Of Sales [Member] / Restructuring Plan Business Acquisition St. Jude And Alere Inc. [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-31restructuringin_progressResearch And Development Expense [Member] / Restructuring Plan Business Acquisition St. Jude And Alere Inc. [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-31restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan Business Acquisition St. Jude And Alere Inc. [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-31restructuringin_progressRestructuring Plan Streamline Operations [Member]USD 23,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-31restructuringin_progressCost Of Sales [Member] / Restructuring Plan Streamline Operations [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-31restructuringin_progressResearch And Development Expense [Member] / Restructuring Plan Streamline Operations [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-31restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan Streamline Operations [Member]USD 21,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-12-31restructuringin_progressMedical Devices (St. Jude Medical integration); Diagnostic Products (Alere integration)USD 72 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year acquisition-integration program approved 2017-2019; FY2019 employee severance and other charges of approximately $72 million (about $19M in Cost of products sold, $4M in R&D, $49M in SG&A); accrued balance of $46 million at December 31, 2019. No employee headcount affected disclosed.
2019-12-31restructuringin_progressNutritional Products, Established Pharmaceutical Products, and Vascular businessesUSD 66 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year streamlining program approved 2016-2019 to reduce costs and improve efficiencies; FY2019 employee severance and other charges of approximately $66 million (about $16M in Cost of products sold, $28M in R&D, $22M in SG&A); accrued balance of $79 million at December 31, 2019. No employee headcount affected disclosed.
2019-12-31restructuringin_progressGlobalMedical Devices; Diagnostic ProductsUSD 72 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Multi-year program (approved 2017-2019) integrating St. Jude Medical and Alere; only FY2019 employee-related severance and other charges captured. Accrued balance of $46M remained at 2019-12-31. No employee-affected count disclosed.
2019-12-31restructuringin_progressGlobalNutritional Products; Established Pharmaceutical Products; VascularUSD 66 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Multi-year streamlining program (approved 2016-2019); only FY2019 employee-related severance and other charges captured. Accrued balance of $79M remained at 2019-12-31. No employee-affected count disclosed.
2019-12-31restructuringcompleted2017-01-012019-12-31GlobalMedical Devices, Diagnostic ProductsUSD 72 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Part of integration of St. Jude Medical and Alere acquisitions. 2019 charges were $72 million for employee-related severance and other costs.
2019-12-31restructuringcompleted2016-01-012019-12-31GlobalNutritional, Established Pharmaceuticals, VascularUSD 66 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Plans to streamline operations to reduce costs and improve efficiencies. 2019 charges were $66 million for employee-related severance and other costs.
2019-12-31restructuringcompletedGlobalMedical Devices, Diagnostic ProductsUSD 72 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Integration of St. Jude Medical and Alere acquisitions. Employee related severance and other charges of approximately $72 million in 2019.
2019-12-31restructuringcompletedGlobalNutritional, Established Pharmaceuticals, VascularUSD 66 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Plans to streamline operations to reduce costs and improve efficiencies. Employee related severance and other charges of approximately $66 million in 2019.
2019-12-31restructuringin_progressCost Of Sales [Member] / Restructuring Plan2017 To2019 Stjude And Alere [Member]USD 19,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-12-31restructuringin_progressResearch And Development Expense [Member] / Restructuring Plan2017 To2019 Stjude And Alere [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-12-31restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan2017 To2019 Stjude And Alere [Member]USD 49,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-12-31restructuringin_progressRestructuring Plan2017 To2019 Stjude And Alere [Member]USD 72,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-12-31restructuringin_progressCost Of Sales [Member] / Restructuring Plan From2016 To2019 [Member]USD 16,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-12-31restructuringin_progressResearch And Development Expense [Member] / Restructuring Plan From2016 To2019 [Member]USD 28,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-12-31restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan From2016 To2019 [Member]USD 22,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-12-31restructuringin_progressRestructuring Plan From2016 To2019 [Member]USD 66,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-09-30restructuringin_progressSt. Jude Medical integration (Cardiovascular and Neuromodulation) and Alere integration (Diagnostics)USD 66 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Charges for 2017-2019 integration plans recognized in first nine months of 2019; $18M in cost of products sold, $4M in R&D, $44M in SG&A. Accrued balance $62M at September 30, 2019. No employee counts disclosed.
2019-09-30restructuringin_progressNutritional, Established Pharmaceuticals and Vascular businessesUSD 35 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2016-2019 streamlining plans; charges recognized in first nine months of 2019 split $10M cost of products sold, $8M R&D, $17M SG&A. Accrued balance $76M at September 30, 2019. No employee counts disclosed.
2019-09-30restructuringin_progressNot specifiedCardiovascular and Neuromodulation; Diagnostic ProductsUSD 66 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2017-2019 plans integrating St. Jude Medical and Alere acquisitions; YTD 2019 charges of $66M ($18M COGS, $4M R&D, $44M SG&A); accrual $62M at 2019-09-30. No employee counts disclosed.
2019-09-30restructuringin_progressNot specifiedNutritional, Established Pharmaceutical, Vascular businessesUSD 35 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2016-2019 cost-reduction/streamlining plans; YTD 2019 charges of $35M ($10M COGS, $8M R&D, $17M SG&A); accrual $76M at 2019-09-30. No employee counts disclosed.
2019-09-30restructuringin_progressCardiovascular and Neuromodulation; DiagnosticsUSD 66 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges related to integration of St. Jude Medical and Alere acquisitions. Employee count not disclosed.
2019-09-30restructuringin_progressNutritional; Established Pharmaceuticals; VascularUSD 35 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges to streamline operations and reduce costs. Employee count not disclosed.
2019-09-30restructuringin_progressRestructuring Plan2017 To2019 Stjude And Alere [Member]USD 66,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-09-30restructuringin_progressCost Of Sales [Member] / Restructuring Plan2017 To2019 Stjude And Alere [Member]USD 18,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-09-30restructuringin_progressResearch And Development Expense [Member] / Restructuring Plan2017 To2019 Stjude And Alere [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-09-30restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan2017 To2019 Stjude And Alere [Member]USD 44,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-09-30restructuringin_progressRestructuring Plan From2016 To2019 [Member]USD 35,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-09-30restructuringin_progressCost Of Sales [Member] / Restructuring Plan From2016 To2019 [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-09-30restructuringin_progressResearch And Development Expense [Member] / Restructuring Plan From2016 To2019 [Member]USD 8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-09-30restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan From2016 To2019 [Member]USD 17,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-06-30restructuringin_progressCardiovascular and Neuromodulation; DiagnosticsUSD 36 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Charges from 2017-2019 plans integrating St. Jude Medical and Alere acquisitions; $16M in cost of products sold, $2M in R&D, $18M in SG&A. Accrued balance rose from $41M to $48M at June 30, 2019. No employee counts disclosed.
2019-06-30restructuringin_progressNutritional, Established Pharmaceuticals and Vascular businessesrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2016-2018 streamlining plans to reduce costs and improve efficiencies; no new charges in H1 2019, payments of $13M reduced accrual from $70M to $57M at June 30, 2019. No employee counts disclosed.
2019-06-30restructuringin_progressNot specifiedCardiovascular and Neuromodulation; Diagnostic ProductsUSD 36 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Integration of St. Jude Medical and Alere acquisitions; $36M charged in first six months of 2019 ($16M COGS, $2M R&D, $18M SG&A). Accrual roll-forward: $41M at 2018-12-31, $36M charges, $(29M) payments, $48M at 2019-06-30. No employee counts disclosed.
2019-06-30restructuringin_progressNot specifiedNutritional; Established Pharmaceutical; Vascular businessesrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Legacy 2016-2018 streamlining plans; no new charges in first six months of 2019. Accrual roll-forward: $70M at 2018-12-31, $(13M) payments, $57M at 2019-06-30. No employee counts disclosed.
2019-06-30restructuringin_progressCardiovascular and Neuromodulation; DiagnosticsUSD 36 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges related to integration of St. Jude Medical and Alere acquisitions. Employee count not disclosed.
2019-06-30restructuringin_progressNutritional; Established Pharmaceuticals; Vascularrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plans to streamline operations approved 2016-2018. No new charges recorded in Q2 2019; only payments/adjustments of $13M. Employee count not disclosed.
2019-06-30restructuringin_progressRestructuring Plan2017 To2019 Stjude And Alere [Member]USD 36,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-06-30restructuringin_progressCost Of Sales [Member] / Restructuring Plan2017 To2019 Stjude And Alere [Member]USD 16,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-06-30restructuringin_progressResearch And Development Expense [Member] / Restructuring Plan2017 To2019 Stjude And Alere [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-06-30restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan2017 To2019 Stjude And Alere [Member]USD 18,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-03-31restructuringin_progressCardiovascular and Neuromodulation; Diagnostics (St. Jude Medical and Alere integration)USD 35 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Employee severance and other charges under 2017-2019 integration plans; $16M in cost of products sold, $2M in R&D, $17M in SG&A. Accrued balance rose from $41M to $61M. No employee count disclosed.
2019-03-31restructuringin_progressGlobalCardiovascular and Neuromodulation Products; Diagnostic ProductsUSD 35 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2017-2019 plans integrating St. Jude Medical and Alere; Q1 2019 charges of $35M ($16M cost of products sold, $2M R&D, $17M SG&A). Severance accrual rose from $41M at 2018-12-31 to $61M at 2019-03-31 after $15M of payments. No employee counts or completion dates disclosed.
2019-03-31restructuringin_progressGlobalNutritional Products; Established Pharmaceutical Products; Vascularrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2016-2018 streamlining plans; no new charges in Q1 2019, only $8M of payments reducing accrual from $70M to $62M. No employee counts disclosed.
2019-03-31restructuringin_progressIntegration of St. Jude Medical and Alere acquisitionsUSD 35 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges of $35 million recognized in Q1 2019 related to integration of St. Jude Medical and Alere acquisitions. Includes $16M in Cost of products sold, $2M in R&D, and $17M in SG&A. Employee count affected not disclosed.
2019-03-31restructuringin_progressRestructuring Plan2017 To2019 Stjude And Alere [Member]USD 35,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-03-31restructuringin_progressCost Of Sales [Member] / Restructuring Plan2017 To2019 Stjude And Alere [Member]USD 16,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-03-31restructuringin_progressResearch And Development Expense [Member] / Restructuring Plan2017 To2019 Stjude And Alere [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-03-31restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan2017 To2019 Stjude And Alere [Member]USD 17,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-12-31restructuringin_progressCardiovascular and Neuromodulation Products; Diagnostic ProductsUSD 52 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		FY2018 activity within a multi-year integration program approved in 2017 and 2018 following the St. Jude Medical and Alere acquisitions, intended to leverage economies of scale and reduce costs. Charges include one-time employee termination benefits; recorded ~$5M in Cost of products sold, ~$10M in R&D, and ~$37M in SG&A. Prior-year (2017) charges were $187M and $23M of restructuring liabilities were assumed with the acquisitions. Payments and other adjustments in 2018 were ~$79M, leaving a $41M accrued balance at December 31, 2018; completion not stated. No headcount figures disclosed — charges are disclosed in dollar terms only.
2018-12-31restructuringin_progressNutritional Products; Established Pharmaceutical Products; Vascular businessesUSD 28 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		FY2018 employee-related severance and other charges under streamlining plans approved from 2016 to 2018 to reduce costs and improve efficiencies in various businesses. Charges recorded ~$10M in Cost of products sold, ~$2M in R&D, and ~$16M in SG&A. Prior-year charges were $32M (2016) and $120M (2017). Payments and other adjustments in 2018 were ~$77M, leaving a $70M accrued balance at December 31, 2018; completion not stated. No headcount figures disclosed — charges are disclosed in dollar terms only.
2018-12-31restructuringin_progressNot specifiedCardiovascular and Neuromodulation Products; Diagnostic ProductsUSD 52 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2018 charges only for integration of St. Jude Medical and Alere acquisitions; program approved in 2017 and 2018. Accrued balance of $41 million at 2018-12-31. Employee headcount affected not disclosed.
2018-12-31restructuringin_progressNot specifiedNutritional Products; Established Pharmaceutical Products; VascularUSD 28 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2018 charges only under a multi-year streamlining program approved 2016-2018; excludes approximately $2 million of accelerated depreciation recorded in prior years. Accrued balance of $70 million at 2018-12-31. Employee headcount affected not disclosed.
2018-12-31restructuringcompleted2018-01-012018-12-31GlobalCardiovascular and Neuromodulation Products; Diagnostic ProductsUSD 52 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Charges of approximately $52 million recorded in 2018 for integration of St. Jude Medical and Alere acquisitions. Employee count not disclosed.
2018-12-31restructuringcompleted2018-01-012018-12-31GlobalNutritional Products; Established Pharmaceutical Products; VascularUSD 28 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Charges of approximately $28 million recorded in 2018 to streamline operations in nutritional, established pharmaceuticals, and vascular businesses. Employee count not disclosed.
2018-12-31restructuringcompleted2018-01-012018-12-31GlobalCardiovascular and Neuromodulation Products; Diagnostic ProductsUSD 52 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Integration of St. Jude Medical and Alere acquisitions. Charges include one-time employee termination benefits. Employee count not disclosed.
2018-12-31restructuringcompleted2018-01-012018-12-31GlobalNutritional Products; Established Pharmaceutical Products; VascularUSD 28 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Streamline operations to reduce costs and improve efficiencies. Charges include employee-related severance. Employee count not disclosed.
2018-12-31restructuringin_progressRestructuring Plan2017 And2018 St Jude And Alere [Member]USD 52,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-31restructuringin_progressRestructuring Plan From2016 To2018 [Member]USD 28,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-31restructuringin_progressCost Of Sales [Member] / Restructuring Plan2017 And2018 St Jude And Alere [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-31restructuringin_progressCost Of Sales [Member] / Restructuring Plan From2016 To2018 [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-31restructuringin_progressResearch And Development Expense [Member] / Restructuring Plan2017 And2018 St Jude And Alere [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-31restructuringin_progressResearch And Development Expense [Member] / Restructuring Plan From2016 To2018 [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-31restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan2017 And2018 St Jude And Alere [Member]USD 37,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-31restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan From2016 To2018 [Member]USD 16,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-09-30restructuringin_progressCardiovascular and Neuromodulation; Diagnostics (St. Jude Medical and Alere integration)USD 45 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		First nine months 2018 charges include one-time employee termination benefits; $4M in cost of products sold, $10M in R&D, $31M in SG&A. Accrual of $55M at September 30, 2018. No employee count disclosed.
2018-09-30restructuringin_progressNutritional, Established Pharmaceuticals and Vascular businessesUSD 18 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Streamlining plans approved 2014-2018; first nine months 2018 charges of $8M in cost of products sold, $1M in R&D, $9M in SG&A. Accrual of $87M at September 30, 2018. No employee count disclosed.
2018-09-30restructuringin_progressGlobalCardiovascular and Neuromodulation; Diagnostic ProductsUSD 45 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Integration-related restructuring for St. Jude Medical and Alere; charges include one-time employee termination benefits. No employee count disclosed.
2018-09-30restructuringin_progressGlobalNutritional; Established Pharmaceuticals; VascularUSD 18 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Streamlining plans approved 2014–2018; no employee count disclosed.
2018-09-30restructuringin_progressCardiovascular and Neuromodulation; DiagnosticsUSD 45 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges related to integration of St. Jude Medical and Alere acquisitions, including one-time employee termination benefits.
2018-09-30restructuringin_progressNutritional; Established Pharmaceuticals; VascularUSD 18 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges related to plans to streamline operations and improve efficiencies in various Abbott businesses.
2018-09-30restructuringin_progressRestructuring Plan2017 And2018 St Jude And Alere [Member]USD 45,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-09-30restructuringin_progressRestructuring Plan From2014 To2018 [Member]USD 18,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-09-30restructuringin_progressCost Of Sales [Member] / Restructuring Plan2017 And2018 St Jude And Alere [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-09-30restructuringin_progressCost Of Sales [Member] / Restructuring Plan From2014 To2018 [Member]USD 8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-09-30restructuringin_progressResearch And Development Expense [Member] / Restructuring Plan2017 And2018 St Jude And Alere [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-09-30restructuringin_progressResearch And Development Expense [Member] / Restructuring Plan From2014 To2018 [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-09-30restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan2017 And2018 St Jude And Alere [Member]USD 31,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-09-30restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan From2014 To2018 [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progressCardiovascular and Neuromodulation; Diagnostics (St. Jude Medical and Alere integration)USD 33 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Charges of approximately $33 million in first six months of 2018 for integration of St. Jude Medical and Alere acquisitions, including one-time employee termination benefits; ~$4M in cost of products sold, ~$10M in R&D, ~$19M in SG&A. Accrued balance $58 million at June 30, 2018. No employee count disclosed.
2018-06-30restructuringin_progressNutritional, Established Pharmaceutical and Vascular businessesUSD 12 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Streamlining plans approved 2014-2018; charges of approximately $12 million in first six months of 2018 (~$7M cost of products sold, ~$5M SG&A). Accrued balance $104 million at June 30, 2018. No employee count disclosed.
2018-06-30restructuringin_progressGlobalCardiovascular and Neuromodulation Products; Diagnostic ProductsUSD 33 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2017-2018 integration restructuring for St. Jude Medical and Alere; charges include one-time employee termination benefits but no headcount affected is disclosed. Accrual roll-forward: $68M at 2017-12-31, $33M charges, $(43)M payments, $58M at 2018-06-30.
2018-06-30restructuringin_progressGlobalNutritional Products; Established Pharmaceutical Products; VascularUSD 12 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2014-2018 operational streamlining plans; no employee count disclosed. Accrual roll-forward: $141M at 2017-12-31, $12M charges, $(49)M payments, $104M at 2018-06-30.
2018-06-30restructuringin_progressCardiovascular and Neuromodulation; DiagnosticsUSD 33 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges related to integration of St. Jude Medical and Alere acquisitions. Includes one-time employee termination benefits. Employee count not disclosed.
2018-06-30restructuringin_progressNutritional; Established Pharmaceuticals; VascularUSD 12 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges related to streamlining operations to reduce costs and improve efficiencies. Employee count not disclosed.
2018-06-30restructuringin_progressRestructuring Plan2017 [Member]USD 33,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progressRestructuring Plan From2014 To2017 [Member]USD 12,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progressCost Of Sales [Member] / Restructuring Plan2017 [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progressCost Of Sales [Member] / Restructuring Plan From2014 To2017 [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progressResearch And Development Expense [Member] / Restructuring Plan2017 [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan2017 [Member]USD 19,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan From2014 To2017 [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-03-31restructuringin_progressCardiovascular and Neuromodulation; DiagnosticsUSD 23 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2017-2018 plans to integrate St. Jude Medical and Alere acquisitions; Q1 2018 charges of ~$23M including one-time employee termination benefits, split ~$3M cost of products sold, ~$8M R&D, ~$12M SG&A. Accrual of $68M at Dec 31, 2017, $23M charges, $25M payments, $66M balance at Mar 31, 2018. No employee counts disclosed.
2018-03-31restructuringin_progressNutritional, Established Pharmaceuticals and Vascular businessesUSD 10 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2014-2018 streamlining plans to reduce costs and improve efficiencies; Q1 2018 charges of ~$10M, ~$7M in cost of products sold and ~$3M in SG&A. Accrual of $141M at Dec 31, 2017, $10M charges, $20M payments, $131M balance at Mar 31, 2018. No employee counts disclosed.
2018-03-31restructuringin_progressGlobalCardiovascular and Neuromodulation Products; Diagnostic ProductsUSD 23 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Integration restructuring for St. Jude Medical and Alere acquisitions; Q1 2018 charges of ~$23M (one-time employee termination benefits) split ~$3M cost of products sold, ~$8M R&D, ~$12M SG&A. Accrued balance $66M at 2018-03-31. No employee count disclosed.
2018-03-31restructuringin_progressGlobalNutritional Products; Established Pharmaceutical Products; VascularUSD 10 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Streamlining plans approved 2014–2018; Q1 2018 charges of ~$10M split ~$7M cost of products sold, ~$3M SG&A. Accrued balance $131M at 2018-03-31. No employee count disclosed.
2018-03-31restructuringin_progressIntegration of St. Jude Medical and Alere acquisitionsUSD 23 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges include one-time employee termination benefits. No specific employee count disclosed.
2018-03-31restructuringin_progressNutritional, established pharmaceuticals, and vascular businessesUSD 10 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plans to streamline operations to reduce costs and improve efficiencies. No specific employee count disclosed.
2018-03-31restructuringin_progressRestructuring Plan2017 [Member]USD 23,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-03-31restructuringin_progressRestructuring Plan From2014 To2017 [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-03-31restructuringin_progressCost Of Sales [Member] / Restructuring Plan2017 [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-03-31restructuringin_progressCost Of Sales [Member] / Restructuring Plan From2014 To2017 [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-03-31restructuringin_progressResearch And Development Expense [Member] / Restructuring Plan2017 [Member]USD 8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-03-31restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan2017 [Member]USD 12,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-03-31restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan From2014 To2017 [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-12-31acquisition_additioncompleted2017-01-04Cardiovascular and Neuromodulation Productsbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquisition of St. Jude Medical completed on this date for approximately $23.6 billion in cash and Abbott shares; the workforce added was not disclosed.
2017-12-31acquisition_additioncompleted2017-10-03Diagnostic Productsbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquisition of Alere Inc. completed on this date for approximately $4.5 billion plus about $0.7 billion of preferred shares; headcount added was not disclosed.
2017-12-31divestiture_reductioncompleted2016-09Abbott Medical Optics (vision care business)other
f5-10k / GLM-5.3-flash-HTML		Definitive agreement announced September 2016; sale to Johnson & Johnson completed February 27, 2017 for $4.325 billion with a pre-tax gain of $1.163 billion. Headcount transferred was not disclosed.
2017-12-31divestiture_reductioncompleted2016Cardiovascular and Neuromodulation Products (vascular closure businesses)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Angio-Seal, Femoseal vascular closure and Vado Steerable Sheath businesses agreed to be sold to Terumo in 2016 for about $1.12 billion; sale closed January 20, 2017 with no gain or loss. Headcount transferred was not disclosed.
2017-12-31divestiture_reductioncompleted2017Diagnostic Products (Alere Triage MeterPro and BNP assay businesses)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Alere agreed in Q3 2017 to sell these businesses to Quidel in connection with antitrust review of the Alere acquisition; closed October 6, 2017 for $400 million upfront, $240 million in installments and up to $40 million contingent. Headcount transferred was not disclosed.
2017-12-31divestiture_reductioncompleted2017Diagnostic Products (Alere Epocal Inc. subsidiary)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Epocal Inc. agreed in Q3 2017 to be sold to Siemens for about $200 million as part of the Alere acquisition regulatory review; sale closed October 31, 2017. Headcount transferred was not disclosed.
2017-12-31restructuringin_progress2017Cardiovascular and Neuromodulation Products and Diagnostic Products (acquisition integration)USD 187 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		2017 plans to integrate St. Jude Medical and Alere; ~$187 million of charges including one-time employee termination benefits ($5 million in cost of products sold, $182 million in SG&A). Also assumed ~$23 million of acquired restructuring liabilities; $68 million accrued at December 31, 2017. Employees affected not disclosed.
2017-12-31restructuringin_progress2014Nutritional, Established Pharmaceutical and Vascular businessesUSD 120 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year streamlining program approved 2014-2017; $120 million reflects fiscal 2017 employee-related severance and other charges (plus ~$2 million primarily for accelerated depreciation). Accrued balance of $141 million at December 31, 2017. Employees affected not disclosed.
2017-12-31acquisition_additioncompleted2017-01-042017-01-04GlobalCardiovascular and Neuromodulation Productsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of St. Jude Medical completed January 4, 2017 for approximately $23.6 billion; headcount added not disclosed.
2017-12-31acquisition_additioncompleted2017-10-032017-10-03GlobalDiagnostic Productsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Alere Inc. completed October 3, 2017 for approximately $4.5 billion in cash plus preferred tender; headcount added not disclosed. Alere represented approximately 13% of total assets at year-end.
2017-12-31divestiture_reductioncompleted2017-02-272017-02-27GlobalVision care (Abbott Medical Optics)discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of Abbott Medical Optics to Johnson & Johnson for $4.325 billion; headcount removed not disclosed.
2017-12-31divestiture_reductioncompleted2017-01-202017-01-20GlobalVascular closure and steerable sheath businesses (Angio-Seal, Femoseal, Vado)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of certain St. Jude Medical and Abbott businesses to Terumo Corporation for approximately $1.12 billion; closed January 20, 2017 with no gain or loss recorded.
2017-12-31divestiture_reductioncompleted2017-10-062017-10-31GlobalDiagnostic Products (Triage MeterPro, BNP assay, Epocal)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Divestitures required by FTC and European Commission in connection with the Alere acquisition: Triage MeterPro and BNP assay businesses sold to Quidel (closed October 6, 2017) and Epocal Inc. sold to Siemens (closed October 31, 2017); no gain or loss recorded.
2017-12-31restructuringin_progress2017-01-01GlobalCardiovascular and Neuromodulation Products and Diagnostic ProductsUSD 187 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2017 restructuring plans approved as part of integrating St. Jude Medical and Alere; charges of approximately $187 million including one-time employee termination benefits (approximately $5 million in cost of products sold and $182 million in SG&A). Accrued balance at December 31, 2017 was $68 million. Employees affected not disclosed.
2017-12-31restructuringin_progress2017-01-01GlobalNutritional, Established Pharmaceuticals and Vascular businessesUSD 120 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Multi-year streamlining program approved 2014-2017; 2017 activity only captured here (employee-related severance and other charges of approximately $120 million in 2017, plus approximately $2 million of accelerated depreciation). Accrued balance at December 31, 2017 was $141 million. Employees affected not disclosed.
2017-12-31restructuringcompleted2017-01-012017-12-31GlobalVarious (Nutritional, Established Pharmaceuticals, Vascular, Cardiovascular, Diagnostics)USD 187 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Charges of approximately $187 million recorded in 2017 for integration of St. Jude Medical and Alere acquisitions, including one-time employee termination benefits.
2017-12-31restructuringcompleted2014-01-012017-12-31GlobalVarious (Nutritional, Established Pharmaceuticals, Vascular)USD 120 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Charges of approximately $120 million recorded in 2017 for plans approved from 2014 to 2017 to streamline operations.
2017-12-31restructuringcompleted2017GlobalCardiovascular and Neuromodulation; Diagnostic ProductsUSD 187 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Charges of approximately $187 million recorded for integration of St. Jude Medical and Alere acquisitions, including one-time employee termination benefits. Employee count not disclosed.
2017-12-31restructuringcompleted2014GlobalNutritional; Established Pharmaceuticals; VascularUSD 120 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Part of multi-year plan approved 2014-2017 to streamline operations. $120 million in employee-related severance and other charges recorded in 2017. Employee count not disclosed.
2017-12-31restructuringin_progressRestructuring Plan2017 [Member]USD 187,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressRestructuring Plan From2014 To2017 [Member]USD 120,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressCost Of Sales [Member] / Restructuring Plan2017 [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressCost Of Sales [Member] / Restructuring Plan From2014 To2017 [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressResearch And Development Expense [Member] / Restructuring Plan From2014 To2017 [Member]USD 77,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan2017 [Member]USD 182,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan From2014 To2017 [Member]USD 36,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-09-30restructuringin_progress2017-01-04Cardiovascular and Neuromodulation ProductsUSD 162 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		St. Jude Medical integration restructuring; charges include one-time employee termination benefits, recorded in SG&A; accrued balance $70 million at September 30, 2017; no employee count disclosed.
2017-09-30restructuringin_progressVascular, Nutritional and Established Pharmaceutical Products businessesUSD 87 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Streamlining plans approved 2014-2017 to reduce costs and improve efficiencies; charges split across cost of products sold (~$4M), R&D (~$76M) and SG&A (~$7M); accrued balance $126 million at September 30, 2017; no employee count disclosed.
2017-09-30restructuringin_progressCardiovascular and Neuromodulation ProductsUSD 162 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2017 plans approved to integrate the St. Jude Medical acquisition; charges of $162M recorded in first nine months of 2017 (one-time employee termination benefits in SG&A), plus $20M of restructuring liabilities assumed in the acquisition; $112M paid, $70M accrued at 2017-09-30. No employee counts or completion dates disclosed.
2017-09-30restructuringin_progressVascular, Nutritional and Established Pharmaceutical Products businessesUSD 87 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plans approved 2014–2017 to streamline operations; $87M of charges in first nine months of 2017 (~$4M in cost of products sold, ~$76M in R&D, ~$7M in SG&A); $66M accrued at 2016-12-31, $27M paid, $126M accrued at 2017-09-30. No employee counts or completion dates disclosed.
2017-09-30restructuringin_progress2017-01-04Cardiovascular and NeuromodulationUSD 162 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges recorded in first nine months of 2017 for integration of St. Jude Medical acquisition, including one-time employee termination benefits.
2017-09-30restructuringin_progressVarious (Vascular, Nutritional, Established Pharmaceuticals)USD 87 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges recorded in first nine months of 2017 for plans approved from 2014 to 2017 to streamline operations.
2017-09-30restructuringin_progressRestructuring Plan2017 [Member]USD 162,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-09-30restructuringin_progressRestructuring Plan From2014 To2017 [Member]USD 87,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-09-30restructuringin_progressCost Of Sales [Member] / Restructuring Plan From2014 To2017 [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-09-30restructuringin_progressResearch And Development Expense [Member] / Restructuring Plan From2014 To2017 [Member]USD 76,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-09-30restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan2017 [Member]USD 162,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-09-30restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan From2014 To2017 [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-06-30restructuringin_progress2017-01-04Cardiovascular and Neuromodulation ProductsUSD 144 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		St. Jude Medical integration restructuring; charges include one-time employee termination benefits, recorded in SG&A. Accrued balance of $94 million at June 30, 2017, including $20 million of liabilities assumed in the acquisition.
2017-06-30restructuringin_progress2014-01-01Nutritional and Established Pharmaceutical Products businessesUSD 17 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Streamlining plans approved 2014-2017 to reduce costs and improve efficiencies; first six months 2017 charges of ~$4 million in cost of products sold, ~$7 million in R&D, ~$6 million in SG&A. Accrued balance $61 million at June 30, 2017.
2017-06-30restructuringin_progressCardiovascular and Neuromodulation ProductsUSD 144 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2017 plans tied to St. Jude Medical integration; charges include one-time employee termination benefits recorded in SG&A, plus $20M restructuring liabilities assumed in the acquisition; accrual $94M at June 30, 2017. No employee count disclosed.
2017-06-30restructuringin_progressNutritional Products; Established Pharmaceutical ProductsUSD 17 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Streamlining plans approved 2014–2017; 1H17 charges split across cost of products sold ($4M), R&D ($7M) and SG&A ($6M); accrual $61M at June 30, 2017. No employee count disclosed.
2017-06-30acquisition_additioncompleted2017-01-042017-01-04Cardiovascular and Neuromodulation Productsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		St. Jude Medical acquisition closed January 4, 2017 for ~$23.6B; no headcount added disclosed in this filing.
2017-06-30divestiture_reductioncompleted2017-02-272017-02-27Abbott Medical Optics (vision care)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of AMO to Johnson & Johnson completed February 2017 with $1.151B pre-tax gain; no headcount removed disclosed.
2017-06-30divestiture_reductioncompleted2017-01-202017-01-20Vascular closure and Vado steerable sheath businessesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of Angio-Seal, Femoseal and Vado businesses to Terumo for ~$1.12B closed January 20, 2017; no gain or loss recorded; no headcount disclosed.
2017-06-30restructuringin_progress2017-01-04Cardiovascular and NeuromodulationUSD 144 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges recorded in first six months of 2017 for integration of St. Jude Medical acquisition, including one-time employee termination benefits.
2017-06-30restructuringin_progressNutritional and Established PharmaceuticalsUSD 17 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges recorded in first six months of 2017 for plans approved from 2014 to 2017 to streamline operations.
2017-06-30restructuringin_progressRestructuring Plan2017 [Member]USD 144,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-06-30restructuringin_progressRestructuring Plan From2014 To2017 [Member]USD 17,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-06-30restructuringin_progressCost Of Sales [Member] / Restructuring Plan From2014 To2017 [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-06-30restructuringin_progressResearch And Development Expense [Member] / Restructuring Plan From2014 To2017 [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-06-30restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan2017 [Member]USD 144,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-06-30restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan From2014 To2017 [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-03-31restructuringin_progress2017-01-01Cardiovascular and Neuromodulation Products (St. Jude Medical integration)USD 121 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2017 integration restructuring plan for St. Jude Medical acquisition; charges include one-time employee termination benefits, recorded in SG&A. Accrued balance $98M at 2017-03-31 (including $20M liabilities assumed in acquisition); $43M paid in the quarter. No employee count disclosed.
2017-03-31restructuringin_progress2014-01-01Nutritional and Established Pharmaceutical Products businessesUSD 10 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Ongoing 2014-2017 streamlining plans; Q1 2017 charges of ~$10M ($6M in R&D, $4M in SG&A). Accrued balance $61M at 2017-03-31. No employee count disclosed.
2017-03-31acquisition_additioncompleted2017-01-042017-01-04Cardiovascular and Neuromodulation ProductsUSD 24 (billions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		St. Jude Medical acquisition completed January 4, 2017 for ~$23.6B; no employee headcount added disclosed. Unvested St. Jude stock options and RSUs converted to Abbott awards.
2017-03-31divestiture_reductioncompleted2016-09-012017-02-27Abbott Medical Optics (vision care)USD 4 (billions)other
f5-10q / GLM-5.3-flash-fp4-HTML		Sale of AMO to Johnson & Johnson completed February 27, 2017 for $4.325B; pre-tax gain $1.151B. No employee headcount removed disclosed.
2017-03-31restructuringin_progress2017-01-01Cardiovascular and Neuromodulation ProductsUSD 121 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Approved in 2017 as part of St. Jude Medical integration; charges include one-time employee termination benefits recorded in SG&A. An additional $20M of restructuring liabilities was assumed in the acquisition; $43M paid in Q1, leaving $98M accrued at 2017-03-31. No employee count disclosed.
2017-03-31restructuringin_progress2014-01-01Nutritional Products; Established Pharmaceutical ProductsUSD 10 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Multi-year streamlining plans approved 2014–2017; Q1 2017 charges of $10M ($6M in R&D, $4M in SG&A). Accrued balance $61M at 2017-03-31. No employee count disclosed.
2017-03-31acquisition_additioncompleted2017-01-042017-01-04GlobalCardiovascular and Neuromodulation Productsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		St. Jude Medical acquisition completed 2017-01-04 for ~$23.6B. Headcount added not disclosed; only financial consideration and purchase price allocation given.
2017-03-31divestiture_reductioncompleted2016-09-012017-02-27GlobalAbbott Medical Optics (vision care) — non-reportable segmentother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of AMO to Johnson & Johnson completed 2017-02-27 for $4.325B; pre-tax gain of $1.151B. Headcount removed not disclosed.
2017-03-31divestiture_reductioncompleted2016-01-012017-01-20GlobalVascular closure and steerable sheath businessesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of Angio-Seal, Femoseal, and Vado Steerable Sheath businesses to Terumo for ~$1.12B, closed 2017-01-20; no gain or loss recorded. Headcount removed not disclosed.
2017-03-31restructuringin_progress2017-01-04Cardiovascular and NeuromodulationUSD 121 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges recorded as part of St. Jude Medical integration, including one-time employee termination benefits.
2017-03-31restructuringin_progress2014-01-01Nutritional and Established PharmaceuticalsUSD 10 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges related to plans to streamline operations approved from 2014 to 2017.
2017-03-31restructuringin_progressRestructuring Plan2017 [Member]USD 121,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-03-31restructuringin_progressRestructuring Plan From2014 To2017 [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-03-31restructuringin_progressResearch And Development Expense [Member] / Restructuring Plan From2014 To2017 [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-03-31restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan2017 [Member]USD 121,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-03-31restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan From2014 To2017 [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-12-31restructuringin_progress2014Nutritional, Established Pharmaceutical Products and Vascular businessesUSD 33 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year streamlining program with plans approved in 2014, 2015 and 2016; $33 million is the fiscal 2016 charge for employee-related severance and other charges (~$9M cost of products sold, ~$5M R&D, ~$19M SG&A). An additional ~$2 million of 2016 charges was primarily accelerated depreciation. Accrued balance of $66 million remained at December 31, 2016. Headcount affected not disclosed.
2016-12-31restructuringin_progress2012Various functional areas, including manufacturing operations (established pharmaceuticals) and commercial operations (diagnostics, established pharmaceuticals, nutritionals)USD 18 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year efficiency program; roll-forward table begins with 2012 charges and narrative cites plans approved 2013–2015 plus a 2012 commercial operations plan. $18 million is the fiscal 2016 employee severance charge (~$4M cost of products sold, ~$14M SG&A). Accrued balance of $16 million remained at December 31, 2016. Headcount affected not disclosed.
2016-12-31acquisition_additioncompleted2016-04-272017-01-04GlobalMedical devices (cardiovascular and neuromodulation); to be combined with Abbott's vascular businessUSD 24 (billions)subsequent_events
f5-10k / GLM-5.3-flash-HTML		St. Jude Medical acquisition completed January 4, 2017; value shown is total purchase consideration. Employees added not separately disclosed — filer reports ~94,000 employees post-acquisition versus ~75,000 at fiscal year-end 2016.
2016-12-31divestiture_reductionannounced2016-09-142017-03Abbott Medical Optics (AMO) — vision care businessUSD 4 (billions)MD&A
f5-10k / GLM-5.3-flash-HTML		Definitive agreement to sell AMO vision care businesses to Johnson & Johnson; value shown is agreed cash sale price. Expected to close in Q1 2017 (date shown is end of that quarter), subject to regulatory approvals. Employee headcount affected not disclosed; AMO results remained in continuing operations with assets/liabilities held for disposition at December 31, 2016.
2016-12-31restructuringin_progressGlobalNutritional, Established Pharmaceutical Products and Vascular businessesUSD 33 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2016 charges under plans approved in 2014-2016 to streamline operations; includes approximately $9M in cost of products sold, $5M in R&D and $19M in SG&A, plus about $2M of accelerated depreciation. Accrued balance was $66M at year-end 2016.
2016-12-31restructuringin_progressGlobalCorporate functions, established pharmaceuticals, diagnostics and nutritionalsUSD 18 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Current-year activity under multi-year cost-reduction plans approved 2012-2015; charges relate to 2016 only, not cumulative program totals. Accrued balance was $16M at year-end 2016.
2016-12-31acquisition_additioncompleted2016-04-272017-01-04GlobalCardiovascular and neuromodulation (medical devices)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		St. Jude Medical acquisition closed January 4, 2017 for approximately $23.6 billion; total employment rose from approximately 75,000 to approximately 94,000 as of January 31, 2017. Headcount added not separately quantified.
2016-12-31divestiture_reductionannounced2016-09-142017-03-31GlobalAbbott Medical Optics (vision care)Item_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Agreement to sell surgical cataract, vision correction and consumer eye health businesses to Johnson & Johnson for $4.325 billion in cash; expected to close in Q1 2017. Workforce impact not quantified.
2016-12-31otherin_progress2016-01-30United StatesDiagnostics (Alere Inc.)Item_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Pending acquisition of Alere at $56.00 per share; Abbott filed suit in Delaware Court of Chancery seeking termination. No workforce impact disclosed.
2016-12-31restructuringcompleted2016-01-012016-12-31GlobalVarious (Nutritional, Established Pharmaceuticals, Vascular)USD 33 (millions)MD&A - Restructurings
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Employee-related severance and other charges of approximately $33 million recorded in 2016 to streamline operations and improve efficiencies.
2016-12-31restructuringcompleted2012-01-012016-12-31GlobalVarious (Core Diagnostics, Established Pharmaceuticals, Nutritionals)USD 18 (millions)MD&A - Restructurings
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Employee-related severance charges of approximately $18 million recorded in 2016 under plans approved from 2012 to 2015 to reduce costs and improve efficiencies.
2016-12-31acquisition_additioncompleted19,0002017-01-042017-01-04GlobalSt. Jude MedicalItem 1. Business - Employees
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of St. Jude Medical completed January 4, 2017. Headcount increased from ~75,000 to ~94,000 (approx. 19,000 added). Disclosed as subsequent event in 2016 10-K.
2016-12-31restructuringcompleted2016GlobalNutritional, Established Pharmaceuticals, VascularUSD 33 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Employee-related severance and other charges of approx $33M recorded in 2016 to streamline operations. Headcount not disclosed.
2016-12-31restructuringcompleted2016GlobalVarious functional areasUSD 18 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Employee-related severance charges of approx $18M recorded in 2016 for plans approved 2013-2015. Headcount not disclosed.
2016-12-31restructuringin_progressRestructuring Plan20162015 And2014 [Member]USD 33,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressRestructuring Plan From2013 To2015 [Member]USD 18,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressCost Of Sales [Member] / Restructuring Plan20162015 And2014 [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressCost Of Sales [Member] / Restructuring Plan From2013 To2015 [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressResearch And Development Expense [Member] / Restructuring Plan20162015 And2014 [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan20162015 And2014 [Member]USD 19,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan From2013 To2015 [Member]USD 14,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-09-30restructuringin_progress2016-01-01Nutritional, Established Pharmaceutical and Vascular businessesUSD 23 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Nine-month 2016 charges of ~$23M for streamlining operations; ~$7M in cost of products sold and ~$16M in SG&A; plus ~$2M primarily for accelerated depreciation. Accrued balance $76M at Sept 30, 2016. No employee counts disclosed.
2016-09-30restructuringin_progress2013-01-01Various functional areasUSD 12 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plans approved 2013-2015 to reduce costs across functional areas; ~$12M of charges recognized in SG&A in first nine months of 2016. Accrued balance $35M at Sept 30, 2016.
2016-09-30restructuringin_progress2013-01-01Global manufacturing; pharmaceutical, vascular, core diagnostics and commercial/R&D operationsrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plans to streamline global manufacturing and other operations; no new charges in 2016, payments of ~$6M in first nine months; accrued balance $5M at Sept 30, 2016.
2016-09-30divestiture_reductionannounced2016-09-012017-03-31Abbott Medical Optics (vision care)other
f5-10q / GLM-5.3-flash-fp4-HTML		Sale of AMO to Johnson & Johnson for $4.325B cash announced September 2016; expected to close Q1 2017. No employee counts disclosed; assets/liabilities held for disposition.
2016-09-30restructuringin_progressGlobalNutritional, Established Pharmaceuticals and Vascular businessesUSD 23 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2016-2014 streamlining plans; nine-month 2016 charges of ~$23M (~$7M in cost of products sold, ~$16M in SG&A) plus ~$2M accelerated depreciation; accrual $76M at 2016-09-30. No employee counts disclosed.
2016-09-30restructuringin_progressGlobalCorporate and functional areasUSD 12 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2013-2015 cost-reduction plans; nine-month 2016 charges of ~$12M in SG&A; accrual $35M at 2016-09-30. No employee counts disclosed.
2016-09-30restructuringin_progressGlobalManufacturing, commercial and R&D operationsrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2013 and prior restructuring plans; no charges recorded in first nine months of 2016; remaining accrual $5M at 2016-09-30. No employee counts disclosed.
2016-09-30divestiture_reductionannounced2016-09-142017-03-31GlobalAbbott Medical Optics (vision care)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of AMO to Johnson & Johnson for $4.325B cash announced September 2016; expected to close Q1 2017. Headcount associated with the business not disclosed; AMO results remain in continuing operations.
2016-09-30acquisition_additionannounced2016-01-30GlobalDiagnostics (Alere Inc.)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pending acquisition at $56 per share (~$5.8B equity value); Alere shareholders approved 2016-10-21; FTC second request outstanding and Alere has filed suit against Abbott. Headcount to be added not disclosed.
2016-09-30acquisition_additionannounced2016-04-27GlobalVascular/cardiovascular devices (St. Jude Medical)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pending acquisition (~$24B equity value; $46.75 cash plus 0.8708 Abbott shares per St. Jude share); St. Jude shareholders approved 2016-10-26; certain products to be divested to Terumo for ~$1.12B. Headcount to be added not disclosed.
2016-09-30restructuringin_progressNutritional, Established Pharmaceuticals, VascularUSD 23 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges recognized in first nine months of 2016 for plans approved in 2016, 2015, and 2014 to streamline operations. Includes $7M in Cost of products sold and $16M in SG&A.
2016-09-30restructuringin_progressVarious functional areas, Established Pharmaceuticals, Core Diagnostics, NutritionalsUSD 12 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges recognized in first nine months of 2016 for plans approved from 2013 to 2015 to reduce costs and improve efficiencies. Recorded in SG&A.
2016-09-30restructuringin_progressPharmaceutical, Vascular, Core Diagnostics, Commercial, R&Drestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plans approved in 2013 and prior years. No new charges recorded in first nine months of 2016; only payments and adjustments of $6M.
2016-09-30restructuringin_progressRestructuring Plan2015 And2013 [Member]USD 12,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressRestructuring Plan2015 And2014 [Member]USD 23,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressCost Of Sales [Member] / Restructuring Plan20162015 And2014 [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan20162015 And2014 [Member]USD 16,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30restructuringin_progressNutritional, Established Pharmaceutical and Vascular businessesUSD 13 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2016-approved streamlining plans; ~$7M in cost of products sold and ~$6M in SG&A recognized in first six months of 2016, plus ~$2M primarily for accelerated depreciation. No employee counts disclosed.
2016-06-30restructuringin_progressVarious functional areasUSD 12 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Charges from 2013-2015 cost-reduction plans recognized in SG&A in first six months of 2016. No employee counts disclosed.
2016-06-30restructuringin_progressGlobalNutritional, Established Pharmaceutical Products and Vascular businessesUSD 13 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plans approved in 2014-2016 to streamline operations; $13M charged in first six months of 2016 ($7M in cost of products sold, $6M in SG&A), plus about $2M of accelerated depreciation. Accrual $88M at 2016-06-30. No employee count disclosed.
2016-06-30restructuringin_progressGlobalFunctional areas and established pharmaceuticals manufacturingUSD 12 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Programs approved 2012-2015 covering cost reduction across functional areas and manufacturing streamlining; $12M charged to SG&A in first six months of 2016. Accrual $54M at 2016-06-30. No employee count disclosed. MD&A reports combined employee-related severance of about $25M for 2016 across these initiatives.
2016-06-30acquisition_additionannounced2016-01-30GlobalDiagnostic Products (point-of-care diagnostics)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pending acquisition of Alere Inc. ($56 per share, ~$5.8B equity value); delayed by Alere's late 10-K and an FTC second request. Headcount to be added not disclosed.
2016-06-30acquisition_additionannounced2016-04-27GlobalVascular Products (cardiovascular devices)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pending acquisition of St. Jude Medical (~$25B equity value); FTC second request received 2016-07-11. Headcount to be added not disclosed.
2016-06-30restructuringin_progressNutritional, Established Pharmaceuticals, VascularUSD 13 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges recognized in first six months of 2016 for plans approved in 2016, 2015, and 2014 to streamline operations. Includes $7M in Cost of products sold and $6M in SG&A. Additional $2M recorded for accelerated depreciation.
2016-06-30restructuringin_progressVarious functional areas, Established Pharmaceuticals, Core Diagnostics, NutritionalsUSD 12 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges recognized in first six months of 2016 for plans approved from 2013 to 2015 to reduce costs and improve efficiencies. Recorded in Selling, general and administrative expense.
2016-06-30restructuringin_progressGlobalPharmaceutical, Vascular, Core Diagnostics, Commercial, R&Drestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plans approved in 2013 and prior years to streamline global manufacturing and commercial operations. No new charges recorded in first six months of 2016; payments and adjustments of $4M reduced accrual.
2016-06-30restructuringin_progressRestructuring Plan2015 And2013 [Member]USD 12,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30restructuringin_progressRestructuring Plan2015 And2014 [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30restructuringin_progressCost Of Sales [Member] / Restructuring Plan20162015 And2014 [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan20162015 And2014 [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-03-31restructuringin_progress2015-01-01Nutritional, Established Pharmaceutical and Vascular businessesUSD 7 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2016 charges of ~$7 million; ~$1 million in cost of products sold and ~$6 million in SG&A. Accrued balance $94 million at March 31, 2016. No employee counts disclosed.
2016-03-31restructuringin_progress2013-01-01Various functional areasUSD 9 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2016 charges of ~$9 million recognized in SG&A. Accrued balance $68 million at March 31, 2016. No employee counts disclosed.
2016-03-31restructuringin_progress2013-01-01Global manufacturing, pharmaceutical, vascular and core diagnostics operationsrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		No new charges in Q1 2016; payments and other adjustments of $2 million. Accrued balance $9 million at March 31, 2016. No employee counts disclosed.
2016-03-31restructuringin_progressGlobalNutritional, Established Pharmaceuticals, and Vascular businessesUSD 7 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2016 charges of ~$7M ($1M in cost of products sold, $6M in SG&A); severance accrual rolled from $100M to $94M. No employee counts disclosed.
2016-03-31restructuringin_progressGlobalFunctional areas (2013–2015 plans) and established pharmaceuticals manufacturing (2013 plan)USD 9 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2016 charges of ~$9M recorded in SG&A; severance accrual rolled from $88M to $68M. No employee counts disclosed.
2016-03-31restructuringin_progressGlobalPharmaceutical, vascular, diagnostics, commercial and R&D operations (2013 and prior plans)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		No new charges in Q1 2016; accrual rolled from $11M to $9M via payments. No employee counts disclosed.
2016-03-31acquisition_additionannounced2016-01-30GlobalDiagnostic Products (point of care diagnostics)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pending acquisition at $56/share (~$5.8B equity value); Alere has ~$2.5B annual sales. No headcount disclosed. FTC second request received 2016-05-02 extends HSR waiting period.
2016-03-31acquisition_additionannounced2016-04-27GlobalVascular Products (cardiovascular devices)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Post-quarter announcement; $46.75 cash + 0.8708 Abbott shares per St. Jude share (~$85/share, ~$25B equity value). No headcount disclosed.
2016-03-31divestiture_reductioncompleted2015-02-272015-02-27Developed marketsEstablished Pharmaceutical Products (branded generics) and animal healthother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Mylan and Zoetis divestitures completed in Q1 2015; residual Q1 2016 activity limited to $25M holdback proceeds with $16M after-tax gain. No headcount disclosed.
2016-03-31restructuringin_progressNutritional, Established Pharmaceuticals, VascularUSD 7 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges recognized in Q1 2016 for plans approved in 2015 and 2014 to streamline operations.
2016-03-31restructuringin_progressVarious functional areas, Established Pharmaceuticals, Core Diagnostics, NutritionalsUSD 9 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges recognized in Q1 2016 for plans approved from 2012 to 2015 to reduce costs and improve efficiencies.
2016-03-31restructuringin_progressRestructuring Plan2015 And2013 [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-03-31restructuringin_progressRestructuring Plan2015 And2014 [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-03-31restructuringin_progressCost Of Sales [Member] / Restructuring Plan2015 And2014 [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-03-31restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan2015 And2014 [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-12-31restructuringin_progress2014Nutritional Products, Established Pharmaceutical Products, and Vascular businessesUSD 95 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Streamlining plans approved in 2014 and 2015 to reduce costs across the nutritional, established pharmaceuticals and vascular businesses. Fiscal 2015 employee-related severance and other charges of approximately $95 million (COGS $18M, R&D $34M, SG&A $43M); an additional ~$45 million in 2015 was recorded primarily for accelerated depreciation. Accrued balance of $100 million remained at December 31, 2015. Affected-employee count not disclosed.
2015-12-31restructuringin_progress2012Functional areas, including commercial operations of core diagnostics, established pharmaceuticals and nutritionals; 2013 additions covering established pharmaceuticals manufacturing operationsUSD 66 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year program with plans approved from 2012 through 2015; figures captured are fiscal 2015 severance charges only (COGS $9M, R&D $2M, SG&A $55M). Accrued balance of $88 million at December 31, 2015. Affected-employee count not disclosed.
2015-12-31divestiture_reductioncompleted2014-072015-02-27Developed marketsEstablished Pharmaceutical Products — developed markets branded generics pharmaceuticals businessdiscontinued_operations_footnote
f5-10k / GLM-5.3-flash-HTML		Completed sale to Mylan Inc. for 110 million Mylan N.V. shares valued at $5.77 billion; pretax gain of $2.84 billion recognized in discontinued operations. Business transferred out of continuing operations; affected-employee count not disclosed.
2015-12-31divestiture_reductioncompleted2014-112015-02-10Animal health businessdiscontinued_operations_footnote
f5-10k / GLM-5.3-flash-HTML		Completed sale to Zoetis Inc. for cash proceeds of $230 million with an after-tax gain of approximately $130 million. Business transferred out of continuing operations; affected-employee count not disclosed.
2015-12-31acquisition_additioncompleted2015-082015-08Vascular — structural heart (minimally invasive mitral valve replacement therapies)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired the remaining equity of Tendyne Holdings for approximately $225 million in cash plus up to $150 million in contingent regulatory milestone payments. Headcount added through the acquisition not disclosed.
2015-12-31restructuringin_progressGlobalNutritional, Established Pharmaceutical Products and Vascular businessesUSD 95 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2015 activity under plans approved in 2014 and 2015 to streamline operations; $95M employee-related severance and other charges recorded in 2015, plus approximately $45M primarily for accelerated depreciation. Employees affected not disclosed.
2015-12-31restructuringin_progressGlobalVarious functional areas, established pharmaceuticals manufacturing, core diagnostics and nutritionals commercial operationsUSD 66 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2015 activity under multi-year plans approved in 2012 and 2013; $66M employee-related severance charges recorded in 2015, plus approximately $4M primarily for accelerated depreciation. Accrued balance at December 31, 2015 was $88M. Employees affected not disclosed.
2015-12-31divestiture_reductioncompleted2014-07-012015-02-27Developed marketsEstablished Pharmaceutical Products (developed markets branded generics pharmaceuticals)discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of developed markets branded generics pharmaceuticals business to Mylan Inc. completed February 27, 2015 for 110 million Mylan N.V. shares. Headcount removed not disclosed.
2015-12-31divestiture_reductioncompleted2014-11-012015-02-10GlobalAnimal health businessdiscontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of animal health business to Zoetis Inc. completed February 10, 2015 for $230 million cash proceeds. Headcount removed not disclosed.
2015-12-31acquisition_additioncompleted2015-08-31United StatesVascular Products (mitral valve replacement therapies)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of remaining equity of Tendyne Holdings, Inc. completed August 2015 for approximately $225 million cash plus up to $150 million contingent milestone payments. Headcount added not disclosed.
2015-12-31acquisition_additionannounced2016-01-30GlobalDiagnostic Products (point of care diagnostics)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire Alere Inc. at $56.00 per share ($5.8 billion equity value, $2.6 billion net debt assumed or refinanced), announced January 30, 2016, subject to Alere shareholder approval and regulatory approvals. Alere annual sales approximately $2.5 billion. Headcount added not disclosed.
2015-12-31restructuringin_progress2015-01-01GlobalVarious (Nutritional, Established Pharmaceuticals, Vascular)USD 95 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Approximately $95 million in employee-related severance and other charges recorded in 2015. Specific headcount not disclosed.
2015-12-31restructuringin_progress2015-01-01GlobalVarious (Core Diagnostics, Established Pharmaceuticals, Nutritionals)USD 66 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Approximately $66 million in employee-related severance charges recorded in 2015 for plans approved from 2012-2013. Specific headcount not disclosed.
2015-12-31divestiture_reductioncompleted2015-02-272015-02-27Developed MarketsEstablished Pharmaceutical Productsdiscontinued_operations_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Sale of developed markets branded generics pharmaceuticals business to Mylan Inc. Headcount removed not explicitly quantified.
2015-12-31divestiture_reductioncompleted2015-02-102015-02-10GlobalAnimal Healthdiscontinued_operations_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Sale of animal health business to Zoetis Inc. Headcount removed not explicitly quantified.
2015-12-31acquisition_additioncompleted2015-08-012015-08-01GlobalVascular ProductsUSD 225 (millions)business_combinations_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of Tendyne Holdings, Inc. Headcount added not explicitly quantified.
2015-12-31restructuringcompleted2015GlobalNutritional, Established Pharmaceuticals, VascularUSD 95 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Employee-related severance and other charges of approximately $95 million recorded in 2015 to streamline operations.
2015-12-31restructuringcompleted2015GlobalVarious functional areasUSD 66 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Employee-related severance charges of approximately $66 million recorded in 2015 for plans approved from 2012-2015 to reduce costs and improve efficiencies.
2015-12-31divestiture_reductioncompleted2015-02-272015-02-27Developed MarketsEstablished Pharmaceutical Productsdiscontinued_operations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Sale of developed markets branded generics pharmaceuticals business to Mylan Inc.
2015-12-31divestiture_reductioncompleted2015-02-102015-02-10GlobalAnimal Healthdiscontinued_operations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Sale of animal health business to Zoetis Inc.
2015-12-31acquisition_additioncompleted2015-08GlobalVascular ProductsUSD 225 (millions)business_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of remaining equity of Tendyne Holdings, Inc. for approximately $225 million in cash.
2015-12-31restructuringin_progressRestructuring Plan2015 And2014 [Member]USD 95,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-12-31restructuringin_progressRestructuring Plan From2013 To2015 [Member]USD 66,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-12-31restructuringin_progressCost Of Sales [Member] / Restructuring Plan2015 And2014 [Member]USD 18,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-12-31restructuringin_progressCost Of Sales [Member] / Restructuring Plan From2013 To2015 [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-12-31restructuringin_progressResearch And Development Expense [Member] / Restructuring Plan2015 And2014 [Member]USD 34,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-12-31restructuringin_progressResearch And Development Expense [Member] / Restructuring Plan From2013 To2015 [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-12-31restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan2015 And2014 [Member]USD 43,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-12-31restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan From2013 To2015 [Member]USD 55,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-09-30restructuringin_progress2015-01-01Nutritional, Established Pharmaceutical and Vascular businessesUSD 80 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2015-approved streamlining plans; nine-month charges of ~$80M plus ~$34M primarily for accelerated depreciation; severance accrual of $120M at Sept 30, 2015. No employee counts disclosed.
2015-09-30restructuringin_progress2013-01-01Various functional areasUSD 38 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2013-2015 approved plans to reduce costs across functional areas; nine-month 2015 charges of ~$38M; accrual of $109M at Sept 30, 2015.
2015-09-30restructuringin_progress2013-01-01Vascular manufacturing and core diagnosticsrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2013 and prior plans to realign vascular manufacturing operations and core diagnostics business; no new 2015 charges; accrual of $30M at Sept 30, 2015.
2015-09-30divestiture_reductioncompleted2015-02-272015-02-27Developed marketsEstablished Pharmaceutical Products (developed markets branded generics)other
f5-10q / GLM-5.3-flash-fp4-HTML		Sale of developed markets branded generics pharmaceuticals business to Mylan N.V.; headcount transferred not disclosed.
2015-09-30divestiture_reductioncompleted2015-02-102015-02-10Animal health businessother
f5-10q / GLM-5.3-flash-fp4-HTML		Sale of animal health business to Zoetis Inc. for $230 million cash; headcount transferred not disclosed.
2015-09-30restructuringin_progressGlobalNutritional, Established Pharmaceutical Products, and Vascular businessesUSD 80 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2015-2014 approved streamlining plans; ~$80M charges in first nine months of 2015 plus ~$34M accelerated depreciation. Severance accrual $120M at 2015-09-30. No employee counts disclosed.
2015-09-30restructuringin_progressGlobalCross-functional areas (2013-2015 plans)USD 38 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cost-reduction plans across functional areas; $38M charges in first nine months of 2015; accrual $109M at 2015-09-30. No employee counts disclosed.
2015-09-30restructuringin_progressGlobalVascular manufacturing and core diagnostics (2013 and prior plans)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Legacy plans; no new charges in 2015, accrual $30M at 2015-09-30 after $9M payments. No employee counts disclosed.
2015-09-30divestiture_reductioncompleted2015-02-272015-02-27Developed marketsEstablished Pharmaceutical Products — developed markets branded generics business (sold to Mylan)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale completed 2015-02-27 for 110 million Mylan N.V. shares; after-tax gain ~$1.6B. No headcount transferred disclosed.
2015-09-30divestiture_reductioncompleted2015-02-102015-02-10GlobalAnimal health business (sold to Zoetis)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale completed 2015-02-10 for $230M cash; after-tax gain ~$130M. No headcount transferred disclosed.
2015-09-30acquisition_additioncompleted2015-08-012015-08-31United StatesVascular Products — structural heart (Tendyne Holdings)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired remaining Tendyne equity for ~$225M cash plus up to $135M milestone payments; completed August 2015. No headcount added disclosed.
2015-09-30restructuringin_progressVarious (Nutritional, Established Pharmaceuticals, Vascular)USD 80 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges recognized in first nine months of 2015 to streamline operations and reduce costs. Employee count not disclosed.
2015-09-30restructuringin_progressVarious functional areasUSD 38 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges recognized in first nine months of 2015 for plans approved from 2013 to 2015 to reduce costs and improve efficiencies. Employee count not disclosed.
2015-09-30divestiture_reductioncompleted2015-02-272015-02-27Established Pharmaceutical Productsbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Sale of developed markets branded generics pharmaceuticals business to Mylan Inc. Employee count not disclosed.
2015-09-30divestiture_reductioncompleted2015-02-102015-02-10Animal Healthbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Sale of animal health business to Zoetis Inc. Employee count not disclosed.
2015-09-30acquisition_additioncompleted2015-08-31Vascular Productsbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of remaining equity of Tendyne Holdings, Inc. Employee count not disclosed.
2015-09-30restructuringin_progressRestructuring Plan2015 And2013 [Member]USD 38,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-30restructuringin_progressRestructuring Plan2015 And2014 [Member]USD 80,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-30restructuringin_progressCost Of Sales [Member] / Restructuring Plan2015 And2013 [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-30restructuringin_progressCost Of Sales [Member] / Restructuring Plan2015 And2014 [Member]USD 25,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-30restructuringin_progressResearch And Development Expense [Member] / Restructuring Plan2015 And2013 [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-30restructuringin_progressResearch And Development Expense [Member] / Restructuring Plan2015 And2014 [Member]USD 38,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-30restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan2015 And2013 [Member]USD 27,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-30restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan2015 And2014 [Member]USD 17,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-30restructuringin_progress2014-01-01Nutritional and Established Pharmaceutical Products businessesUSD 19 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		First six months 2015 charges of ~$19M for employee severance and other costs; ~$1M in cost of products sold, ~$18M in SG&A. Additional ~$25M recorded primarily for accelerated depreciation. Accrued severance balance $93M at June 30, 2015. No employee counts disclosed.
2015-06-30restructuringin_progress2013-01-01Various functional areasUSD 25 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		First six months 2015 charges of ~$25M: ~$9M cost of products sold, ~$2M R&D, ~$14M SG&A. Accrued balance $118M at June 30, 2015. No employee counts disclosed.
2015-06-30divestiture_reductioncompleted2015-02-272015-02-27Developed marketsEstablished Pharmaceutical Products (developed markets branded generics)other
f5-10q / GLM-5.3-flash-fp4-HTML		Sale of developed markets branded generics pharmaceuticals business to Mylan N.V. completed February 27, 2015; headcount transferred not disclosed. Animal health business sold to Zoetis on February 10, 2015 for $230M cash.
2015-06-30restructuringin_progress2014-01-01GlobalNutritional and Established Pharmaceutical ProductsUSD 19 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		First-half 2015 charges of ~$19M ($1M in COGS, $18M in SG&A) plus ~$25M accelerated depreciation; severance accrual rolled from $118M to $93M. No employee counts disclosed.
2015-06-30restructuringin_progress2013-01-01GlobalFunctional areas (2013–2015 cost-reduction plans)USD 25 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		First-half 2015 charges of ~$25M ($9M COGS, $2M R&D, $14M SG&A); accrual rolled from $135M to $118M. No employee counts disclosed.
2015-06-30restructuringin_progress2013-01-01GlobalVascular manufacturing and core diagnosticsrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		No charges recorded in first half of 2015; accrual rolled from $39M to $32M via payments. No employee counts disclosed.
2015-06-30divestiture_reductioncompleted2015-02-272015-02-27Developed marketsEstablished Pharmaceutical Products — developed markets branded genericsother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale to Mylan N.V. completed 2015-02-27; after-tax gain ~$1.6B. No headcount transferred disclosed.
2015-06-30divestiture_reductioncompleted2015-02-102015-02-10GlobalAnimal health businessother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale to Zoetis Inc. completed 2015-02-10; cash proceeds $230M, after-tax gain ~$130M. No headcount transferred disclosed.
2015-06-30acquisition_additioncompleted2014-09-262014-09-26Latin AmericaEstablished Pharmaceutical ProductsUSD 3,400 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Controlling interest acquired for ~$2.9B cash; total cost $3.4B including assumed debt. No headcount added disclosed.
2015-06-30acquisition_additioncompleted2014-12-012014-12-01RussiaEstablished Pharmaceutical ProductsUSD 415 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired control of Veropharm for ~$315M plus assumed debt; total value ~$415M. No headcount added disclosed.
2015-06-30acquisition_additioncompleted2014-12-012014-12-01United StatesVascular Products — ElectrophysiologyUSD 250 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired for ~$250M cash plus up to $300M milestone payments. No headcount added disclosed.
2015-06-30restructuringin_progressNutritional and Established PharmaceuticalsUSD 19 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges recognized in first six months of 2015 for plans approved in 2014 to streamline operations.
2015-06-30restructuringin_progressVarious functional areasUSD 25 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges recognized in first six months of 2015 for plans approved from 2013 to 2015 to reduce costs and improve efficiencies.
2015-06-30restructuringin_progressVascular manufacturing and Core diagnosticsrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plans approved in 2013 and prior years to realign operations. No new charges recorded in first six months of 2015; payments and adjustments of $7 million reduced accrual.
2015-06-30restructuringin_progressRestructuring Plan2014 [Member]USD 19,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-30restructuringin_progressRestructuring Plan2015 [Member]USD 25,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-30restructuringin_progressResearch And Development Expense [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-30restructuringin_progressCost Of Sales [Member] / Restructuring Plan2014 [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-30restructuringin_progressCost Of Sales [Member] / Restructuring Plan2015 [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-30restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan2014 [Member]USD 18,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-30restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan2015 [Member]USD 14,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-31restructuringin_progress2014-01-01Nutritional and Established Pharmaceutical Products businessesUSD 13 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2014-approved plan to streamline operations; Q1 2015 charges primarily for accelerated depreciation. Accrued balance $118M at Dec 31, 2014, $103M at Mar 31, 2015 after $15M payments.
2015-03-31restructuringin_progress2013-01-01Various functional areasUSD 8 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2015 charges of ~$8M: ~$1M in cost of products sold, ~$7M in SG&A. Accrued balance $135M at Dec 31, 2014, $109M at Mar 31, 2015.
2015-03-31restructuringin_progress2013-01-01Vascular manufacturing operations and core diagnostics businessrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plans to realign vascular manufacturing and core diagnostics to reduce costs. Accrued balance $39M at Dec 31, 2014, $33M at Mar 31, 2015 after $6M payments.
2015-03-31divestiture_reductioncompleted2015-02-272015-02-27Developed marketsEstablished Pharmaceutical ProductsUSD 1,737 (millions)other
f5-10q / GLM-5.3-flash-fp4-HTML		Sale of developed markets branded generics pharmaceuticals business to Mylan for 110 million Mylan N.V. shares valued at $5.77B; after-tax gain ~$1.6B (pretax gain $2.821B). Headcount transferred not disclosed.
2015-03-31divestiture_reductioncompleted2015-02-102015-02-10Animal health businessUSD 131 (millions)other
f5-10q / GLM-5.3-flash-fp4-HTML		Sale of animal health business to Zoetis Inc. for cash proceeds of $230 million; after-tax gain ~$131 million. Headcount transferred not disclosed.
2015-03-31acquisition_additioncompleted2014-09-262014-09-26Latin AmericaEstablished Pharmaceutical ProductsUSD 2,900 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of controlling interest in CFR Pharmaceuticals S.A. for ~$2.9B cash; headcount added not disclosed.
2015-03-31acquisition_additioncompleted2014-12-012014-12-01RussiaEstablished Pharmaceutical ProductsUSD 315 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of control of Veropharm for ~$315M excluding assumed debt; headcount added not disclosed.
2015-03-31restructuringin_progress2014-01-01Nutritional and Established Pharmaceutical Products businessesUSD 13 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2014-approved streamlining plan; Q1 2015 charges primarily accelerated depreciation. Accrual fell from $118M to $103M. No employee counts disclosed.
2015-03-31restructuringin_progress2013-01-01Various functional areasUSD 8 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2013-2015 cost-reduction plans; Q1 2015 charges of $8M ($1M in COGS, $7M in SG&A), severance-related. Accrual $135M to $109M. No employee counts disclosed.
2015-03-31restructuringin_progress2013-01-01Vascular manufacturing and core diagnosticsrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2013 and prior-year plans; no Q1 2015 charges, accrual $39M to $33M. No employee counts disclosed.
2015-03-31divestiture_reductioncompleted2015-02-272015-02-27Developed marketsEstablished Pharmaceutical Products (branded generics)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of developed markets branded generics business to Mylan; 110M Mylan N.V. shares received, after-tax gain ~$1.6B. Headcount impact not disclosed.
2015-03-31divestiture_reductioncompleted2015-02-102015-02-10Animal health businessother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of animal health business to Zoetis for $230M cash; after-tax gain ~$131M. Headcount impact not disclosed.
2015-03-31acquisition_additioncompleted2014-09-262014-09-26Latin AmericaEstablished Pharmaceutical Productsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		CFR Pharmaceuticals acquisition (~$2.9B); included for context as ongoing integration. Headcount added not disclosed.
2015-03-31acquisition_additioncompleted2014-12-012014-12-01RussiaEstablished Pharmaceutical Productsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Veropharm acquisition (~$315M). Headcount added not disclosed.
2015-03-31acquisition_additioncompleted2014-12-012014-12-01United StatesVascular Products (Electrophysiology)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Topera, Inc. acquisition (~$250M plus up to $300M milestones). Headcount added not disclosed.
2015-03-31restructuringin_progressVarious functional areasUSD 8 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges of approximately $8 million recognized in Q1 2015 for plans approved 2013-2015 to reduce costs and improve efficiencies. Includes $1 million in Cost of products sold and $7 million in SG&A. Employee count not disclosed.
2015-03-31restructuringin_progressNutritional and Established PharmaceuticalsUSD 13 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Additional charges of approximately $13 million recorded primarily for accelerated depreciation related to 2014 plans to streamline operations. Employee count not disclosed.
2015-03-31divestiture_reductioncompleted2015-02-272015-02-27Developed MarketsEstablished Pharmaceutical Productsbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Sale of developed markets branded generics pharmaceuticals business to Mylan Inc. Employee count not disclosed.
2015-03-31divestiture_reductioncompleted2015-02-102015-02-10Animal Healthbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Sale of animal health business to Zoetis Inc. Employee count not disclosed.
2015-03-31restructuringin_progressRestructuring Plan2014 [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-31restructuringin_progressRestructuring Plan2015 [Member]USD 8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-31restructuringin_progressCost Of Sales [Member] / Restructuring Plan2015 [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-31restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan2015 [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-12-31restructuringin_progress2014Nutritional Products and Established Pharmaceutical Products businessesUSD 164 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		2014-approved plans to streamline operations and improve efficiencies; charges split roughly $20M cost of products sold, $53M R&D, $91M SG&A; an additional ~$39M was recorded primarily for accelerated depreciation; accrued balance of $118M remained at December 31, 2014. Headcount affected not disclosed.
2014-12-31restructuringin_progress2014Various functional areas; Established Pharmaceuticals manufacturing operationsUSD 125 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year program approved in 2013 and 2014; the $125M represents severance charges recorded in fiscal 2014 only (prior-year charges of $78M in 2013 and $167M in 2012 excluded); accrued balance of $135M at December 31, 2014. Headcount affected not disclosed.
2014-12-31divestiture_reductioncompleted2014-072015-02-27Developed marketsEstablished Pharmaceutical Products (developed markets branded generics business)discontinued_operations_footnote
f5-10k / GLM-5.3-flash-HTML		Sale to Mylan Inc. in exchange for 110 million shares of a newly formed public entity; business reported as discontinued operations/held for sale at December 31, 2014; transaction closed on the filing date, February 27, 2015. Headcount transferring to Mylan not disclosed.
2014-12-31divestiture_reductioncompleted2014-112015-02-10Animal health businessdiscontinued_operations_footnote
f5-10k / GLM-5.3-flash-HTML		Agreement entered November 2014 to sell the animal health business to Zoetis Inc.; closed February 10, 2015; business reported within discontinued operations at year-end. Headcount not disclosed.
2014-12-31acquisition_additioncompleted2014-09-26Latin AmericaEstablished Pharmaceutical Productsbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired approximately 99.9% of CFR Pharmaceuticals S.A. for ~$2.9B in cash (~$3.4B total including ~$570M assumed debt); consideration not a workforce charge. Headcount added not disclosed.
2014-12-31acquisition_additioncompleted2014-12RussiaEstablished Pharmaceutical Productsbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired control of Veropharm (via holding company Garden Hills) for ~$315M excluding assumed debt; ~$410M total value including ~$90M of debt. Headcount added not disclosed.
2014-12-31acquisition_additioncompleted2014-12Electrophysiologybusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired Topera, Inc. for ~$250M cash plus up to $300M in contingent milestone payments; provides entry into the electrophysiology market. Headcount added not disclosed.
2014-12-31restructuringin_progressNutritional Products; Established Pharmaceutical ProductsUSD 164 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2014 charges for a program approved in 2014 to streamline operations and reduce costs; employee-related severance and other charges of ~$164M plus ~$39M of additional charges primarily for accelerated depreciation; headcount affected not disclosed; accrued balance of $118M at 2014-12-31
2014-12-31restructuringin_progressCorporate functions; Established Pharmaceutical ProductsUSD 125 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2014 activity under programs approved in 2012-2014 to reduce costs across functional areas and streamline manufacturing in established pharmaceuticals; severance charges of ~$125M plus ~$4M of additional charges primarily for accelerated depreciation; headcount affected not disclosed; accrued balance of $135M at 2014-12-31
2014-12-31acquisition_additioncompleted2014-09-26Latin AmericaEstablished Pharmaceutical Productsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of ~99.9% of CFR Pharmaceuticals S.A. for ~$2.9B cash (~$3.4B including assumed debt); annualized net sales expected ~$800M; acquired headcount not disclosed
2014-12-31acquisition_additioncompleted2014-12-12RussiaEstablished Pharmaceutical Productsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of control of Veropharm via LLC Garden Hills for ~$315M excluding assumed debt (~$410M total value); acquired headcount not disclosed
2014-12-31acquisition_additioncompletedNon-reportable segment (electrophysiology entry)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Topera, Inc. completed December 2014 for ~$250M cash plus up to $300M contingent milestone payments; exact announcement/completion date and acquired headcount not disclosed
2014-12-31divestiture_reductioncompleted2014-072015-02-27Developed marketsEstablished Pharmaceutical Products (developed markets branded generics)discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of developed markets branded generics business to Mylan Inc. for 110 million Mylan N.V. shares; announced July 2014, closed 2015-02-27 (subsequent to fiscal year-end); headcount removed not disclosed; business reported as discontinued operations for full-year 2014
2014-12-31divestiture_reductioncompleted2014-112015-02-10Animal health businessdiscontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Agreement announced November 2014 to sell animal health business to Zoetis Inc.; closed 2015-02-10 (subsequent to fiscal year-end); headcount removed not disclosed; reported within discontinued operations
2014-12-31restructuringcompleted2014GlobalVarious (Nutritional, Established Pharmaceuticals)USD 164 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Plans to streamline operations in nutritional and established pharmaceuticals businesses. Employee-related severance and other charges of approximately $164 million recorded in 2014. No specific employee count disclosed.
2014-12-31restructuringcompleted2014GlobalVarious (Functional areas, Manufacturing)USD 125 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Plans to reduce costs and improve efficiencies across functional areas and streamline manufacturing operations in established pharmaceuticals. Employee-related severance charges of approximately $125 million recorded in 2014. No specific employee count disclosed.
2014-12-31acquisition_additioncompleted2014-09-26Latin AmericaEstablished Pharmaceutical ProductsUSD 2,900 (millions)Item 1. Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of approximately 99.9% of CFR Pharmaceuticals, S.A. for approximately $2.9 billion in cash. No specific employee count disclosed.
2014-12-31acquisition_additioncompleted2014-12RussiaEstablished Pharmaceutical ProductsUSD 315 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of control of Veropharm, a leading Russian pharmaceutical company, for approximately $315 million excluding assumed debt. No specific employee count disclosed.
2014-12-31acquisition_additioncompleted2014-12GlobalVascular Products / ElectrophysiologyUSD 250 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of Topera, Inc. for approximately $250 million in cash plus additional payments up to $300 million. No specific employee count disclosed.
2014-12-31restructuringin_progress2014GlobalNutritional and Established PharmaceuticalsUSD 164 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Plans to streamline operations in nutritional and established pharmaceuticals businesses. Employee related severance and other charges of approximately $164 million recorded in 2014. Employee count not disclosed.
2014-12-31restructuringin_progress2014GlobalVarious functional areas and Established Pharmaceuticals manufacturingUSD 125 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Plans to reduce costs and improve efficiencies across various functional areas and streamline manufacturing in established pharmaceuticals. Employee related severance charges of approximately $125 million recorded in 2014. Employee count not disclosed.
2014-12-31restructuringin_progress2013GlobalPharmaceutical and Vascular manufacturing, Commercial and R&DUSD 11 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Plans to realign worldwide pharmaceutical and vascular manufacturing and selected commercial/R&D operations. Employee severance charges of approximately $11 million recorded in 2014 (program initiated in 2013). Employee count not disclosed.
2014-12-31restructuringin_progress2011GlobalCore Diagnosticrestructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Plans to streamline global manufacturing operations and improve efficiencies in core diagnostic business. Accrued balance of $21 million at Dec 31, 2014. No specific 2014 charge or employee count disclosed for this program in the current year.
2014-12-31restructuringin_progressRestructuring Plan2014 And2013 [Member]USD 125,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progressCost Of Sales [Member] / Restructuring Plan2014 And2013 [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progressCost Of Sales [Member] / Restructuring Plan2014 [Member]USD 20,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progressResearch And Development Expense [Member] / Restructuring Plan2014 And2013 [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progressResearch And Development Expense [Member] / Restructuring Plan2014 [Member]USD 53,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan2014 [Member]USD 91,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-09-30restructuringin_progress2014-01-01Vascular, Diagnostics and Nutritional businessesUSD 107 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2014-approved plans to streamline operations; charges split approximately $17M cost of products sold, $41M R&D, $49M SG&A; accrued balance $73M at September 30, 2014. Employee counts not disclosed.
2014-09-30restructuringin_progress2014-01-01Various functional areas and Established Pharmaceuticals businessUSD 120 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2014/2013-approved plans to reduce costs across functional areas; charges split approximately $7M cost of products sold, $2M R&D, $111M SG&A; accrued balance $186M at September 30, 2014. Employee counts not disclosed.
2014-09-30divestiture_reductionannounced2014-07-142015-03-31Developed marketsEstablished Pharmaceutical Products (developed markets branded generics)other
f5-10q / GLM-5.3-flash-fp4-HTML		Sale of developed markets branded generics pharmaceuticals business to Mylan Inc. for equity in a combined publicly traded entity; expected to close in Q1 2015. Headcount affected not disclosed.
2014-09-30acquisition_additioncompleted2014-09-262014-09-26Latin AmericaEstablished Pharmaceutical ProductsUSD 3 (billions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquired controlling interest in CFR Pharmaceuticals S.A. for approximately $2.9 billion cash ($3.4 billion total including assumed debt); headcount added not disclosed.
2014-09-30acquisition_additionannounced2014-06-302014-12-31RussiaEstablished Pharmaceutical Productsother
f5-10q / GLM-5.3-flash-fp4-HTML		Definitive agreement to acquire Verophym holding company Garden Hills for 13.6-17 billion rubles plus assumption of 4.7 billion rubles net debt; expected close Q4 2014. Headcount not disclosed.
2014-09-30restructuringin_progressNot specifiedVascular, Diagnostic Products, and Nutritional Products segmentsUSD 107 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2014 approved plans to streamline operations; charges comprise $17M in cost of products sold, $41M in R&D, $49M in SG&A; $34M paid through 2014-09-30, leaving $73M accrued. No employee counts disclosed.
2014-09-30restructuringin_progressNot specifiedVarious functional areas and Established Pharmaceutical ProductsUSD 120 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plans approved in 2014 and 2013; 2014 charges comprise $7M in cost of products sold, $2M in R&D, $111M in SG&A; accrual grew from $148M at 2013-12-31 to $186M at 2014-09-30. No employee counts disclosed.
2014-09-30restructuringin_progressNot specifiedVascular manufacturing operationsrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program approved in 2013 and prior years to realign vascular manufacturing; $2M of payments in 2014, accrual of $18M at 2014-09-30. No new charges or employee counts disclosed.
2014-09-30restructuringin_progressGlobalDiagnostic Products manufacturing and operationsrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Programs approved in 2011 and 2008 to streamline global manufacturing and core diagnostics; $17M of payments in 2014, accrual of $24M at 2014-09-30. No new charges or employee counts disclosed.
2014-09-30acquisition_additioncompletedLatin AmericaEstablished Pharmaceutical Productsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Controlling interest (99.9%) in CFR Pharmaceuticals S.A. acquired 2014-09-26 for ~$2.9B cash ($3.4B including ~$570M assumed debt); annualized net sales ~$800M. No headcount added disclosed.
2014-09-30divestiture_reductionannounced2014-07-142015-03-31Developed marketsEstablished Pharmaceutical Products (branded generics pharmaceuticals business)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement to sell developed markets branded generics business to Mylan Inc. for equity in a new public entity; expected to close Q1 2015 subject to regulatory approvals. Business reported as discontinued operations; no headcount reduction disclosed.
2014-09-30restructuringin_progress2014-01-01GlobalVascular, Diagnostics, NutritionalUSD 107 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges recorded in first nine months of 2014 to streamline operations in vascular, diagnostics, and nutritional businesses. Employee count not disclosed.
2014-09-30restructuringin_progress2014-01-01GlobalVarious functional areas, Established PharmaceuticalsUSD 120 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges recorded in 2014 to reduce costs and improve efficiencies across various functional areas and established pharmaceuticals business. Employee count not disclosed.
2014-09-30restructuringin_progress2013-01-01GlobalVascular Manufacturingrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plans approved in 2013 to realign vascular manufacturing operations. Accrual balance decreased by $2 million in first nine months of 2014. Employee count not disclosed.
2014-09-30restructuringin_progress2011-01-01GlobalCore Diagnosticsrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plans approved in 2011 and 2008 to streamline global manufacturing operations in core diagnostics. Accrual balance decreased by $17 million in first nine months of 2014. Employee count not disclosed.
2014-09-30restructuringin_progressRestructuring Plan2014 And2013 [Member]USD 120,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-30restructuringin_progressRestructuring Plan2014 [Member]USD 107,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-30restructuringin_progressCost Of Sales [Member] / Restructuring Plan2014 And2013 [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-30restructuringin_progressCost Of Sales [Member] / Restructuring Plan2014 [Member]USD 17,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-30restructuringin_progressResearch And Development Expense [Member] / Restructuring Plan2014 And2013 [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-30restructuringin_progressResearch And Development Expense [Member] / Restructuring Plan2014 [Member]USD 41,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-30restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan2014 And2013 [Member]USD 111,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-30restructuringin_progressSelling General And Administrative Expenses [Member] / Restructuring Plan2014 [Member]USD 49,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-30restructuringin_progress2014-01-01Vascular, Diagnostics and Nutritional businessesUSD 80 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Employee severance and other charges approved in first six months of 2014 to streamline operations; $17M in cost of products sold, $41M in R&D, $22M in SG&A; accrued balance $60M at June 30, 2014. No employee count disclosed.
2014-06-30restructuringin_progress2014-01-01Various functional areasUSD 76 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Charges to reduce costs and improve efficiencies across functional areas; ~$2M in cost of products sold, ~$74M in SG&A; accrued balance $182M at June 30, 2014. No employee count disclosed.
2014-06-30divestiture_reductionannounced2014-07-142015-03-31Developed marketsEstablished Pharmaceutical Products (developed markets branded generics)subsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Sale of developed markets branded generics business to Mylan valued at ~$5.3 billion; business generated ~$2 billion in 2013 sales. No headcount impact disclosed.
2014-06-30restructuringin_progressGlobalVascular Products; Diagnostic Products; Nutritional ProductsUSD 80 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		First six months of 2014 severance and other charges for streamlining operations; split $17M cost of products sold, $41M R&D, $22M SG&A. No employee counts or completion dates disclosed. Accrued balance $60M at 2014-06-30.
2014-06-30restructuringin_progressGlobalVarious functional areasUSD 76 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Charges under 2014 and 2013 plans to reduce costs across functional areas; $2M in cost of products sold, $74M in SG&A. No employee counts disclosed. Accrued balance $182M at 2014-06-30.
2014-06-30divestiture_reductionannounced2014-07-142015-03-31Developed marketsEstablished Pharmaceutical Products (branded generics)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement to sell developed markets branded generics business to Mylan for equity valued ~$5.3B; business had ~$2B 2013 sales. No headcount disclosed; to be reported as discontinued operations from Q3 2014.
2014-06-30acquisition_additionannounced2014-09-30Latin AmericaEstablished Pharmaceutical Productsother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire CFR Pharmaceuticals; ~$2.9B purchase price plus ~$430M net debt assumed. No headcount disclosed.
2014-06-30acquisition_additionannounced2014-12-31RussiaEstablished Pharmaceutical Productsother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement to acquire Veropharm (via Garden Hills) for 13.6–17B rubles (~$395M–$495M) plus ~$136M net debt. No headcount disclosed.
2014-06-30restructuringin_progress2014-01-01GlobalVascular, Diagnostics, NutritionalUSD 80 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plans approved in first six months of 2014 to streamline operations in vascular, diagnostics, and nutritional businesses. Employee-related severance and other charges of $80 million recorded. Employee count not disclosed.
2014-06-30restructuringin_progress2014-01-01GlobalVarious functional areasUSD 76 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plans approved in 2014 to reduce costs and improve efficiencies across various functional areas. Additional charges of $76 million recognized in 2014. Employee count not disclosed.
2014-06-30restructuringin_progressThe entity's 2014 and 2013 restructuring plan to streamline global manufacturing and commercial operations in order to reduce costs and improve efficiencies in entity's core diagnostics, established pharmaceutical and nutritionals businesses.USD 76,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-30restructuringin_progressThe entity's 2014 restructuring plans to streamline various commercial operations in order to reduce costs and improve efficiencies in the entity's core diagnostics, established pharmaceuticals and nutritionals businesses. / Research and Development Expense [Member]USD 41,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-30restructuringin_progressThe entity's 2014 restructuring plans to streamline various commercial operations in order to reduce costs and improve efficiencies in the entity's core diagnostics, established pharmaceuticals and nutritionals businesses. / Selling, General and Administrative Expenses [Member]USD 22,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-30restructuringin_progressThe entity's 2014 restructuring plans to streamline various commercial operations in order to reduce costs and improve efficiencies in the entity's core diagnostics, established pharmaceuticals and nutritionals businesses. / Cost of Sales [Member]USD 17,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-30restructuringin_progressThe entity's 2014 and 2013 restructuring plan to streamline global manufacturing and commercial operations in order to reduce costs and improve efficiencies in entity's core diagnostics, established pharmaceutical and nutritionals businesses. / Selling, General and Administrative Expenses [Member]USD 74,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-30restructuringin_progressThe entity's 2014 and 2013 restructuring plan to streamline global manufacturing and commercial operations in order to reduce costs and improve efficiencies in entity's core diagnostics, established pharmaceutical and nutritionals businesses. / Cost of Sales [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-30restructuringin_progressThe entity's 2014 restructuring plans to streamline various commercial operations in order to reduce costs and improve efficiencies in the entity's core diagnostics, established pharmaceuticals and nutritionals businesses.USD 80,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-31restructuringin_progress2014-01-01Vascular, Diagnostics, and Nutritional businessesUSD 80 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2014 plan to streamline operations and improve efficiencies; charges split across Cost of products sold ($17M), R&D ($41M), and SG&A ($22M); accrued balance of $76M at March 31, 2014
2014-03-31restructuringin_progress2014-01-01Various functional areasUSD 25 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2014 plan to reduce costs across functional areas; approximately $2M in Cost of products sold and $23M in SG&A; accrued balance of $145M at March 31, 2014 including prior-year accrual
2014-03-31restructuringin_progressVascular, Diagnostic Products, and Nutritional Products businessesUSD 80 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2014 severance and other charges for streamlining operations; allocated $17M to cost of products sold, $41M to R&D, $22M to SG&A. No employee counts or completion dates disclosed. Accrual $76M at 2014-03-31 after $4M payments.
2014-03-31restructuringin_progressVarious functional areasUSD 25 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Additional 2014 charges under plans approved in 2014 and prior years to reduce costs across functional areas; $2M in cost of products sold, $23M in SG&A. No employee counts disclosed. Accrual $145M at 2014-03-31.
2014-03-31restructuringin_progress2014-03-31GlobalVascular, Diagnostics, NutritionalUSD 80 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plans approved in Q1 2014 to streamline operations in vascular, diagnostics, and nutritional businesses. Charge includes employee-related severance and other charges. Employee count not disclosed.
2014-03-31restructuringin_progress2014-03-31GlobalVarious functional areasUSD 25 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plans approved in Q1 2014 to reduce costs and improve efficiencies across various functional areas. Employee count not disclosed.
2014-03-31restructuringin_progressThe entity's 2014 and 2013 restructuring plan to streamline global manufacturing and commercial operations in order to reduce costs and improve efficiencies in entity's core diagnostics, established pharmaceutical and nutritionals businesses.USD 25,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-31restructuringin_progressThe entity's 2014 restructuring plans to streamline various commercial operations in order to reduce costs and improve efficiencies in the entity's core diagnostics, established pharmaceuticals and nutritionals businesses. / Research and Development Expense [Member]USD 41,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-31restructuringin_progressThe entity's 2014 restructuring plans to streamline various commercial operations in order to reduce costs and improve efficiencies in the entity's core diagnostics, established pharmaceuticals and nutritionals businesses. / Selling, General and Administrative Expenses [Member]USD 22,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-31restructuringin_progressThe entity's 2014 restructuring plans to streamline various commercial operations in order to reduce costs and improve efficiencies in the entity's core diagnostics, established pharmaceuticals and nutritionals businesses. / Cost of Sales [Member]USD 17,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-31restructuringin_progressThe entity's 2014 restructuring plans to streamline various commercial operations in order to reduce costs and improve efficiencies in the entity's core diagnostics, established pharmaceuticals and nutritionals businesses.USD 80,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-31restructuringin_progressThe entity's 2014 and 2013 restructuring plan to streamline global manufacturing and commercial operations in order to reduce costs and improve efficiencies in entity's core diagnostics, established pharmaceutical and nutritionals businesses. / Selling, General and Administrative Expenses [Member]USD 23,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-31restructuringin_progressThe entity's 2014 and 2013 restructuring plan to streamline global manufacturing and commercial operations in order to reduce costs and improve efficiencies in entity's core diagnostics, established pharmaceutical and nutritionals businesses. / Cost of Sales [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-12-31divestiture_reductioncompleted2011-102013-01-01GlobalProprietary Pharmaceutical Products (research-based pharmaceuticals business, spun off as AbbVie Inc.)discontinued_operations_footnote
f5-10k / GLM-5.3-flash-HTML		Tax-free spin-off completed January 1, 2013 via special dividend distribution (one AbbVie share per Abbott share, announced October 2011). Assets of $26.6B and liabilities of $23.9B transferred; headcount transferred not disclosed. Roughly $115M of accrued restructuring reserves (Solvay-related plans) and about $1B of benefit-plan-related AOCI losses moved to AbbVie.
2013-12-31restructuringin_progress2013Various functional areas (cross-functional cost reduction)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Plan approved in 2013 to reduce costs and improve efficiencies across functional areas. Disclosure combines it with the parallel 2013 manufacturing-streamlining plan and 2012 commercial-streamlining plans: ~$78M of employee severance charges were recorded in 2013 across those plans (plus ~$4M asset impairments), ~$35M in cost of products sold and ~$47M in SG&A; $148M accrued at December 31, 2013. Headcount affected not disclosed.
2013-12-31restructuringin_progress2013Established Pharmaceutical Products — certain manufacturing operationsrestructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Plan approved in 2013 to streamline certain manufacturing operations and improve efficiencies in the established pharmaceuticals business. Charges are combined with the parallel functional-area plan in disclosure (combined ~$78M severance recorded in 2013); headcount affected not disclosed.
2013-12-31restructuringin_progressWorldwide (manufacturing); U.S. and international (commercial and R&D)Pharmaceutical and vascular manufacturing operations; selected commercial and research and development operationsUSD 11 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year realignment program approved in 2013 and prior years; ~$11M of employee severance charges recorded in 2013. $62M of related liability was transferred to AbbVie on January 1, 2013 as part of the separation; accrued balance of $20M at December 31, 2013. Headcount affected not disclosed.
2013-12-31acquisition_additioncompleted2013-082013-08Vascular Products — endovascular portfoliobusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired 100% of IDEV Technologies, net of debt, for $310 million in cash in August 2013. Employee headcount added through the acquisition is not disclosed.
2013-12-31acquisition_additioncompleted2013-082013-08Medical Optics — laser assisted cataract surgerybusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired 100% of OptiMedica in August 2013 for $260 million in cash plus up to $150 million in milestone payments; ~$70M of contingent consideration recorded. Employee headcount added through the acquisition is not disclosed.
2013-12-31restructuringin_progressWorldwideCorporate functions; Established Pharmaceuticals manufacturing; diagnostics, established pharmaceutical and nutritionals commercial operationsUSD 78 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2013 severance charges under cost-reduction and manufacturing-streamlining plans approved in 2012 and 2013; an additional approximately $4 million of asset impairment charges was also recorded in 2013. Accrued restructuring balance was $148 million at December 31, 2013. Employees affected not disclosed.
2013-12-31restructuringin_progressWorldwidePharmaceutical and vascular manufacturing; selected commercial and R&D operationsUSD 11 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2013 activity under a multi-year realignment program; an additional approximately $41 million recorded in 2013, primarily accelerated depreciation. Accrued balance was $20 million at December 31, 2013. Employees affected not disclosed.
2013-12-31acquisition_additioncompletedUnited StatesVascular Products (endovascular)USD 310 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of 100% of IDEV Technologies, net of debt, for $310 million cash in August 2013. Purchase price shown for context; acquired headcount not disclosed.
2013-12-31acquisition_additioncompletedUnited StatesMedical Optics (non-reportable segment)USD 260 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of 100% of OptiMedica for $260 million cash plus up to $150 million contingent milestones, August 2013. Purchase price shown for context; acquired headcount not disclosed.
2013-12-31divestiture_reductioncompleted2012-11-282013-01-01WorldwideProprietary Pharmaceutical Products (research-based pharmaceuticals business)discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Spin-off of AbbVie Inc. completed January 1, 2013; $26.6 billion of assets and $23.9 billion of liabilities transferred. Employees transferring with the business not disclosed. A small portion of operations remained held for disposition at year-end with transfer expected during 2014.
2013-12-31restructuringcompleted2013-01-01GlobalVarious functional areas and manufacturing operationsUSD 82 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Plan to reduce costs and improve efficiencies across various functional areas and streamline manufacturing operations in established pharmaceuticals business. Charges of $78 million for employee severance and $4 million for asset impairments.
2013-12-31restructuringin_progress2011-01-01GlobalPharmaceutical and vascular manufacturing, commercial and R&D operationsUSD 52 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Multi-year plan to realign worldwide pharmaceutical and vascular manufacturing operations. $11 million in employee severance and $41 million in accelerated depreciation recorded in 2013.
2013-12-31restructuringin_progress2013GlobalVarious functional areas and established pharmaceuticals manufacturingUSD 78 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Plan approved in 2013 to reduce costs and improve efficiencies across various functional areas and streamline manufacturing operations in established pharmaceuticals. Employee-related severance charges of approximately $78 million recorded in 2013. Additional charges of $4 million recorded primarily for asset impairments.
2013-12-31restructuringin_progress2013GlobalPharmaceutical and vascular manufacturing, commercial and R&D operationsUSD 11 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Plan approved in 2013 and prior years to realign worldwide pharmaceutical and vascular manufacturing operations and selected domestic and international commercial and R&D operations. Employee severance charges of approximately $11 million recorded in 2013. Additional charges of $41 million recorded primarily for accelerated depreciation.
2013-12-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Restructuring Plan 2012USD 47,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progressCost of Sales [Member] / Restructuring Plan 2012USD 35,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progressRestructuring Plan 2012USD 78,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progressThe entity's 2013 and prior years restructuring plans to realign its worldwide pharmaceutical and vascular manufacturing operations and selected domestic and international commercial and research and development operations in order to reduce costs.USD 11,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progressThe entity's 2013 and prior years restructuring plans to realign its worldwide pharmaceutical and vascular manufacturing operations and selected domestic and international commercial and research and development operations in order to reduce costs. / Cost of Sales [Member]USD 11,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-09-30restructuringin_progress2013-07-01Established Pharmaceutical Products — manufacturing operationsUSD 19 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q3 2013 plan to streamline manufacturing operations and reduce costs in the established pharmaceutical business; additional ~$4 million of charges primarily for asset impairments; ~$23 million recorded in Cost of products sold; accrued balance of $109 million at September 30, 2013 (includes 2012 charges).
2013-09-30restructuringin_progress2012-07-01Core diagnostics, established pharmaceutical and nutritionals commercial operationsUSD 167 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q3 2012 plan to streamline commercial operations; additional ~$22 million of charges primarily for asset impairments; ~$70 million in Cost of products sold and ~$119 million in SG&A in 2012; payments and other adjustments of $77 million in first nine months 2013.
2013-09-30restructuringin_progress2013-01-01Worldwide pharmaceutical and vascular manufacturing; domestic and international commercial and R&D operationsUSD 11 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2013 realignment plan; additional ~$12 million of charges primarily for accelerated depreciation; ~$23 million recorded in Cost of products sold; liability of $62 million transferred to AbbVie; accrued balance $31 million at September 30, 2013.
2013-09-30restructuringcompleted2012-01-01Sites, functions and commercial organizations related to Solvay Pharmaceuticals acquisitionUSD 150 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2012 and 2010 plans to streamline operations and reduce costs; $150 million of charges recorded in 2012; entire $115 million accrued liability transferred to AbbVie in 2013; accrued balance zero at September 30, 2013.
2013-09-30restructuringin_progress2011-01-01Global manufacturing operations — core diagnostics businessUSD 6 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2011 and 2008 plans to streamline global manufacturing operations; ~$6 million of additional charges in first nine months 2013 primarily for product transfer costs; accrued balance $46 million at September 30, 2013.
2013-09-30divestiture_reductioncompleted2012-11-282013-01-01Research-based proprietary pharmaceuticals business (AbbVie Inc.)other
f5-10q / GLM-5.3-flash-fp4-HTML		Tax-free spin-off of AbbVie completed January 1, 2013; $26.5 billion of assets and $23.8 billion of liabilities transferred; net assets of $2.7 billion distributed; employee benefit plans and equity awards separated; small portion of assets held for disposition pending regulatory transfers.
2013-09-30restructuringin_progressNot specifiedEstablished Pharmaceutical Products — manufacturing operationsUSD 19 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Approved in Q3 2013 to streamline manufacturing in the established pharmaceutical business; $19M employee-related severance plus ~$4M additional charges (mainly asset impairments) recorded in 2013, of which ~$23M sits in Cost of products sold. Accrued balance $109M at 2013-09-30 after $77M of payments. No employee count or completion date disclosed.
2013-09-30restructuringin_progressNot specifiedCore diagnostics, established pharmaceutical and nutritionals — commercial operationsUSD 167 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Approved in Q3 2012; $167M severance plus ~$22M other charges recorded in 2012 (~$70M in Cost of products sold, ~$119M in SG&A). Program still open: accrued balance $109M at 2013-09-30 after $77M of 2013 payments. No significant cash payments through 2012-12-31. No employee count disclosed.
2013-09-30restructuringin_progressWorldwidePharmaceutical and vascular manufacturing; selected commercial and R&D operationsUSD 11 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Long-running realignment program approved in 2013 and prior years; $11M severance plus ~$12M other charges (mainly accelerated depreciation) in 2013, ~$23M in Cost of products sold. $62M of liability transferred to AbbVie at separation; accrued balance $31M at 2013-09-30. No employee count disclosed.
2013-09-30divestiture_reductioncompleted2012-11-282013-01-01GlobalResearch-based proprietary pharmaceuticals business (spun off as AbbVie Inc.)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Separation completed 2013-01-01 via special dividend distribution; $26.5B of assets and $23.8B of liabilities transferred, including $6.1B goodwill and pension/post-employment obligations. No headcount transferred or retained disclosed. Assets/liabilities of a small portion of operations still pending transfer in 2013-2014 (held for disposition).
2013-09-30restructuringin_progress2013-07-01GlobalEstablished Pharmaceutical ProductsUSD 19 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan approved in Q3 2013 to streamline manufacturing operations. Includes $19M employee-related severance and $4M other charges (primarily asset impairments).
2013-09-30restructuringin_progress2013-01-01GlobalPharmaceutical and Vascular Manufacturing; Commercial and R&DUSD 11 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Ongoing plan to realign worldwide operations. Includes $11M employee-related severance and $12M other charges (primarily accelerated depreciation) recorded in 2013.
2013-09-30restructuringin_progressCost of products sold / Restructuring Plan 2012USD 23,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-09-30restructuringin_progressRestructuring Plan 2012USD 19,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-09-30restructuringin_progressThe entity's 2013 and prior years restructuring plans to realign its worldwide pharmaceutical and vascular manufacturing operations and selected domestic and international commercial and research and development operations in order to reduce costs. / Cost of products soldUSD 23,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-09-30restructuringin_progressThe entity's 2013 and prior years restructuring plans to realign its worldwide pharmaceutical and vascular manufacturing operations and selected domestic and international commercial and research and development operations in order to reduce costs.USD 11,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-30restructuringin_progress2012-07-01Diagnostics, Established Pharmaceutical Products, and Nutritionals commercial operationsUSD 167 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Approved Q3 2012 to streamline commercial operations; additional ~$22 million of 2012 charges primarily for asset impairments; ~$70 million recorded in cost of products sold and ~$119 million in SG&A. Payments and other adjustments of $73 million through June 30, 2013; accrued balance of $94 million at June 30, 2013. No employee counts disclosed.
2013-06-30restructuringin_progress2011-01-01Pharmaceutical and vascular manufacturing; commercial and R&D operationsUSD 16 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Worldwide manufacturing and commercial/R&D realignment; $16 million of charges in first six months of 2013, primarily accelerated depreciation. $62 million of liability transferred to AbbVie in separation; $40 million payments; accrued balance $27 million at June 30, 2013. No employee counts disclosed.
2013-06-30restructuringcompleted2012-01-01Sites and functions related to Solvay Pharmaceuticals acquisitionrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2012 and 2010 plans to streamline operations and reduce costs; full $115 million accrued liability transferred to AbbVie in the January 1, 2013 separation; accrued balance zero at June 30, 2013. No employee counts disclosed.
2013-06-30restructuringin_progress2011-01-01Diagnostics global manufacturing operationsUSD 4 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Streamline global manufacturing and reduce costs in core diagnostics business; ~$4 million of charges in first six months of 2013, primarily product transfer costs; payments of $6 million; accrued balance $50 million at June 30, 2013. No employee counts disclosed.
2013-06-30divestiture_reductioncompleted2012-11-28Research-based proprietary pharmaceuticals business (AbbVie)other
f5-10q / GLM-5.3-flash-fp4-HTML		Tax-free spin-off of AbbVie completed January 1, 2013; $27.1 billion of assets and $23.8 billion of liabilities transferred, including $6.1 billion goodwill and $14.6 billion long-term debt. Headcount transferred not disclosed. Remaining assets held for disposition to be transferred to AbbVie in 2013-2014.
2013-06-30restructuringin_progressWorldwideCommercial operations in diagnostics, established pharmaceuticals and nutritionalsrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Approved in Q3 2012; no employee counts disclosed. Severance charges of $167M plus about $22M of asset impairment charges were recorded in 2012; $73M of payments/adjustments in 2013 left a $94M accrual at June 30, 2013.
2013-06-30restructuringin_progressWorldwidePharmaceutical and vascular manufacturing, commercial and R&D operationsUSD 16 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plans approved in 2011 and prior years; no employee counts disclosed. $16M of additional charges (primarily accelerated depreciation) in the first six months of 2013; $62M of liability transferred to AbbVie and $40M of payments left a $27M accrual at June 30, 2013.
2013-06-30restructuringcompletedVarious countriesSolvay Pharmaceuticals acquisition integration — sites, functions and commercial organizationsrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plans approved in 2012 and 2010; no employee counts disclosed. The entire $115M accrual was transferred to AbbVie on January 1, 2013, leaving a $0 balance at June 30, 2013 from Abbott's perspective.
2013-06-30restructuringin_progressWorldwideGlobal manufacturing operations and core diagnostics businessUSD 4 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plans approved in 2011 and 2008; no employee counts disclosed. Approximately $4M of additional charges (primarily product transfer costs) in the first six months of 2013; $50M accrual at June 30, 2013.
2013-06-30divestiture_reductioncompleted2012-11-282013-01-01WorldwideResearch-based proprietary pharmaceuticals business (spun off as AbbVie Inc.)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Spin-off distributed $27.1B of assets and $23.8B of liabilities to AbbVie; no employee headcount transferred or retained was disclosed in the filing.
2013-06-30restructuringin_progress2012-07-01GlobalDiagnostics, Established Pharmaceutical, NutritionalsUSD 167 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Approved Q3 2012 to streamline commercial operations. $167M severance and $22M asset impairments recorded in 2012. Accrued balance $94M at June 30, 2013.
2013-06-30restructuringin_progress2011-01-01GlobalPharmaceutical, Vascular, Manufacturing, R&DUSD 16 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Approved 2011 and prior to realign manufacturing and commercial ops. $16M additional charges in first six months 2013 primarily for accelerated depreciation. Accrued balance $27M at June 30, 2013.
2013-06-30restructuringcompleted2012-01-01GlobalSolvay Pharmaceuticals acquisition integrationUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plans approved 2012 and 2010 related to Solvay acquisition. Liability transferred to AbbVie. Accrued balance $0 at June 30, 2013.
2013-06-30restructuringin_progress2011-01-01GlobalDiagnostic ManufacturingUSD 4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plans approved 2011 and 2008 to streamline global manufacturing. $4M additional charges in first six months 2013 primarily for product transfer costs. Accrued balance $50M at June 30, 2013.
2013-06-30restructuringin_progress Restructuring Plan2012USD 167,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-31divestiture_reductioncompleted2012-11-282013-01-01GlobalProprietary Pharmaceutical Products (AbbVie Inc.)other
f5-10q / GLM-5.3-flash-fp4-HTML		Spin-off of research-based pharmaceuticals business completed January 1, 2013; net assets of $3.3 billion transferred to AbbVie. No employee headcount disclosed. Certain operations held for disposition pending regulatory transfers, expected to transfer in 2013-2014.
2013-03-31restructuringin_progress2012-08-31Diagnostics, Established Pharmaceutical and Nutritionals businesses (commercial operations)USD 167 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plan approved in Q3 2012 to streamline commercial operations; additional $22 million of charges in 2012, primarily asset impairments. $70 million recorded in cost of products sold and $119 million in SG&A. $50 million paid/adjusted in Q1 2013, leaving $117 million accrued at March 31, 2013. Employee count not disclosed.
2013-03-31restructuringin_progress2011-12-31Worldwide pharmaceutical and vascular manufacturing; domestic and international commercial and R&D operationsUSD 8 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plan approved in 2011 and prior years to realign manufacturing and commercial/R&D operations. Q1 2013 charges of $8 million, primarily accelerated depreciation. $62 million of liability transferred to AbbVie; $19 million paid/adjusted in Q1 2013, leaving $48 million accrued at March 31, 2013. Employee count not disclosed.
2013-03-31restructuringcompleted2012-12-31Sites and functions and commercial organizations related to Solvay Pharmaceuticals acquisitionrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plan approved in 2012 and 2010 to streamline operations and reduce costs following the Solvay Pharmaceuticals acquisition. Entire $115 million accrued liability transferred to AbbVie in Q1 2013; accrued balance at March 31, 2013 is zero. Employee count not disclosed.
2013-03-31restructuringin_progress2011-12-31Global manufacturing operations — core diagnostics businessUSD 2 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plan approved in 2011 and 2008 to streamline global manufacturing operations in the diagnostics business. Q1 2013 charges of approximately $2 million, primarily accelerated depreciation and product transfer costs. $3 million paid/adjusted in Q1 2013, leaving $53 million accrued at March 31, 2013. Employee count not disclosed.
2013-03-31restructuringin_progress2012GlobalDiagnostics, Established Pharmaceuticals and Nutritionals commercial operationsUSD 167 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Approved Q3 2012; severance charges of $167M plus about $22M of other charges (mainly asset impairments) recorded in 2012. No employee count disclosed. Payments of $50M in Q1 2013 left an accrued balance of $117M at 2013-03-31.
2013-03-31restructuringin_progress2011GlobalPharmaceutical and vascular manufacturing; selected commercial and R&D operationsUSD 8 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program approved in 2011 and prior years; no employee count disclosed. Additional Q1 2013 charges of $8M, primarily accelerated depreciation. Accrued balance $48M at 2013-03-31 after $62M transferred to AbbVie and $19M of payments.
2013-03-31restructuringcompleted2010GlobalSolvay Pharmaceuticals acquisition integration — sites, functions and commercial organizationsrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan approved in 2012 and 2010; no employee count disclosed. Entire $115M accrued balance transferred to AbbVie on 2013-01-01, leaving a $0 balance at 2013-03-31.
2013-03-31restructuringin_progress2008GlobalDiagnostics manufacturing operationsUSD 2 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan approved in 2011 and 2008; no employee count disclosed. Additional Q1 2013 charges of about $2M, mainly accelerated depreciation and product transfer costs. Accrued balance $53M at 2013-03-31.
2013-03-31divestiture_reductioncompleted2012-11-282013-01-01GlobalResearch-based proprietary pharmaceuticals business (spun off as AbbVie Inc.)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Spin-off completed 2013-01-01; $27.1B of assets and $23.8B of liabilities transferred. No employee headcount associated with the separation is disclosed in this filing.
2013-03-31restructuringin_progress2012-07-01GlobalCommercial operations (Diagnostics, Established Pharmaceutical, Nutritionals)USD 167 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Approved Q3 2012. $167M employee-related severance and $22M asset impairments recorded in 2012. Accrued balance $117M at March 31, 2013.
2013-03-31restructuringin_progress2011-01-01GlobalPharmaceutical and vascular manufacturing; commercial and R&DUSD 8 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Approved 2011 and prior. $8M additional charges in Q1 2013 primarily for accelerated depreciation. Liability of $62M transferred to AbbVie.
2013-03-31restructuringcompleted2012-01-01GlobalSolvay Pharmaceuticals acquisition integrationUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Approved 2012 and 2010. Entire liability of $115M transferred to AbbVie in Q1 2013. Accrued balance $0 at March 31, 2013.
2013-03-31restructuringin_progress2011-01-01GlobalDiagnostic business manufacturingUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Approved 2011 and 2008. $2M additional charges in Q1 2013 for accelerated depreciation and product transfer costs. Accrued balance $53M.
2013-03-31restructuringin_progress Restructuring Plan2012USD 167,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-12-31restructuringin_progress2012Commercial operations of the Diagnostics, Established Pharmaceutical Products and Nutritionals businessesUSD 167 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Plan approved in 2012 to streamline commercial operations for cost reduction and efficiency. Employee severance charges of ~$167 million plus ~$22 million primarily for asset impairments, recorded ~$70 million in cost of products sold and ~$119 million in SG&A. No significant cash payments made as of December 31, 2012.
2012-12-31restructuringin_progress2012Primarily exit from a research and development facility; Solvay-related sites and commercial organizationsUSD 150 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year program under plans approved in 2012 and 2010 tied to the Solvay Pharmaceuticals integration. 2012 charge of ~$150 million for employee severance and contractual obligations (~$142 million in R&D, ~$8 million in SG&A); accrued balance of $115 million at December 31, 2012.
2012-12-31restructuringin_progress2011WorldwidePharmaceutical and vascular manufacturing operations; selected commercial and R&D operationsUSD 110 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Continuation of a multi-year program approved in 2011 and prior years. Current-year activity: additional charges of ~$110 million primarily for accelerated depreciation and ~$48 million of payments and other adjustments; accrued balance $129 million at December 31, 2012. No new employee severance charges disclosed for 2012 under this plan.
2012-12-31restructuringin_progress2011WorldwideDiagnostics global manufacturing operationsUSD 16 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Continuation of plans approved in 2011 and 2008 to streamline global manufacturing in the diagnostics business. 2012 charges of ~$16 million primarily for accelerated depreciation and product transfer costs; accrued balance $56 million at December 31, 2012.
2012-12-31divestiture_reductioncompleted21,0002011-102013-01-01WorldwideProprietary Pharmaceutical Products (research-based pharmaceuticals business transferred to AbbVie Inc.)USD 405 (millions)Item_1_Business
f5-10k / GLM-5.3-flash-HTML		Spin-off of AbbVie completed January 1, 2013 (after fiscal year-end, before filing date). ~21,000 of the ~91,000 year-end 2012 employees were transferred to AbbVie. 2012 SG&A included ~$405 million of AbbVie separation-related costs; this is a transaction cost, not a severance charge.
2012-12-31restructuringin_progressGlobalDiagnostics, Established Pharmaceuticals and Nutritional Products — commercial operationsUSD 167 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2012 program to streamline commercial operations and improve efficiencies; employee-related severance charges of approximately $167 million plus approximately $22 million of additional charges, primarily asset impairments. Approximately $70 million recorded in cost of products sold and approximately $119 million as SG&A. No significant cash payments made as of December 31, 2012. Employees affected not disclosed; announcement date stated only as 'in 2012'.
2012-12-31restructuringin_progressGlobalResearch and Development / pharmaceutical operations (Solvay integration)USD 150 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2012 charge of approximately $150 million for employee severance and contractual obligations, primarily related to the exit from a research and development facility; approximately $142 million recorded as research and development and $8 million as SG&A. Part of multi-year Solvay integration restructuring; only current-year activity extracted. Employees affected not disclosed.
2012-12-31divestiture_reductioncompleted21,0002011-102013-01-01GlobalProprietary Pharmaceutical Products (research-based pharmaceuticals business)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Approximately 21,000 persons transferred to AbbVie in connection with the spin-off distribution completed January 1, 2013 (after fiscal year-end, before the February 15, 2013 filing date). Plan announced October 2011. Separation-related expenses of approximately $405 million recorded in 2012 selling, general and administrative expenses.
2012-12-31restructuringin_progress2012GlobalDiagnostics, Established Pharmaceutical, NutritionalsUSD 189 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Plans approved in 2012 to streamline commercial operations. Charges of $167 million for employee severance and $22 million for asset impairments. No significant cash payments made as of Dec 31, 2012.
2012-12-31restructuringin_progress2012GlobalPharmaceuticals (Solvay-related)USD 150 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Plans related to acquisition of Solvay's pharmaceuticals business. Charge of $150 million for employee severance and contractual obligations, primarily exit from R&D facility.
2012-12-31divestiture_reductioncompleted21,0002013-01-012013-01-01GlobalProprietary Pharmaceutical ProductsItem 1_Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Approximately 21,000 persons transferred to AbbVie in connection with the separation completed on January 1, 2013.
2012-12-31restructuringin_progress2012WorldwideCore diagnostics, established pharmaceutical, and nutritionals businessesUSD 167 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Plans approved in 2012 to streamline commercial operations. Employee related severance charges of approximately $167 million recorded. No significant cash payments made as of year-end.
2012-12-31restructuringin_progress2012WorldwideSolvay pharmaceuticals business integrationUSD 150 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Plans primarily related to acquisition of Solvay. Charge of approximately $150 million for employee severance and contractual obligations, primarily related to exit from R&D facility.
2012-12-31divestiture_reductioncompleted21,0002013-01-012013-01-01WorldwideResearch-based pharmaceuticals (AbbVie separation)Item_1_Business
f5-10k / Qwen3.6-27B-Q8_0		Approximately 21,000 persons transferred to AbbVie in connection with the separation completed on January 1, 2013.
2012-12-31restructuringin_progress Restructuring Plan2012 And2010USD 150,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-12-31restructuringin_progress Cost Of Sales / Restructuring Plan2012USD 70,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-12-31restructuringin_progress Selling General And Administrative Expenses / Restructuring Plan2012USD 119,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-12-31restructuringin_progress Selling General And Administrative Expenses / Restructuring Plan2012 And2010USD 8,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-12-31restructuringin_progress Research And Development Expense / Restructuring Plan2012 And2010USD 142,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-12-31restructuringin_progressUSD 395,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-12-31restructuringin_progressGlobalDiagnostics, Established Pharmaceutical Products and Nutritional Products — commercial operationsUSD 167 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2012 plans to streamline commercial operations; severance charges of approximately $167 million plus approximately $22 million of additional charges, primarily asset impairments. No significant cash payments made as of year-end.
2012-12-31restructuringin_progressGlobalSolvay integration — research and development facility exit and commercial organizationsUSD 150 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2012 charge of approximately $150 million for employee severance and contractual obligations, primarily related to exit from an R&D facility; approximately $142 million recorded in R&D and $8 million in SG&A. Multi-year Solvay integration program; only FY2012 activity shown.
2012-12-31restructuringin_progressGlobalDiagnostic Products — manufacturing and operationsrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Program approved in 2011/2008; no restructuring charge recorded in 2012, only payments and other adjustments of $23 million plus approximately $16 million of accelerated depreciation and product transfer costs.
2012-12-31divestiture_reductioncompleted21,0002011-102013-01-01GlobalProprietary Pharmaceutical Products (research-based pharmaceuticals business)Item_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Approximately 21,000 persons transferred to AbbVie in connection with the spin-off completed January 1, 2013 (after fiscal year-end, before filing).
2012-12-31restructuringin_progress2012GlobalCore diagnostics, established pharmaceutical, and nutritionals businessesUSD 167 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Abbott recorded employee related severance charges of approximately $167 million in 2012 to streamline various commercial operations. No significant cash payments made as of Dec 31, 2012.
2012-12-31restructuringin_progress2012GlobalSolvay pharmaceuticals business integrationUSD 150 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Abbott recorded a charge of approximately $150 million for employee severance and contractual obligations, primarily related to the exit from a research and development facility.
2012-12-31divestiture_reductioncompleted21,0002013-01-012013-01-01GlobalResearch-based pharmaceuticals (AbbVie)Item_1_Business
f5-10k / Qwen3.6-27B-Q8_0		Approximately 21,000 persons were transferred to AbbVie in connection with the separation completed on January 1, 2013.
2012-09-30restructuringin_progress2012-09-30Diagnostics, Established Pharmaceutical Products, and Nutritional Products commercial operationsUSD 167 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q3 2012 plan to streamline commercial operations and reduce costs; approximately $70 million recorded in Cost of products sold and $119 million in SG&A. No significant cash payments made as of September 30, 2012.
2012-09-30restructuringin_progress2012-09-30Diagnostics, Established Pharmaceutical Products, and Nutritional ProductsUSD 22 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Additional Q3 2012 charges primarily for asset impairments related to the commercial operations streamlining plan.
2012-09-30restructuringin_progress2012-09-30Research and development facility exit (Solvay Pharmaceuticals-related restructuring plan)USD 150 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q3 2012 charge for employee severance and contractual obligations, primarily related to exit from a research and development facility; approximately $142 million recorded in R&D and $8 million in SG&A.
2012-09-30restructuringin_progress2011-01-01Worldwide pharmaceutical and vascular manufacturing; commercial and R&D operationsUSD 83 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Additional first nine months 2012 charges, primarily accelerated depreciation, under plans approved in 2011 and prior years to realign manufacturing and commercial/R&D operations.
2012-09-30restructuringin_progress2010-01-01Solvay sites and functions; Abbott and Solvay commercial organizationsUSD 29 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Additional first nine months 2012 charges under 2012/2010 Solvay-related plans, primarily accelerated depreciation, asset impairment and employee severance.
2012-09-30restructuringin_progress2008-01-01Diagnostics global manufacturing operationsUSD 12 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Additional first nine months 2012 charges under 2011/2008 plan to streamline global diagnostics manufacturing; primarily accelerated depreciation and product transfer costs. Additional charges expected through 2012.
2012-09-30divestiture_reductionannounced2011-10-012013-01-01Proprietary Pharmaceutical Products segment (research-based pharmaceuticals business, ~$17.4 billion 2011 net sales)other
f5-10q / GLM-5.3-flash-fp4-HTML		Planned tax-free distribution to shareholders of a new research-based pharmaceuticals company (AbbVie); separation expected January 1, 2013 subject to approvals. No headcount figures disclosed.
2012-09-30restructuringin_progressDiagnostics, Established Pharmaceutical Products, and Nutritional Products commercial operationsUSD 167 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Approved in Q3 2012 to streamline commercial operations; severance charges of approximately $167 million plus approximately $22 million of additional charges, primarily asset impairments. About $70 million recorded in Cost of products sold and $119 million in SG&A. No significant cash payments made as of 2012-09-30. Employee affected count not disclosed.
2012-09-30restructuringin_progressSolvay Pharmaceuticals integration; exit from a research and development facilityUSD 150 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q3 2012 charge of approximately $150 million for employee severance and contractual obligations under the Solvay-related restructuring plan, primarily for the exit from an R&D facility; approximately $142 million recorded as Research and development and $8 million as SG&A. Employee affected count not disclosed.
2012-09-30restructuringin_progress2012-09-30GlobalCore diagnostics, established pharmaceutical, and nutritionals businessesUSD 189 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Approved in Q3 2012 to streamline commercial operations. Charges include $167M employee severance and $22M asset impairments. No significant cash payments made as of Sept 30, 2012.
2012-09-30restructuringin_progress2012-09-30GlobalSolvay Pharmaceuticals integrationUSD 150 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Approved in Q3 2012 related to Solvay acquisition. Charges include employee severance and contractual obligations, primarily exit from R&D facility. $142M recorded as R&D, $8M as SG&A.
2012-06-30restructuringin_progress2012-12-31WorldwidePharmaceutical and vascular manufacturing operations; selected commercial and R&D operationsUSD 53 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Additional first-half 2012 charges primarily for accelerated depreciation; accrued severance balance of $171 million at June 30, 2012; no employee counts disclosed.
2012-06-30restructuringin_progress2010-01-01Various countriesSolvay Pharmaceuticals sites and functions; Abbott and Solvay commercial organizationsUSD 14 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2010 plan to streamline operations after Solvay acquisition; first-half 2012 charges primarily accelerated depreciation and employee severance; accrued balance $18 million at June 30, 2012.
2012-06-30restructuringin_progress2008-01-012012-12-31GlobalDiagnostics manufacturing operationsUSD 8 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plan to streamline global manufacturing in core diagnostics business; first-half 2012 charges primarily accelerated depreciation and product transfer costs; accrued balance $62 million at June 30, 2012.
2012-06-30divestiture_reductionannounced2011-10-012012-12-31WorldwideProprietary Pharmaceutical Products segmentother
f5-10q / GLM-5.3-flash-fp4-HTML		Planned tax-free spin-off of research-based pharmaceuticals business into a new publicly traded company; no headcount figures disclosed.
2012-06-30restructuringin_progress2011WorldwidePharmaceutical and vascular manufacturing; selected commercial and R&D operationsUSD 53 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan approved in 2011 and prior years to realign manufacturing and selected commercial/R&D operations; first-six-months 2012 charges primarily accelerated depreciation. No employee counts or completion date disclosed; accrual balance $171M at 2012-06-30.
2012-06-30restructuringin_progress2010Worldwide (Solvay sites and commercial organizations in various countries)Solvay Pharmaceuticals integration — sites, functions, commercial organizationsUSD 14 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan primarily related to the Solvay Pharmaceuticals acquisition; 2012 charges approximately $14M, primarily accelerated depreciation and employee severance. No employee counts disclosed; accrual balance $18M at 2012-06-30.
2012-06-30restructuringin_progress2011WorldwideDiagnostic Products — manufacturingUSD 8 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan approved in 2011 (originating 2008) to streamline global diagnostic manufacturing; 2012 charges approximately $8M, primarily accelerated depreciation and product transfer costs, with additional charges expected through 2012. No employee counts disclosed; accrual balance $62M at 2012-06-30.
2012-06-30divestiture_reductionannounced2011-102012-12-31WorldwideProprietary Pharmaceutical Products segment (research-based pharmaceuticals business)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Planned tax-free spin-off creating a separate research-based pharmaceutical company; Abbott expects to be ready to separate by end of 2012 subject to required approvals. No headcount associated with the separation disclosed; new company 2011 net sales approximately $17.4B.
2012-06-30restructuringin_progress2011-01-01WorldwidePharmaceutical and vascular manufacturing; domestic and international commercial and R&DUSD 53 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Additional charges of $53 million recorded in first six months of 2012, primarily for accelerated depreciation. Accrued balance at June 30, 2012 was $171 million.
2012-06-30restructuringin_progress2010-01-01Various countriesSolvay Pharmaceuticals sites and functions; Abbott and Solvay commercial organizationsUSD 14 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Additional charges of approximately $14 million recorded in first six months of 2012, primarily for accelerated depreciation and employee severance. Accrued balance at June 30, 2012 was $18 million.
2012-06-30restructuringin_progress2011-01-012012-12-31GlobalCore diagnostic business manufacturingUSD 8 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Additional charges of approximately $8 million recorded in first six months of 2012, primarily for accelerated depreciation and product transfer costs. Additional charges expected through 2012 due to product re-registration and transition timelines. Accrued balance at June 30, 2012 was $62 million.
2012-03-31restructuringin_progressWorldwidePharmaceutical and vascular manufacturing; commercial and R&D operationsUSD 116 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plan approved in 2011 and prior years to realign manufacturing and selected commercial/R&D operations to reduce costs; charges of $116 million recorded in Q1 2011 (prior-year comparative). Accrued balance $178 million at March 31, 2012; no new charges in Q1 2012, plus $30 million primarily for accelerated depreciation. No employee counts disclosed.
2012-03-31restructuringin_progress2010-01-01Various countriesSolvay Pharmaceuticals sites and functions; Abbott and Solvay commercial organizationsrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2010 plan to streamline operations and reduce costs following Solvay Pharmaceuticals acquisition; approximately $2 million of additional charges in Q1 2012, primarily employee severance. Accrued balance $47 million at March 31, 2012. No employee counts disclosed.
2012-03-31restructuringin_progress2008-01-012012-12-31GlobalDiagnosticsrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plan approved in 2011 and 2008 to streamline global manufacturing operations in the core diagnostics business; approximately $4 million of additional charges in Q1 2012, primarily accelerated depreciation and product transfer costs. Additional charges expected through 2012. No employee counts disclosed.
2012-03-31divestiture_reductionannounced2011-10-012012-12-31WorldwideProprietary Pharmaceutical Products (AbbVie)other
f5-10q / GLM-5.3-flash-fp4-HTML		Plan to separate research-based pharmaceuticals business into a new publicly traded company (AbbVie) via tax-free distribution to shareholders, expected by end of 2012; headcount impact not quantified.
2012-03-31restructuringin_progress2011-01-01WorldwidePharmaceutical and vascular manufacturing; commercial and R&DUSD 30 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Additional charges of $30 million recorded in Q1 2012, primarily for accelerated depreciation. No employee count disclosed for this period.
2012-03-31restructuringin_progress2010-01-01Various countriesSolvay Pharmaceuticals integrationUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Additional charges of approximately $2 million recorded in Q1 2012, primarily for employee severance. No employee count disclosed for this period.
2012-03-31restructuringin_progress2011-01-012012-12-31GlobalDiagnostic businessUSD 4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Additional charges of approximately $4 million recorded in Q1 2012, primarily for accelerated depreciation and product transfer costs. Additional charges expected through 2012.
2011-12-31restructuringin_progressWorldwide (manufacturing); selected domestic and international commercial and R&D operationsPharmaceutical and Vascular manufacturing operations; commercial and research and development operationsUSD 194 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year plan approved in 2011 and prior years to realign operations and reduce costs; 2011 charge reflects facility/asset impairments, employee severance and related costs ($76M cost of products sold, $69M R&D, $49M SG&A). An additional $25 million recorded in 2011, primarily accelerated depreciation. Accrued balance $177 million at December 31, 2011.
2011-12-31restructuringin_progress2010-09Various countriesSolvay sites and functions; certain Abbott and Solvay commercial organizationsUSD 102 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Plan announced September 2010, primarily related to the Solvay pharmaceuticals acquisition, to streamline operations and reduce costs; 2011 charge primarily additional employee severance and accelerated depreciation. Accrued balance $108 million at December 31, 2011. No employee counts disclosed.
2011-12-31restructuringin_progress2012-12-31Diagnostics — global manufacturing operationsUSD 28 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Plans approved in 2011 and 2008 to streamline global manufacturing, reduce costs and improve efficiencies in the core diagnostic business; 2011 charge recorded in Cost of products sold. Approximately $42 million additionally recorded in 2011 for accelerated depreciation and product transfer costs; further charges expected through 2012 due to product re-registration and transition timelines. Accrued balance $79 million at December 31, 2011.
2011-12-31divestiture_reductionannounced2011-10-192012-12-31Proprietary Pharmaceutical Products (research-based pharmaceuticals business)other
f5-10k / GLM-5.3-flash-HTML		Announced plan to separate into two publicly traded companies via tax-free distribution of stock of a new research-based pharmaceutical company comprising the Proprietary Pharmaceutical Products segment; expected completion by end of 2012. No headcount figures disclosed.
2011-12-31restructuringin_progressWorldwidePharmaceutical and vascular manufacturing; selected commercial and research and development operationsUSD 194 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2011 charges only for a multi-year program approved in 2011 and prior years; covers impairment, severance and related charges ($76M cost of products sold, $69M R&D, $49M SG&A). Accrued balance at year-end was $177M. Employees affected not disclosed.
2011-12-31restructuringin_progress2010-09WorldwideSolvay Pharmaceuticals sites, functions and commercial organizationsUSD 102 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Plan announced September 2010; $523M was charged in 2010. This record captures only the additional FY2011 charges (severance and accelerated depreciation). Accrued balance fell to $108M at 2011 year-end. Employees affected not disclosed.
2011-12-31restructuringin_progress2011WorldwideDiagnostic Products (core diagnostics manufacturing)USD 28 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Program approved in 2011 (originating from a 2008 plan) to streamline global manufacturing and improve efficiencies in core diagnostics; FY2011 charge recorded in cost of products sold, accrued balance $79M at year-end. Additional charges expected through 2012. Employees affected not disclosed.
2011-12-31divestiture_reductionannounced2011-10-192012-12-31WorldwideProprietary Pharmaceutical Products segment (research-based pharmaceuticals company)other
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Planned tax-free separation into two publicly traded companies, announced October 19, 2011 and expected to be completed by end of 2012; no headcount or charge quantification disclosed for the separation.
2011-12-31restructuringin_progress2010-09GlobalPharmaceuticals, Vascular, DiagnosticsUSD 194 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Charges of approximately $194 million recorded in 2011 for realignment of worldwide pharmaceutical and vascular manufacturing operations and selected commercial/R&D operations. Includes impairment of facilities, employee severance, and other related charges. Employee count not explicitly disclosed for this specific 2011 charge.
2011-12-31restructuringin_progress2010-09GlobalPharmaceuticalsUSD 102 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Additional charges of $102 million recorded in 2011 relating to the Solvay acquisition restructuring plan, primarily for additional employee severance and accelerated depreciation. Employee count not explicitly disclosed.
2011-12-31restructuringin_progress2011GlobalDiagnosticsUSD 28 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Charge of $28 million recorded in 2011 in Cost of products sold for streamlining global manufacturing operations in core diagnostic business. Employee count not explicitly disclosed.
2011-12-31restructuringin_progress2011WorldwidePharmaceutical and vascular manufacturing; domestic and international commercial and R&DUSD 194 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Charges reflect impairment of manufacturing facilities and other assets, employee severance and other related charges. Accrued balance at Dec 31, 2011 was $177 million.
2011-12-31restructuringin_progress2010-09Various countriesSolvay sites and functions; Abbott and Solvay commercial organizationsUSD 102 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Plan approved in Sept 2010 related to Solvay acquisition. Additional $102 million recorded in 2011 primarily for additional employee severance and accelerated depreciation. Accrued balance at Dec 31, 2011 was $108 million.
2011-12-31restructuringin_progress2011GlobalCore diagnostic businessUSD 28 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Plans to streamline global manufacturing operations and improve efficiencies in core diagnostic business. Charge of $28 million recorded in Cost of products sold. Accrued balance at Dec 31, 2011 was $79 million.
2011-12-31restructuringin_progressUSD 25,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2011-12-31restructuringin_progress Restructuring Plan2011 And2008USD 42,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2011-09-30restructuringin_progressWorldwidePharmaceutical and vascular manufacturing; commercial and R&D operationsUSD 116 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plan to realign worldwide manufacturing and selected commercial and R&D operations to reduce costs; accrued balance of $122 million at September 30, 2011. No employee counts disclosed.
2011-09-30restructuringin_progress2010-08-012012-12-31Various countriesSolvay sites and functions; Abbott and Solvay commercial organizationsUSD 436 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Third-quarter 2010 plan to streamline operations and reduce costs following the Solvay Pharmaceuticals acquisition; accrued balance of $231 million at September 30, 2011. No employee counts disclosed.
2011-09-30restructuringin_progress2015-12-31GlobalDiagnosticsUSD 31 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plan to streamline global manufacturing operations in the core diagnostic business; accrued balance of $92 million at September 30, 2011. No employee counts disclosed.
2011-09-30acquisition_additioncompleted2010-02-15GlobalProprietary Pharmaceutical ProductsUSD 6 (billions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of Solvay's pharmaceuticals business for approximately $6.1 billion in cash plus contingent milestone payments; headcount added not disclosed.
2011-09-30acquisition_additioncompleted2010-09-08IndiaEstablished Pharmaceutical ProductsUSD 2 (billions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of Piramal Healthcare Limited's Healthcare Solutions business for $2.2 billion in cash plus annual milestone payments; headcount added not disclosed.
2011-09-30restructuringin_progress2011-01-01WorldwidePharmaceutical and vascular manufacturing; selected commercial and R&D operationsUSD 116 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program to realign worldwide pharmaceutical and vascular manufacturing and selected commercial/R&D operations. Charges of $116M recorded in first nine months 2011; accrued balance $122M at 2011-09-30. No employee count disclosed.
2011-09-30restructuringin_progress2010-07-012012-12-31WorldwideSolvay Pharmaceuticals integration — sites, functions, and commercial organizationsUSD 95 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Solvay acquisition-related restructuring approved Q3 2010 ($436M charged in 2010). $95M charged in first nine months 2011, primarily accelerated depreciation; accrued balance $231M at 2011-09-30. Additional charges expected through 2012 for employee-related and asset disposal costs. No employee count disclosed.
2011-09-30restructuringin_progress2011-01-012015-12-31WorldwideDiagnostic Products — global manufacturing operationsUSD 31 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan to streamline global manufacturing and improve efficiencies in core diagnostic business (originally approved 2008). $31M charged to cost of products sold in 2011; accrued balance $92M at 2011-09-30. Additional charges through 2015 for product re-registration and transition timelines. No employee count disclosed.
2011-09-30otherannounced2011-10-012012-12-31WorldwideProprietary Pharmaceutical Products segment — planned separation into two publicly traded companiessubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Announced October 2011 (post-quarter); tax-free distribution of research-based pharmaceuticals company expected complete by end of 2012. No workforce impact quantified in filing.
2011-09-30restructuringin_progress2011-01-01WorldwidePharmaceutical and vascular manufacturing; domestic and international commercial and R&DUSD 116 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan approved in 2011 and prior years to realign operations. Charges recorded in Q1 2011 and first nine months 2011 primarily for accelerated depreciation and product transfer costs.
2011-09-30restructuringin_progress2010-07-012012-12-31Various countriesSolvay Pharmaceuticals integrationUSD 95 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan approved in Q3 2010 related to Solvay acquisition. Charges in first nine months 2011 primarily for accelerated depreciation. Additional charges expected through 2012 for employee-related and asset disposal costs.
2011-09-30restructuringin_progress2011-01-012015-12-31GlobalDiagnostic businessUSD 59 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plans approved in 2011 and 2008 to streamline global manufacturing. $31M charge in Q1 2011 and ~$28M in first nine months 2011. Additional charges expected through 2015 due to product re-registration and transition timelines.
2011-09-30restructuringin_progressUSD 12,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2011-09-30restructuringin_progress Restructuring Plan2011 And2008USD 28,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2011-06-30restructuringin_progress2011-12-31WorldwidePharmaceutical and vascular manufacturing; commercial and R&D operationsUSD 116 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plan to realign worldwide manufacturing and selected commercial/R&D operations to reduce costs; charges recorded in Q1 2011 across cost of products sold, R&D and SG&A; accrued balance of $144 million at June 30, 2011. No employee counts disclosed.
2011-06-30restructuringin_progress2010-07-012011-12-31Various countriesSolvay Pharmaceuticals sites and functions; Abbott and Solvay commercial organizationsUSD 65 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plan approved in Q3 2010 primarily related to the Solvay Pharmaceuticals acquisition; first-half 2011 charges primarily accelerated depreciation; accrued balance of $293 million at June 30, 2011. No employee counts disclosed.
2011-06-30restructuringin_progress2008-10-012011-12-31GlobalDiagnosticsUSD 18 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plan to streamline global manufacturing operations and improve efficiencies in the core diagnostics business; first-half 2011 charges primarily accelerated depreciation and product transfer costs; accrued balance of $71 million at June 30, 2011. No employee counts disclosed.
2011-06-30restructuringin_progressWorldwidePharmaceutical and vascular manufacturing; selected commercial and R&D operationsUSD 116 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program approved in 2011 and prior years to realign manufacturing and selected commercial/R&D operations. Charges of $116M recorded in 2011 through June 30 (accrued balance $144M at June 30, 2011); no employee count disclosed. Charges recorded in Q1 2011: $49M to cost of products sold, $18M to R&D, $49M to SG&A.
2011-06-30restructuringin_progress2010-09-30WorldwideSolvay Pharmaceuticals sites, functions and commercial organizationsUSD 65 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan approved in the third quarter of 2010 following the Solvay Pharmaceuticals acquisition; approximately $65M charged in the first six months of 2011, primarily accelerated depreciation (accrued balance $293M at June 30, 2011). Additional employee-related and asset disposal charges expected through 2011. Announcement date is the quarter of approval; exact date not disclosed. No employee count disclosed.
2011-06-30restructuringin_progress2008-12-31WorldwideDiagnostics manufacturing operationsUSD 18 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan approved in 2008 to streamline global manufacturing and improve efficiencies in core diagnostics; approximately $18M charged in the first six months of 2011, primarily accelerated depreciation and product transfer costs (accrued balance $71M at June 30, 2011). Additional charges expected through 2011. Announcement year only disclosed. No employee count disclosed.
2011-06-30restructuringin_progress2011-01-01WorldwidePharmaceutical and vascular manufacturing; domestic and international commercial and R&DUSD 116 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan approved in 2011 and prior years to realign operations. Charges of $116M recorded in first six months of 2011, primarily for accelerated depreciation and product transfer costs. Employee count not disclosed.
2011-06-30restructuringin_progress2010-07-012011-12-31Various countriesSolvay Pharmaceuticals sites and functions; Abbott and Solvay commercial organizationsUSD 65 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan approved in Q3 2010 related to Solvay acquisition. Charges of approx $65M recorded in first six months of 2011, primarily for accelerated depreciation. Additional charges expected through 2011 for employee-related and asset disposal costs. Employee count not disclosed.
2011-06-30restructuringin_progress2008-01-012011-12-31GlobalCore diagnostic business manufacturingUSD 18 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan approved in 2008 to streamline global manufacturing. Charges of approx $18M recorded in first six months of 2011, primarily for accelerated depreciation and product transfer costs. Additional charges expected through 2011. Employee count not disclosed.
2011-06-30restructuringin_progress Restructuring Plan2011 And Prior YearsUSD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2011-06-30restructuringin_progress Restructuring Plan2010USD 65,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2011-06-30restructuringin_progress Restructuring Plan2008USD 18,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2011-03-31restructuringin_progressWorldwidePharmaceutical and vascular manufacturing; selected commercial and R&D operationsUSD 116 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program approved in 2011 and prior years to realign manufacturing and selected commercial/R&D operations. Q1 2011 charges: $49M to cost of products sold, $18M to R&D, $49M to SG&A. Accrued balance $163M at 2011-03-31 (from $77M at 2011-01-01); payments and other adjustments of $30M. No employee count disclosed.
2011-03-31restructuringin_progressWorldwideSolvay Pharmaceuticals sites and functions; Abbott and Solvay commercial organizationsUSD 44 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan approved in Q3 2010 primarily related to the Solvay Pharmaceuticals acquisition; Q1 2011 charges of approximately $44M, primarily accelerated depreciation. Additional charges expected through 2011 for employee-related and asset disposal costs. Accrued balance $348M at 2011-03-31 (from $410M at 2011-01-01). No employee count disclosed.
2011-03-31restructuringin_progressWorldwideDiagnostic Products manufacturingUSD 9 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan approved in 2008 to streamline global manufacturing operations in the core diagnostic business; Q1 2011 charges of approximately $9M, primarily accelerated depreciation and product transfer costs. Additional charges expected through 2011 tied to product re-registration and transition timelines. Accrued balance $85M at 2011-03-31. No employee count disclosed.
2011-03-31restructuringin_progressWorldwidePharmaceutical and vascular manufacturing; domestic and international commercial and R&DUSD 116 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges recorded in Q1 2011 include $49M to Cost of products sold, $18M to R&D, and $49M to SG&A. Includes accelerated depreciation and product transfer costs.
2011-03-31restructuringin_progress2010-07-012011-12-31Various countriesSolvay Pharmaceuticals sites and functions; Abbott and Solvay commercial organizationsUSD 44 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan approved in Q3 2010. Q1 2011 charges primarily for accelerated depreciation. Additional charges expected through 2011 for employee-related and asset disposal costs.
2011-03-31restructuringin_progress2008-01-012011-12-31GlobalDiagnostic business manufacturingUSD 9 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan approved in 2008 to streamline global manufacturing. Q1 2011 charges primarily for accelerated depreciation and product transfer costs. Additional charges expected through 2011.
2011-03-31restructuringin_progress Restructuring Plan2010USD 44,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2011-03-31restructuringin_progress Restructuring Plan2008USD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2011-03-31restructuringin_progress Restructuring Plan2011 And Prior YearsUSD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2010-12-31acquisition_additioncompleted2010-02-15Pharmaceutical Productsbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquisition of Solvay's pharmaceuticals business completed for approximately $6.1 billion in cash, plus milestone payments of up to EUR 100 million per year for 2011-2013; added approximately $3.1 billion to 2010 net sales. Employee headcount added was not disclosed.
2010-12-31acquisition_additioncompleted2010-03Laboratory informaticsbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired STARLIMS Technologies for approximately $100 million in cash, net of cash held, adding laboratory informatics products and expertise. Employee headcount added was not disclosed.
2010-12-31acquisition_additioncompleted2010-04Pharmaceutical Products (early- and mid-stage pipeline)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired outstanding shares of Facet Biotech Corporation for approximately $430 million in cash, net of cash held; adds a multiple sclerosis biologic and oncology compounds to the pipeline. Employee headcount added was not disclosed.
2010-12-31restructuringin_progress2010-09Various countriesPrimarily Solvay pharmaceutical sites and functions; also Abbott and Solvay commercial organizationsUSD 523 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Plan approved in 2010, primarily related to the Solvay acquisition. Expected total pretax charges of approximately $810-$970 million over the life of the plan, including approximately $650 million of employee-related costs; most action plans expected to be implemented within the next two years. An additional $12 million was subsequently recorded, primarily for accelerated depreciation. Accrued liability of $410 million at December 31, 2010. Number of employees affected not disclosed.
2010-12-31acquisition_additioncompleted2010-09-08IndiaPharmaceutical Products (Indian branded generics)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired Piramal Healthcare Limited's Healthcare Solutions business, a leader in the Indian branded generics market, for $2.2 billion in cash plus $400 million annually in 2011-2014. Employee headcount added was not disclosed.
2010-12-31restructuringin_progressWorldwidePharmaceutical and Vascular manufacturing; selected domestic and international commercial and R&D operationsUSD 56 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Ongoing multi-year program comprising plans approved in 2010 and prior years; charge shown reflects only fiscal 2010 activity (impairment of manufacturing facilities and other assets, employee severance and other related charges). An additional $13 million was subsequently recorded in 2010, primarily for accelerated depreciation. Accrued balance of $77 million at December 31, 2010. Employees affected not disclosed.
2010-12-31restructuringin_progress20082011GlobalDiagnostics — core diagnostic business manufacturingUSD 60 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Plan approved in 2008 to streamline global manufacturing operations in the core diagnostic business. Charge shown reflects additional fiscal 2010 charges, primarily accelerated depreciation and product transfer costs; the original 2008 charge was approximately $129 million. Additional charges expected through 2011 due to product re-registration and transition timelines. Employees affected not disclosed.
2010-12-31restructuringannounced2011-01Pharmaceutical business — manufacturing and commercial operationsUSD 295 (millions)subsequent_events
f5-10k / GLM-5.3-flash-HTML		Plan approved in January 2011, after fiscal year-end. Pre-tax charges of approximately $295 million expected over the next several years, including product transfers; approximately $165 million forecast for 2011, with about $140 million projected in the first quarter of 2011. Employees affected not disclosed.
2010-12-31restructuringin_progress2010-09Various countries (Solvay sites and commercial organizations)Pharmaceutical ProductsUSD 523 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Solvay-related plan; 2010 charge of $523M. Full program estimated at $810M-$970M pretax over its life, most actions expected within two years. Employee-affected counts not disclosed.
2010-12-31restructuringin_progressWorldwidePharmaceutical and Vascular manufacturing; commercial and R&D operationsUSD 56 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Multi-year realignment program approved in 2010 and prior years; $56M charged in 2010 (classified in cost of products sold), plus $13M subsequently recorded primarily for accelerated depreciation. Current-year activity only; employee-affected counts not disclosed.
2010-12-31restructuringin_progress2008WorldwideDiagnostic Products manufacturingUSD 60 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Program approved in 2008 ($129M initial charge); $60M of additional charges recorded in 2010, primarily accelerated depreciation and product transfer costs, with further charges expected through 2011. Current-year activity only; employee-affected counts not disclosed.
2010-12-31restructuringannounced2011-01Not specifiedPharmaceutical business — manufacturing and commercial operationsUSD 295 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Approved January 2011, after fiscal year-end; approximately $295M pretax charges over several years, with about $165M forecast for 2011 including roughly $140M in Q1 2011. Employee-affected counts not disclosed.
2010-12-31acquisition_additioncompleted2010-02-152010-02-15Worldwide (primarily outside the U.S.)Pharmaceutical Productsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Solvay Group's pharmaceuticals business for approximately $6.1 billion cash plus contingent payments; added approximately $3.1 billion of 2010 net sales. Headcount added not disclosed.
2010-12-31acquisition_additioncompleted2010-09-082010-09-08IndiaPharmaceutical Productsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Piramal Healthcare Limited's Healthcare Solutions business for $2.2 billion cash plus $400 million annual payments 2011-2014. Headcount added not disclosed.
2010-12-31restructuringin_progress2010-092012-12-31GlobalPharmaceutical ProductsUSD 523 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Plan related to acquisition of Solvay's pharmaceuticals business. Charges include employee-related costs, accelerated depreciation, and exit costs. Most actions expected within two years.
2010-12-31restructuringin_progress2010-01-01GlobalPharmaceutical and Vascular ProductsUSD 56 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Realignment of worldwide pharmaceutical and vascular manufacturing operations and selected commercial/R&D operations. Charges reflect impairment of facilities, severance, and other costs.
2010-12-31restructuringin_progress2008-01-012011-12-31GlobalDiagnostic ProductsUSD 60 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Plan to streamline global manufacturing operations in core diagnostic business. Additional charges incurred through 2011 for product re-registration and transition.
2010-12-31restructuringannounced2011-01GlobalPharmaceutical ProductsUSD 295 (millions)subsequent_events
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Plan approved in January 2011 to streamline manufacturing and commercial operations. Approximately $165 million of charges forecast for 2011, with $140 million in Q1 2011.
2010-12-31restructuringin_progress2010-09Various countriesPharmaceutical Products; Solvay sites and functions; Abbott and Solvay commercial organizationsUSD 523 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Plan approved in September 2010 primarily related to Solvay acquisition. Total expected pretax charges $810M-$970M over life of plan. 2010 charge of $523M includes employee-related costs, accelerated depreciation, and exit costs. Employee count not explicitly disclosed for this specific action.
2010-12-31restructuringin_progressWorldwidePharmaceutical and Vascular manufacturing; Domestic and international commercial and R&DUSD 56 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Plans approved in 2010 and prior years to realign manufacturing and commercial operations. 2010 charge of $56M reflects impairment, severance, and other charges. Employee count not explicitly disclosed.
2010-12-31restructuringin_progress2011GlobalDiagnostic ProductsUSD 60 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Plan approved in 2008 to streamline global diagnostic manufacturing. 2010 charge of $60M primarily for accelerated depreciation and product transfer costs. Additional charges expected through 2011. Employee count not explicitly disclosed.
2010-12-31restructuringannounced2011-01GlobalPharmaceutical ProductsUSD 295 (millions)subsequent_events
f5-10k / Qwen3.6-27B-Q8_0		Plan approved in January 2011 to streamline manufacturing and commercial operations. Total expected pre-tax charges $295M over next several years. Approximately $165M forecast for 2011. Employee count not explicitly disclosed.
2010-12-31restructuringin_progress Restructuring Plan2010 And Prior YearsUSD 56,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2010-09-30restructuringin_progress2010-09-302012-09-30InternationalSolvay sites and functions; Abbott and Solvay commercial organizationsUSD 436 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plan approved Q3 2010 primarily related to Solvay pharmaceuticals acquisition; expected total pretax charges of $810-$970 million over two years, including ~$650 million employee-related costs, ~$105 million accelerated depreciation/asset write-downs, and up to ~$215 million other exit costs. Q3 charges recorded: ~$81M cost of products sold, ~$133M R&D, ~$222M SG&A. Accrued balance $399 million at September 30, 2010. No employee count disclosed.
2010-09-30restructuringin_progress2009-01-01WorldwidePharmaceutical and vascular manufacturing; commercial and R&D operationsUSD 7 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2009 and prior plans to realign worldwide pharmaceutical and vascular manufacturing and selected commercial/R&D operations; $7 million charges in first nine months 2010, primarily accelerated depreciation and product transfer costs. Accrued balance $49 million at September 30, 2010. No employee count disclosed.
2010-09-30restructuringin_progress2008-01-012011-12-31GlobalDiagnostics business manufacturing operationsUSD 45 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2008 plan to streamline global manufacturing operations in core diagnostics business; ~$45 million charges in first nine months 2010, primarily accelerated depreciation and product transfer costs. Additional charges expected through 2011. Accrued balance $89 million at September 30, 2010. No employee count disclosed.
2010-09-30restructuringin_progress2010-09-302012-09-30GlobalPharmaceutical ProductsUSD 436 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Approved by Abbott management in Q3 2010 (exact approval date not disclosed; announcement_date set to quarter-end). Primarily related to the Solvay Pharmaceuticals acquisition; streamlines Solvay sites/functions and certain Abbott and Solvay commercial organizations across various countries. Q3 2010 charge of $436M recorded (COGS $81M, R&D $133M, SG&A $222M); total pretax charges of approximately $810M to $970M expected over the next two years (employee-related ~$650M, accelerated depreciation/asset write-downs ~$105M, other exit costs up to ~$215M). Accrued balance at September 30, 2010 was $399M. No number of employees affected disclosed. Expected completion date approximate, based on disclosure that most actions would be implemented within two years.
2010-09-30restructuringin_progressGlobalPharmaceutical Products; Vascular Products; commercial and R&D operationsUSD 7 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Legacy plan approved in 2009 and prior years to realign worldwide pharmaceutical and vascular manufacturing operations and selected domestic/international commercial and R&D operations. Announcement date not disclosed (plan predates the quarter). Charges of $7M recorded in the first nine months of 2010, primarily accelerated depreciation and product transfer costs; accrued balance of $49M at September 30, 2010. No employee counts disclosed.
2010-09-30restructuringin_progress2011-12-31GlobalDiagnostic Products — manufacturingUSD 45 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan approved in 2008 to streamline global manufacturing operations and improve efficiencies in the core diagnostics business; announcement date not disclosed (plan predates the quarter). Charges of approximately $45M recorded in the first nine months of 2010, primarily accelerated depreciation and product transfer costs; accrued balance of $89M at September 30, 2010. Additional charges expected through 2011 due to product re-registration and transition timelines. No employee counts disclosed.
2010-09-30restructuringin_progress2010-09-302012-09-30GlobalPharmaceutical ProductsUSD 436 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan approved in Q3 2010 primarily related to Solvay acquisition. Total expected charges $810M-$970M over two years, including ~$650M employee-related costs. Q3 charges recorded: $81M Cost of products sold, $133M R&D, $222M SG&A. Employee count not explicitly disclosed.
2010-09-30restructuringin_progress Restructuring Plan2008USD 45,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2010-09-30restructuringin_progress Restructuring Plan2009 And Prior YearsUSD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2010-06-30restructuringin_progress20082011GlobalDiagnostic Products (manufacturing)USD 29 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2008 plan to streamline global manufacturing and improve diagnostics efficiencies; charges of $29M in first six months 2010, primarily accelerated depreciation and product transfer costs. No employee count disclosed; additional charges expected through 2011.
2010-06-30restructuringin_progress2009GlobalPharmaceutical and Vascular manufacturing; commercial and R&D operationsUSD 3 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2009/prior-year plan to realign worldwide pharmaceutical and vascular manufacturing plus selected commercial and R&D operations; charges of $3M in first six months 2010. No employee count disclosed.
2010-06-30acquisition_additioncompleted2010-02-152010-02-15GlobalPharmaceutical Productsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Solvay Pharmaceuticals for approximately $6.1 billion cash plus contingent payments; control obtained 2010-02-15. Headcount added through the acquisition is not disclosed in this filing.
2010-06-30restructuringin_progress20082011GlobalDiagnostic business; Manufacturing operationsUSD 29 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan approved in 2008 to streamline global manufacturing and improve efficiencies in core diagnostic business. Charges of $29 million recorded in first six months of 2010, primarily for accelerated depreciation and product transfer costs. Additional charges expected through 2011.
2010-06-30restructuringin_progress2009WorldwidePharmaceutical and vascular manufacturing; Commercial and R&D operationsUSD 3 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plans approved in 2009 and prior years to realign worldwide pharmaceutical and vascular manufacturing and selected commercial/R&D operations. Charges of $3 million recorded in first six months of 2010, primarily for accelerated depreciation and product transfer costs.
2010-06-30restructuringin_progress Restructuring Plan2008USD 29,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2010-06-30restructuringin_progress Restructuring Plan2009 And Prior YearsUSD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2010-03-31restructuringin_progress2008-01-012011-12-31Diagnostics / global manufacturingUSD 14 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2008-approved plan to streamline global manufacturing and improve diagnostic business efficiency; Q1 2010 charges primarily accelerated depreciation and product transfer costs. Additional charges expected through 2011. No employee counts disclosed.
2010-03-31restructuringin_progress2009-01-01Pharmaceutical and vascular manufacturing; commercial and R&D operationsUSD 3 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2009-and-prior plans to realign worldwide pharmaceutical and vascular manufacturing and selected commercial and R&D operations to reduce costs; Q1 2010 charges primarily accelerated depreciation and product transfer costs. No employee counts disclosed.
2010-03-31acquisition_additioncompleted2010-02-15Pharmaceutical ProductsUSD 6 (billions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of Solvay's pharmaceuticals business for approximately $6.1 billion cash plus milestone payments; no headcount figures disclosed.
2010-03-31acquisition_additioncompleted2010-03-01Diagnostic Products (laboratory informatics)USD 105 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		March 2010 acquisition of STARLIMS Technologies for approximately $105 million cash; no headcount figures disclosed.
2010-03-31restructuringin_progress20082011-12-31GlobalDiagnostic Products; global manufacturing operationsUSD 14 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2010 charge of $14 million, primarily accelerated depreciation and product transfer costs; accrued balance $98 million at 2010-03-31. Additional charges expected through 2011. No employee counts disclosed.
2010-03-31restructuringin_progress2009GlobalPharmaceutical and vascular manufacturing; selected commercial and R&D operationsUSD 3 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2010 charge of $3 million, primarily accelerated depreciation and product transfer costs; accrued balance $114 million at 2010-03-31 after $31 million of payments. No employee counts disclosed.
2010-03-31acquisition_additioncompleted2010-02-15GlobalPharmaceutical Productsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Solvay Pharmaceuticals for approximately $6.1 billion cash plus contingent payments; acquired operations contributed approximately $210 million of net sales from 2010-02-15. Headcount added not disclosed.
2010-03-31acquisition_additioncompleted2010-04-20United StatesPharmaceutical Products (pipeline; multiple sclerosis and oncology)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Post-quarter acquisition of Facet Biotech Corporation for approximately $430 million cash, net of cash held. Headcount added not disclosed.
2010-03-31restructuringin_progress20082011-12-31GlobalDiagnostic ProductsUSD 14 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan approved in 2008 to streamline global manufacturing and improve efficiencies in core diagnostic business. Charges primarily for accelerated depreciation and product transfer costs. Additional charges expected through 2011.
2010-03-31restructuringin_progress2009GlobalPharmaceutical and Vascular ProductsUSD 3 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan approved in 2009 and prior years to realign worldwide pharmaceutical and vascular manufacturing and selected commercial/R&D operations. Charges primarily for accelerated depreciation and product transfer costs.
2009-12-31restructuringin_progress20082011GlobalDiagnostics (global manufacturing operations)USD 54 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Plan approved in 2008 to streamline global manufacturing and improve diagnostics efficiencies; fiscal 2009 charges were primarily accelerated depreciation and product transfer costs (a $129 million charge was recorded in 2008); accrued liability of $98 million at December 31, 2009; additional charges expected through 2011. Number of employees affected not disclosed.
2009-12-31restructuringin_progress2009WorldwidePharmaceutical and Vascular manufacturing; selected commercial and R&D operationsUSD 114 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Plans approved in 2009 and prior years to realign worldwide pharmaceutical and vascular manufacturing and selected domestic/international commercial and R&D operations; 2009 charge reflects facility impairments, employee severance and related items, plus a further $47 million of accelerated depreciation recorded in 2009; accrued balance $145 million at December 31, 2009. Number of employees affected not disclosed.
2009-12-31acquisition_additioncompleted2009-02-25Vision care (Advanced Medical Optics)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired outstanding AMO shares for approximately $1.4 billion cash net of cash held; control obtained February 25, 2009 and results consolidated from that date. Employees added not disclosed; 2,899,411 AMO stock options were converted to Abbott options under the incentive stock program.
2009-12-31acquisition_additioncompleted2009-01Diagnostics (molecular diagnostics for infectious disease)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired Ibis for $175 million cash in January 2009; with a $40 million 2008 investment, Abbott holds 100% of shares; goodwill of approximately $120 million allocated to the Diagnostics segment. Employees added not disclosed.
2009-12-31acquisition_additioncompleted2009-10Vision care (accommodating intraocular lens technology)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired 100% of Visiogen for $400 million cash in October 2009, adding next-generation accommodating intraocular lens technology for presbyopia/cataract patients. Employees added not disclosed.
2009-12-31acquisition_additioncompleted2009-10Vascular (percutaneous treatment for structural heart disease)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired 100% of Evalve for $320 million cash plus a $90 million payment contingent on regulatory milestones; prior investment revalued to fair value with $28 million of income recorded. Employees added not disclosed.
2009-12-31acquisition_additioncompleted2009-092010-02-15Pharmaceutical Productssubsequent_events
f5-10k / GLM-5.3-flash-HTML		Agreement announced September 2009; transaction closed February 15, 2010, after fiscal year-end, for EUR 4.5 billion (approximately $6.2 billion) cash plus up to EUR 300 million in sales milestones. Headcount to be added not disclosed.
2009-12-31restructuringin_progress2011-12-31GlobalDiagnostic ProductsUSD 54 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Program approved in 2008 to streamline global manufacturing and improve diagnostics efficiencies; $54M of additional charges recorded in FY2009 (primarily accelerated depreciation and product transfer costs), on top of the $129M 2008 charge. Accrued balance $98M at year-end; charges expected through 2011. Employees affected not disclosed.
2009-12-31restructuringin_progressGlobalPharmaceutical Products; Vascular Products; commercial and R&D operationsUSD 114 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2009 charges of $114M for realigning pharmaceutical and vascular manufacturing plus selected commercial and R&D operations (asset impairments, severance, other), classified as SG&A; an additional $47M of accelerated depreciation was recorded in 2009 for these restructurings. Accrued balance $145M at year-end. Employees affected not disclosed.
2009-12-31acquisition_additioncompleted2009-01-012009-01-31United StatesDiagnostic ProductsUSD 175 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquired Ibis Biosciences, Inc. for $175M cash to expand molecular diagnostics; exact closing date not stated (January 2009). Headcount added not disclosed.
2009-12-31acquisition_additioncompleted2009-02-252009-02-25United StatesVision care (Advanced Medical Optics)USD 1,400 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquired Advanced Medical Optics, Inc. for approximately $1.4B cash net of cash held; control obtained February 25, 2009, financed with long-term debt. AMO represented approximately 7% of consolidated total assets and 3% of net sales for FY2009. Headcount added not disclosed.
2009-12-31acquisition_additioncompleted2009-10-012009-10-31United StatesVision care (Visiogen)USD 400 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquired 100% of Visiogen, Inc. for $400M cash (October 2009) for accommodating intraocular lens technology. Exact closing date not stated. Headcount added not disclosed.
2009-12-31acquisition_additioncompleted2009-10-012009-10-31United StatesVascular Products (Evalve)USD 320 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquired Evalve, Inc. for $320M cash plus up to $90M contingent on regulatory milestones (October 2009), adding a percutaneous structural heart disease presence. Exact closing date not stated. Headcount added not disclosed.
2009-12-31acquisition_additionannounced2009-09-012010-02-15GlobalPharmaceutical ProductsUSD 6,200 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Agreement announced September 2009 to acquire Solvay Group's pharmaceuticals business for EUR 4.5B (~$6.2B) cash plus up to EUR 300M milestone payments; transaction closed February 15, 2010 (after fiscal year-end, before filing). Expected to add approximately $500M of R&D spending; acquired business forecast at ~$2.9B of 2010 sales. Headcount added not disclosed.
2009-12-31restructuringin_progress20082011GlobalDiagnostic ProductsUSD 54 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2008 plan to streamline global manufacturing operations and improve efficiencies in core diagnostic business. $54 million charged in 2009 for accelerated depreciation and product transfer costs. Additional charges expected through 2011.
2009-12-31restructuringin_progress2007GlobalPharmaceutical and Vascular ManufacturingUSD 114 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Plans to realign worldwide pharmaceutical and vascular manufacturing operations and selected domestic and international commercial and R&D operations. $114 million charged in 2009 reflecting impairment of facilities, employee severance, and other related charges.
2009-12-31restructuringin_progress20082011GlobalDiagnostic ProductsUSD 183 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Plan to streamline global manufacturing operations and improve efficiencies in core diagnostic business. $129M charge in 2008, $54M in 2009. Additional charges expected through 2011.
2009-12-31restructuringin_progress2007GlobalPharmaceutical and VascularUSD 161 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Plans to realign worldwide pharmaceutical and vascular manufacturing and selected commercial/R&D operations. $114M charge in 2009, $36M in 2008, $107M in 2007. Includes asset impairments and severance.
2009-12-31acquisition_additioncompleted2009-02-25GlobalDiagnostic ProductsUSD 1,400 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Advanced Medical Optics, Inc. (AMO) for approx $1.4 billion. Headcount not explicitly disclosed.
2009-12-31acquisition_additioncompleted2009-10GlobalDiagnostic ProductsUSD 400 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Visiogen, Inc. for $400 million. Headcount not explicitly disclosed.
2009-12-31acquisition_additioncompleted2009-10GlobalVascular ProductsUSD 320 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Evalve, Inc. for $320 million plus $90 million milestones. Headcount not explicitly disclosed.
2009-12-31acquisition_additioncompleted2009-01GlobalDiagnostic ProductsUSD 175 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Ibis Biosciences, Inc. for $175 million. Headcount not explicitly disclosed.
2009-09-30acquisition_additioncompleted2009-02-25Ophthalmic surgical technology and devices (Other segment)USD 1 (billions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of Advanced Medical Optics, Inc. for approximately $1.4 billion cash net of cash acquired; no headcount figure disclosed
2009-09-30acquisition_additioncompleted2009-01-01Molecular diagnostics (Diagnostic Products segment)USD 175 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of Ibis Biosciences, Inc. for $175 million cash; no headcount figure disclosed
2009-09-30acquisition_additioncompleted2009-10-20Ophthalmology / intraocular lens technologyUSD 400 (millions)subsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of Visiogen, Inc. for $400 million cash; no headcount figure disclosed
2009-09-30acquisition_additioncompleted2009-10-30Structural heart disease (non-surgical treatment)USD 320 (millions)subsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of Evalve, Inc. for $320 million cash plus up to $90 million on regulatory milestones; no headcount figure disclosed
2009-09-30acquisition_additionannounced9,0002009-09-282010-03-31Global (majority outside the U.S.)Pharmaceutical Products; vaccines; molecular diagnosticsEUR 5 (billions)other
f5-10q / GLM-5.3-flash-fp4-HTML		Announced agreement to acquire Solvay's pharmaceuticals business for EUR 4.5 billion plus up to EUR 300 million in milestone payments; Solvay Pharmaceuticals employs more than 9,000 people; expected to close in Q1 2010
2009-09-30restructuringin_progress2008-01-012011-12-31GlobalGlobal manufacturing operations; core diagnostic businessUSD 38 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plan to streamline global manufacturing and improve diagnostic efficiencies; approximately $38 million of additional charges in first nine months 2009, primarily accelerated depreciation and product transfer costs; additional charges through 2011; no employee counts disclosed
2009-09-30restructuringin_progress2009-01-01WorldwidePharmaceutical and vascular manufacturing; commercial and R&D operationsUSD 26 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plans to realign worldwide pharmaceutical and vascular manufacturing and selected commercial and R&D operations; $26 million of additional charges in first nine months 2009; no employee counts disclosed
2009-09-30restructuringin_progress2008-01-012011-12-31GlobalDiagnostic Products (manufacturing)USD 38 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program approved in 2008 to streamline global manufacturing and improve diagnostics efficiencies; charges primarily accelerated depreciation and product transfer costs. No employee count disclosed.
2009-09-30restructuringin_progress2009-01-01GlobalPharmaceutical and Vascular manufacturing; commercial and R&D operationsUSD 26 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program to realign worldwide pharmaceutical and vascular manufacturing plus selected commercial and R&D operations; charges primarily accelerated depreciation and product transfer costs. No employee count disclosed.
2009-09-30acquisition_additioncompleted2009-02-252009-02-25United StatesOphthalmic surgical technology and eye care (Other segment)USD 1,400 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Advanced Medical Optics, Inc. for approximately $1.4 billion cash; no headcount added disclosed.
2009-09-30acquisition_additioncompleted2009-01-012009-01-31United StatesMolecular diagnostics (Diagnostic Products segment)USD 175 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Ibis Biosciences, Inc. for $175 million cash; no headcount added disclosed.
2009-09-30acquisition_additionannounced2009-09-262010-03-31GlobalPharmaceutical ProductsUSD 6,600 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement to acquire Solvay's pharmaceuticals business for EUR 4.5 billion (~$6.6 billion); Solvay unit employs more than 9,000 people worldwide per press release. Expected close Q1 2010.
2009-09-30acquisition_additionannounced2009-10-202009-10-20United StatesOphthalmic (vision care)USD 400 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Post-quarter acquisition of Visiogen, Inc. for $400 million cash; no headcount disclosed.
2009-09-30acquisition_additionannounced2009-10-302009-10-30United StatesVascular / structural heart diseaseUSD 320 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Post-quarter acquisition of Evalve, Inc. for $320 million cash plus up to $90 million in milestones; no headcount disclosed.
2009-09-30restructuringin_progress2008-01-012011-12-31GlobalDiagnostic ProductsUSD 38 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan approved in 2008 to streamline global manufacturing operations and improve efficiencies in core diagnostic business. Additional charges of $38 million recorded in first nine months of 2009, primarily for accelerated depreciation and product transfer costs. Additional charges expected through 2011.
2009-09-30restructuringin_progress2009-01-01GlobalPharmaceutical and VascularUSD 26 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plans approved in 2009 and prior years to realign worldwide pharmaceutical and vascular manufacturing operations and selected domestic and international commercial and R&D operations. Additional charges of $26 million recorded in first nine months of 2009, primarily for accelerated depreciation and product transfer costs.
2009-09-30acquisition_additioncompleted2009-02-25GlobalOther (Advanced Medical Optics)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired Advanced Medical Optics, Inc. on February 25, 2009. Headcount not explicitly disclosed.
2009-09-30acquisition_additioncompleted2009-01-01GlobalDiagnostic Products (Ibis Biosciences)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired Ibis Biosciences, Inc. in January 2009. Headcount not explicitly disclosed.
2009-09-30acquisition_additionannounced2009-09-262010-03-31GlobalPharmaceutical Products (Solvay)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Announced agreement to acquire Solvay's pharmaceuticals business. Expected to close in first quarter of 2010. Headcount not explicitly disclosed.
2009-09-30acquisition_additionannounced2009-10-20GlobalOther (Visiogen)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Acquired Visiogen, Inc. on October 20, 2009. Headcount not explicitly disclosed.
2009-09-30acquisition_additionannounced2009-10-30GlobalVascular Products (Evalve)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Acquired Evalve, Inc. on October 30, 2009. Headcount not explicitly disclosed.
2009-06-30restructuringin_progress2008-01-012011-12-31Global manufacturing operations and core diagnostic businessUSD 23 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2008-approved plan to streamline global manufacturing and improve diagnostic efficiencies; first-half 2009 charges primarily accelerated depreciation and product transfer costs; additional charges expected through 2011. Accrued balance $101 million at June 30, 2009. No employee counts disclosed.
2009-06-30restructuringin_progress2009-01-01Worldwide pharmaceutical and vascular manufacturing; selected domestic and international commercial and R&D operationsUSD 20 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2009 and prior-year plans to realign manufacturing and commercial/R&D operations to reduce costs; first-half 2009 charges primarily accelerated depreciation and product transfer costs. Accrued balance $97 million at June 30, 2009. No employee counts disclosed.
2009-06-30acquisition_additioncompleted2009-02-252009-02-25Ophthalmic surgical technology and eye care (reported in Other)USD 1 (billions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of Advanced Medical Optics, Inc. for approximately $1.4 billion cash net of cash acquired; no headcount figures disclosed.
2009-06-30acquisition_additioncompleted2009-01-012009-01-31Molecular diagnostics for infectious disease (Diagnostic Products segment)USD 175 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of Ibis Biosciences, Inc. for $175 million cash; no headcount figures disclosed.
2009-06-30restructuringin_progress2008-01-012011-12-31GlobalDiagnostic Products (manufacturing)USD 23 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan approved in 2008 to streamline global manufacturing and improve diagnostics efficiencies; $23M additional charges in first six months of 2009, primarily accelerated depreciation and product transfer costs. Accrued balance $101M at June 30, 2009. No employee count disclosed.
2009-06-30restructuringin_progress2009-01-01GlobalPharmaceutical and Vascular manufacturing; commercial and R&D operationsUSD 20 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plans approved in 2009 and prior years to realign worldwide pharmaceutical/vascular manufacturing and selected commercial and R&D operations; $20M additional charges in first six months of 2009. Accrued balance $97M at June 30, 2009. No employee count disclosed.
2009-06-30acquisition_additioncompleted2009-02-252009-02-25United StatesOphthalmic surgical technology and eye care (Other segment)USD 1,400 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Advanced Medical Optics, Inc. for approximately $1.4 billion cash net of cash held; control acquired February 25, 2009. Headcount added not disclosed.
2009-06-30acquisition_additioncompleted2009-01-012009-01-01United StatesDiagnostic Products (molecular diagnostics)USD 175 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Ibis Biosciences, Inc. for $175 million cash. Headcount added not disclosed.
2009-06-30restructuringin_progress20082011-12-31GlobalDiagnostic ProductsUSD 23 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan approved in 2008 to streamline global manufacturing operations and improve efficiencies in core diagnostic business. Charges primarily for accelerated depreciation and product transfer costs.
2009-06-30restructuringin_progress2009GlobalPharmaceutical and VascularUSD 20 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plans to realign worldwide pharmaceutical and vascular manufacturing operations and selected domestic and international commercial and R&D operations. Charges primarily for accelerated depreciation and product transfer costs.
2009-03-31restructuringin_progress2008-01-012011-12-31GlobalDiagnostic Products / global manufacturingUSD 9 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plan to streamline global manufacturing operations and improve efficiencies in core diagnostics business; Q1 2009 charges primarily accelerated depreciation and product transfer costs; additional charges expected through 2011. Accrued balance $110 million at March 31, 2009. No employee counts disclosed.
2009-03-31restructuringin_progress2009-01-01WorldwidePharmaceutical and vascular manufacturing; commercial and R&D operationsUSD 26 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plans approved in 2009 and prior years to realign worldwide pharmaceutical and vascular manufacturing and selected commercial and R&D operations to reduce costs; Q1 2009 charges of $26 million (vs. $11 million in Q1 2008), primarily accelerated depreciation and product transfer costs. Accrued balance $107 million at March 31, 2009. No employee counts disclosed.
2009-03-31acquisition_additioncompleted2009-02-252009-02-25Ophthalmic surgical technology and eye care (Vascular/medical devices)USD 1 (billions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquired Advanced Medical Optics, Inc. for approximately $1.4 billion cash net of cash acquired; results consolidated from February 25, 2009. Headcount added not disclosed.
2009-03-31acquisition_additioncompleted2009-01-012009-01-31Molecular diagnostics (Diagnostic Products segment)USD 175 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquired Ibis Biosciences, Inc. for $175 million cash (including a $40 million 2008 investment), expanding molecular diagnostics for infectious disease. Headcount added not disclosed.
2009-03-31restructuringin_progress2008-01-012011-12-31GlobalDiagnostic Products — manufacturing operationsUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2008 plan to streamline global manufacturing and improve efficiencies in core diagnostics. Roll-forward shows $1M accrual charge in Q1 2009; narrative cites approximately $9M of additional charges, primarily accelerated depreciation and product transfer costs. Accrued balance $110M at 2009-03-31. No employee count disclosed.
2009-03-31restructuringin_progress2009-01-01GlobalPharmaceutical and vascular manufacturing; selected commercial and R&D operationsUSD 26 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plans to realign worldwide pharmaceutical and vascular manufacturing plus selected commercial and R&D operations. Q1 2009 restructuring charges of $26M per roll-forward; narrative also cites $9M of additional charges, primarily accelerated depreciation and product transfer costs. Accrued balance $107M at 2009-03-31. No employee count disclosed.
2009-03-31acquisition_additioncompleted2009-02-252009-02-25United StatesOphthalmic surgical technology and eye care solutions (Vascular/other)USD 1,400 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Advanced Medical Optics, Inc. for approximately $1.4 billion cash, net of cash held; control obtained 2009-02-25. Purchase price shown, not a workforce charge. Headcount added not disclosed.
2009-03-31acquisition_additioncompleted2009-01-012009-01-01United StatesDiagnostic Products — molecular diagnosticsUSD 175 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Ibis Biosciences, Inc. for $175 million in cash in January 2009. Purchase price shown, not a workforce charge. Exact announcement date not disclosed; month only. Headcount added not disclosed.
2009-03-31restructuringin_progress2011-12-31GlobalDiagnostic ProductsUSD 9 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan to streamline global manufacturing operations and improve efficiencies in core diagnostic business. Charges primarily for accelerated depreciation and product transfer costs. Additional charges expected through 2011.
2009-03-31restructuringin_progressGlobalPharmaceutical and VascularUSD 26 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plans to realign worldwide pharmaceutical and vascular manufacturing operations and selected domestic and international commercial and R&D operations. Charges primarily for accelerated depreciation and product transfer costs.
2008-12-31restructuringin_progress20082011GlobalGlobal manufacturing operations with focus on core Diagnostic businessUSD 370 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Plan to streamline global manufacturing and improve diagnostic efficiency; expected pretax charges comprise ~$110M employee-related costs, ~$75M accelerated depreciation and ~$185M other exit costs mainly for product transfers. Recorded in 2008: ~$129M to cost of products sold plus ~$16M additional primarily accelerated depreciation; accrued balance $110M at year-end 2008.
2008-12-31restructuringin_progress2008Worldwide; selected domestic and internationalPharmaceutical and vascular manufacturing operations; selected commercial and R&D operationsUSD 36 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		2008 tranche of realignment plans approved 2006-2008; charge reflects facility impairments, employee severance and related costs. An additional ~$81M was recorded in 2008 across these restructurings, primarily accelerated depreciation; accrued employee-related and other balance $105M at year-end 2008. Headcount affected not disclosed.
2008-12-31acquisition_additioncompleted2008-04-302008-04-30United StatesPharmaceutical Products — Lupron businessother
f5-10k / GLM-5.3-flash-HTML		Transaction date April 30, 2008: Abbott exchanged its 50% TAP equity interest for the Lupron business including its employees. TAP had ~2,900 employees in total, but the number transferring to Abbott (Lupron-related personnel) is not disclosed. ~$94M gain at closing; ~$700M intangibles and ~$350M goodwill recorded.
2008-12-31divestiture_reductioncompleted20082008Spine businessother
f5-10k / GLM-5.3-flash-HTML		Spine business sold in the fourth quarter of 2008 for ~$360M cash; after-tax gain of ~$147M presented as gain on sale of discontinued operations. Headcount removed with the divestiture not disclosed.
2008-12-31acquisition_additionannounced2009-012009-03Ophthalmic surgical technology and devices; eye care solutions (vision care)subsequent_events
f5-10k / GLM-5.3-flash-HTML		Agreement to acquire Advanced Medical Optics, Inc. for ~$2.8B in cash and debt, to be financed with operating cash flow and debt; expected to close in the first quarter of 2009. AMO annual sales exceed $1B. Headcount not disclosed.
2008-12-31restructuringin_progress20082011-12-31GlobalDiagnostic Products — manufacturing operationsUSD 370 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Multi-year program approved in 2008 to streamline global manufacturing and improve diagnostics efficiencies; total pretax charges of approximately $370 million over several years, of which $129 million was charged to cost of products sold in 2008 plus approximately $16 million of accelerated depreciation. Charges comprise employee-related costs of ~$110M, accelerated depreciation of ~$75M, and other exit costs of ~$185M. Employees affected not disclosed. Accrued balance at 2008 year-end was $110 million.
2008-12-31restructuringin_progress2008GlobalPharmaceutical Products and Vascular Products — manufacturing, commercial and R&D operationsUSD 36 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Ongoing multi-year realignment program (first approved in prior years) covering pharmaceutical and vascular manufacturing plus selected commercial and R&D operations. Current-year 2008 charges of approximately $36 million, plus approximately $81 million of subsequent charges primarily for accelerated depreciation recorded in 2008. Employees affected not disclosed; accrued balance at 2008 year-end was $105 million. Prior-year activity (2006: $210M; 2007: $159M) not extracted.
2008-12-31divestiture_reductioncompleted2008-10-012008-12-31Not disclosedSpine businessdiscontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Spine business sold in Q4 2008 for approximately $360 million in cash, producing an after-tax gain of approximately $147 million. Announcement date approximated to the quarter; employees affected not disclosed. Operations not presented as discontinued operations because effects were not significant.
2008-12-31acquisition_additioncompleted2008-04-302008-04-30United StatesPharmaceutical Products — Lupron businessrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		TAP joint venture concluded 2008-04-30; Abbott exchanged its 50% TAP interest for the assets, liabilities and employees related to TAP's Lupron business. Employees added through the exchange not quantified. Recorded intangibles of ~$700M, goodwill of ~$350M, and a $94M gain at closing.
2008-12-31acquisition_additionannounced2009-01-312009-03-31Not disclosedAdvanced Medical Optics, Inc. — ophthalmic surgical technology and eye careUSD 2,800 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Announced January 2009, after fiscal year-end and before filing date; agreement to acquire AMO for approximately $2.8 billion in cash and debt, expected to close in Q1 2009. AMO annual sales exceed $1 billion. Announcement date given only as month (2009-01); employees to be added not disclosed.
2008-12-31restructuringin_progress2008-01-012011-12-31GlobalDiagnostic ProductsUSD 370 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Plan to streamline global manufacturing operations and improve efficiencies in core diagnostic business. Pretax charges of approx $370M over several years, including $110M employee-related costs. Charges occur through 2011.
2008-12-31restructuringin_progress2006-01-01GlobalPharmaceutical and VascularUSD 117 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Realignment of worldwide pharmaceutical and vascular manufacturing and selected commercial/R&D operations. $36M charge in 2008 (employee severance/impairments) and $81M accelerated depreciation. Part of multi-year program initiated in 2006.
2008-12-31acquisition_additioncompleted2008-04-302008-04-30United StatesPharmaceutical ProductsItem_1_Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Conclusion of TAP joint venture; Abbott exchanged equity for assets, liabilities, and employees related to Lupron business. Employees transferred to Abbott.
2008-12-31restructuringin_progress20082011-12-31GlobalDiagnostic Products; ManufacturingUSD 370 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Plan to streamline global manufacturing operations and improve efficiencies in core diagnostic business. Total pretax charges approx $370M over several years. Includes employee-related costs of approx $110M. Charges to occur through 2011.
2008-12-31restructuringin_progress2006GlobalPharmaceutical Products; Vascular Products; Commercial; R&DUSD 36 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Realignment of worldwide pharmaceutical and vascular manufacturing, commercial, and R&D operations. $36M charge recorded in 2008 (impairment, severance, other). Additional $81M recorded in 2008 for accelerated depreciation. Up to $21M additional expected in future periods.
2008-09-30restructuringin_progress2008-09-302011-12-31GlobalGlobal manufacturing operations and core diagnostics businessUSD 370 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q3 2008 plan to streamline global manufacturing and improve diagnostics efficiency; total pre-tax charges of ~$370M comprise ~$110M employee-related, ~$75M accelerated depreciation, and ~$185M other exit costs. ~$136M recorded in Q3 2008 ($129M in cost of products sold plus ~$7M accelerated depreciation); remainder through 2011 due to product re-registration and transition timelines. No employee counts disclosed.
2008-09-30divestiture_reductioncompleted2008-09-302008-10-31Spine businessUSD 360 (millions)other
f5-10q / GLM-5.3-flash-fp4-HTML		Agreement to sell the spine business for $360 million in cash; transaction closed in October 2008 with a pretax gain of ~$150 million to be recorded in Q4 2008. Not presented as discontinued operations. No headcount figures disclosed.
2008-09-30restructuringin_progress2011-12-31GlobalDiagnostic ProductsUSD 370 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan approved in Q3 2008 to streamline global manufacturing and improve efficiencies in the core diagnostics business; $129M charged to cost of products sold in Q3 2008 plus ~$7M additional accelerated depreciation; no employee count disclosed. Charges comprise ~$110M employee-related, ~$75M accelerated depreciation, ~$185M other exit costs, running through 2011.
2008-09-30restructuringin_progressGlobalPharmaceutical Products; commercial and R&D operationsUSD 36 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ongoing plans approved in 2008, 2007 and 2006 to realign worldwide pharmaceutical manufacturing and selected commercial and R&D operations; $36M of charges recorded in the nine months ended 2008-09-30 (includes $61M of additional accelerated depreciation charges recorded in the period); accrued balance of $145M at 2008-09-30. No employee count disclosed.
2008-09-30acquisition_additioncompleted2008-04-302008-04-30United StatesPharmaceutical Products (Lupron business)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		On conclusion of the TAP joint venture, Abbott exchanged its 50% interest for the assets, liabilities and employees related to TAP's Lupron business; no headcount transferred disclosed.
2008-09-30divestiture_reductionannounced2008-10-31Not specifiedSpine businesssubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement to sell the spine business for $360M cash announced in Q3 2008; transaction closed in October 2008 with an expected pretax gain of ~$150M recorded in Q4 2008. No employee count disclosed; business not presented as discontinued operations.
2008-09-30restructuringin_progress2008-09-302011-12-31GlobalDiagnostic ProductsUSD 370 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan to streamline global manufacturing operations and improve efficiencies in core diagnostic business. Charges include employee-related costs of approx $110M, accelerated depreciation of $75M, and other exit costs of $185M. Charges to occur through 2011.
2008-09-30restructuringin_progress2008-01-01GlobalPharmaceutical ProductsUSD 61 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Realignment of worldwide pharmaceutical manufacturing operations and selected domestic/international commercial and R&D operations. Charges primarily for accelerated depreciation.
2008-06-30restructuringin_progressWorldwideWorldwide pharmaceutical manufacturing operations; selected domestic and international commercial and R&D operationsUSD 44 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Additional charges of $44 million recorded in first six months of 2008 under realignment plans approved in 2005-2007, primarily for accelerated depreciation. Accrued restructuring balance declined from $194 million at January 1, 2008 to $146 million at June 30, 2008 after $59 million of payments and adjustments. No employee counts disclosed.
2008-06-30acquisition_additioncompleted2008-04-302008-04-30United StatesPharmaceutical Products (Lupron business)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Abbott exchanged its 50 percent equity interest in the TAP joint venture for the assets, liabilities and employees related to TAP's Lupron business; transaction closed April 30, 2008. Headcount transferred not quantified.
2008-06-30restructuringin_progressWorldwidePharmaceutical manufacturing; selected commercial and R&D operationsUSD 44 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Programs approved in 2005-2007 to realign manufacturing and selected commercial/R&D operations; $44M additional charges in first six months of 2008, primarily accelerated depreciation. No employee counts disclosed. Restructuring accrual balance was $146M at 2008-06-30 (charges of $11M and payments/adjustments of $59M during the period).
2008-06-30acquisition_additioncompleted2008-04-302008-04-30United StatesPharmaceutical Products (Lupron business)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Abbott exchanged its 50% TAP joint venture interest for the assets, liabilities and employees of TAP's Lupron business; headcount transferred not quantified. Recorded ~$700M intangibles, ~$350M goodwill, and a ~$1.1B contingent liability.
2008-06-30restructuringin_progressworldwidepharmaceutical manufacturing, commercial, and R&DUSD 11 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges primarily for accelerated depreciation related to realignment of operations approved in 2005-2007.
2008-06-30acquisition_additioncompleted2008-04-30United StatesPharmaceutical Productsbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Abbott exchanged equity interest in TAP for assets, liabilities, and employees related to TAP's Lupron business.
2008-03-31restructuringin_progressWorldwidePharmaceutical and vascular manufacturing; commercial and R&D operations; Kos Pharmaceuticals facilitiesUSD 22 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2008 charges of $22 million (plus $14 million in Q1 2007) relate to previously approved realignment plans, primarily accelerated depreciation; no employee counts disclosed. Accrued restructuring balance fell from $194 million at January 1 to $157 million at March 31, 2008.
2008-03-31acquisition_additioncompleted2008-04-302008-04-30United StatesPharmaceutical Products (Lupron business)subsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		On April 30, 2008 Abbott and Takeda concluded the TAP joint venture; Abbott exchanged its equity interest for the assets, liabilities and employees related to TAP's Lupron business. Headcount transferred not disclosed.
2008-03-31restructuringin_progressWorldwidePharmaceutical and vascular manufacturing; selected commercial and R&D operationsUSD 22 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Multi-year realignment programs approved in 2005-2007, including Kos facilities restructuring; Q1 2008 additional charge of $22 million, primarily accelerated depreciation. Restructuring accrual was $157 million at 2008-03-31. No employee counts, severance-specific amounts, or completion dates disclosed.
2008-03-31acquisition_additioncompleted2008-03-192008-04-30United StatesPharmaceutical Productssubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Contribution and Exchange Agreement dated 2008-03-19; TAP joint venture concluded 2008-04-30 with Abbott taking TAP's Lupron assets, liabilities and related employees. No headcount transferred disclosed.
2008-03-31restructuringin_progressWorldwidePharmaceutical and Vascular manufacturing; Commercial and R&D operationsUSD 22 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges primarily for accelerated depreciation related to plans approved in 2005-2007.
2008-03-31otherannounced2008-04-302008-05-01United StatesPharmaceutical Productssubsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Abbott exchanged equity interest in TAP joint venture for assets, liabilities, and employees related to Lupron business.
2007-12-31restructuringin_progress2007WorldwidePharmaceutical and Vascular manufacturing operations; selected domestic and international commercial and research and development operationsUSD 160 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		FY2007 roll-forward charges of $160M comprise $122M employee-related and other plus $38M asset impairments; MD&A narrative separately cites roughly $107M pretax charges plus $90M subsequent accelerated depreciation (figures do not reconcile in the filing). Severance payments of $121M in 2007 left a $194M accrual at year-end; up to $73M of additional charges expected, primarily accelerated depreciation. No employee headcount affected is disclosed.
2007-12-31restructuringcompleted2007United StatesPharmaceutical Products (acquired Kos Pharmaceuticals Inc. operations)USD 52 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Facilities restructuring plans implemented during fiscal 2007 for the acquired Kos operations; approximately $52M of costs capitalized, increasing goodwill rather than expensed. No headcount or severance amounts disclosed.
2007-12-31restructuringin_progressWorldwidePharmaceutical and vascular manufacturing; selected domestic and international commercial and R&D operationsUSD 107 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2007 pretax charges of approximately $107 million for asset impairment, employee severance and related charges; an additional $90 million, primarily accelerated depreciation, was also recorded in 2007. Accrued restructuring balance of $194 million remained at December 31, 2007 and Abbott expected up to $73 million of future charges. Number of employees affected was not disclosed. Includes 2007 facilities restructuring related to the acquired Kos Pharmaceuticals operations, which increased goodwill by approximately $52 million.
2007-12-31restructuringin_progress2007-01-01WorldwidePharmaceutical and Vascular Manufacturing; Commercial and R&D OperationsUSD 107 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Pretax charges of approximately $107 million recorded in 2007 reflecting impairment of manufacturing facilities and other assets, employee severance and other related charges. Additional $90 million recorded for accelerated depreciation. Future charges up to $73 million expected.
2007-12-31acquisition_additioncompleted2006-12-13United StatesPharmaceutical Productsbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of Kos Pharmaceuticals Inc. completed December 13, 2006. Financial results included beginning on that date. No specific headcount disclosed.
2007-12-31acquisition_additioncompleted2006-04-21WorldwideVascular Productsbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of Guidant's vascular intervention and endovascular solutions businesses completed April 21, 2006. Financial results included beginning on that date. No specific headcount disclosed.
2007-12-31restructuringin_progress2007WorldwidePharmaceutical and vascular manufacturing; domestic and international commercial and R&DUSD 107 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Pretax charges of approximately $107 million recorded in 2007 reflecting impairment of manufacturing facilities and other assets, employee severance and other related charges. Additional $90 million recorded for accelerated depreciation. Employee count not explicitly disclosed in text.
2007-12-31acquisition_additioncompleted2006-12-13United StatesPharmaceutical ProductsMD&A
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Kos Pharmaceuticals Inc. in December 2006. Headcount added not explicitly disclosed.
2007-12-31acquisition_additioncompleted2006-04-21WorldwideVascular ProductsMD&A
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Guidant's vascular intervention and endovascular solutions businesses in April 2006. Headcount added not explicitly disclosed.
2007-09-30restructuringin_progressWorldwide pharmaceutical manufacturing operations and selected domestic and international commercial and R&D operationsUSD 45 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Restructuring charges of $44.7 million recorded in first nine months of 2007, primarily accelerated depreciation; accrued liability of $131.8 million at September 30, 2007. No employee counts disclosed. Also includes facilities restructuring related to Kos Pharmaceuticals operations that increased goodwill by approximately $52 million.
2007-09-30othercompleted2007-07-11Core laboratory diagnostics businessUSD 99 (millions)MD&A
f5-10q / GLM-5.3-flash-fp4-HTML		Abbott and GE mutually terminated the contract to sell the core laboratory diagnostics business; assets reclassified to held and used, with approximately $99 million of suspended depreciation and amortization recorded in Q3 2007. No workforce impact quantified.
2007-09-30restructuringin_progressWorldwidePharmaceutical manufacturing; selected domestic and international commercial and R&D operationsUSD 45 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Programs approved in 2005-2007 to realign manufacturing and selected commercial/R&D operations; $44.7M charged in 2007 YTD (vs. none in 2006 YTD), primarily accelerated depreciation. Accrued balance $131.8M at 2007-09-30. No employee counts or completion dates disclosed.
2007-09-30restructuringin_progress2007-04-01United StatesKos Pharmaceuticals Inc. acquired operations — facilities restructuringUSD 52 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Facilities restructuring implemented in Q2 2007 for acquired Kos operations; charge increased goodwill by approximately $52M. No employee counts disclosed.
2007-09-30restructuringin_progressWorldwidePharmaceutical manufacturing, commercial, and R&DUSD 77 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges primarily for accelerated depreciation related to realignment of worldwide pharmaceutical manufacturing and selected domestic/international commercial and R&D operations.
2007-09-30restructuringcompletedKos Pharmaceuticals Inc. acquired operationsUSD 52 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Facilities restructuring plans implemented in Q2 2007 resulted in an increase to goodwill of approximately $52 million.
2007-06-30restructuringin_progressWorldwidePharmaceutical manufacturing operations and selected domestic and international commercial and R&D operationsUSD 59 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Multi-year realignment program approved in 2007, 2006 and 2005 to reduce costs; first-half 2007 charges of $67 million primarily for accelerated depreciation, of which $58.8 million recorded as restructuring charges in the accrual roll-forward. Accrued balance of $188.6 million at June 30, 2007. No employee counts disclosed.
2007-06-30restructuringcompleted2007-04-01Kos Pharmaceuticals Inc. acquired operationsUSD 52 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Facilities restructuring plans implemented in Q2 2007 related to acquired Kos operations; resulted in an increase to goodwill of approximately $52 million. No employee counts disclosed.
2007-06-30divestiture_reductionannounced2007-07-11Core laboratory diagnostics business, including Abbott Point of Careother
f5-10q / GLM-5.3-flash-fp4-HTML		Abbott and GE mutually agreed to terminate the previously announced contract to sell the core laboratory diagnostics business to GE; assets and liabilities held for sale ($3,484.8 million assets, $608.1 million liabilities) will no longer be classified as held for sale beginning Q3 2007. No headcount figures disclosed.
2007-06-30restructuringin_progressWorldwidePharmaceutical manufacturing; selected commercial and R&D operationsUSD 59 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Multi-year realignment plans approved in 2005-2007; roll-forward shows $58.8M charges in 2007 YTD and $188.6M accrued at June 30, 2007. Narrative also cites $67M of additional charges (primarily accelerated depreciation) in first six months of 2007. No employee counts, completion dates, or severance-specific amounts disclosed.
2007-06-30restructuringin_progressKos Pharmaceuticals Inc. acquired operations (facilities)USD 52 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Facilities restructuring plans implemented in Q2 2007 for acquired Kos operations; charge recorded as an increase to goodwill rather than expense. No headcount impact disclosed.
2007-06-30restructuringin_progressworldwidepharmaceutical manufacturing, commercial, and R&DUSD 59 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges primarily for accelerated depreciation related to realignment of operations.
2007-06-30restructuringcompletedKos Pharmaceuticals Inc. acquired operationsUSD 52 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Facilities restructuring plans resulted in an increase to goodwill of approximately $52 million.
2007-03-31restructuringin_progressWorldwide (manufacturing); domestic and international (commercial and R&D)Pharmaceutical manufacturing; selected commercial and research and development operationsUSD 6 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Programs approved in 2005, 2006 and 2007 to realign manufacturing and selected commercial/R&D operations; Q1 2007 charge of $6.4M plus $14M of additional charges (primarily accelerated depreciation). Accrued balance fell from $193.3M to $166.5M. No employee counts, severance-specific amounts, or completion dates disclosed.
2007-03-31divestiture_reductionannounced2007-01-182007-09-30GlobalDiagnostic Products segment — core laboratory diagnostics business, including Abbott Point of Careother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement to sell the business to GE for $8.13 billion cash; expected to close no later than Q3 2007 subject to regulatory approvals. No headcount associated with the divested operations is disclosed; estimated after-tax gain of approximately $3.5 billion.
2007-03-31restructuringin_progressworldwidepharmaceutical manufacturing, commercial, and research and developmentUSD 14 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges primarily for accelerated depreciation related to realignment of operations.
2006-12-31restructuringin_progress2006WorldwideWorldwide pharmaceutical manufacturing; selected domestic and international commercial and research and development operationsUSD 210 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Plans approved in 2005 and 2006 to realign manufacturing and commercial/R&D operations. 2006 pretax charge of $210.3M comprises $117.7M employee-related and other plus $92.6M asset impairments. Accrued employee-related balance of $193.3M at year-end 2006; up to an additional $128M expected, primarily accelerated depreciation. Manufacturing realignments expected to continue into 2007. Number of employees affected not disclosed.
2006-12-31acquisition_additioncompleted2006-04-21Not disclosedVascular Products (Guidant vascular intervention and endovascular solutions businesses)USD 4,128 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquisition completed April 21, 2006 (date used in lieu of a separately disclosed announcement date) for approximately $4.1B in cash, in connection with Boston Scientific's acquisition of Guidant; total preliminary allocation of acquisition cost $4,128M. Employee headcount added through the acquisition not disclosed.
2006-12-31acquisition_additioncompleted2006-12-13United StatesPharmaceutical ProductsUSD 3,770 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquisition of Kos Pharmaceuticals Inc. completed December 13, 2006 (date used in lieu of a separately disclosed announcement date) for cash of approximately $3.8B net of cash held; total preliminary allocation of acquisition cost $3,770M, financed primarily with short-term debt. Employee headcount added through the acquisition not disclosed.
2006-12-31divestiture_reductionannounced2007-01-18Not disclosedDiagnostics Products — core laboratory diagnostics business, including Abbott Point of Care (excludes Molecular Diagnostics and Diabetes Care)USD 8,130 (millions)subsequent_events
f5-10k / GLM-5.3-flash-HTML		Subsequent event: definitive agreement announced to sell the core laboratory diagnostics business to General Electric Company for $8.13B in cash, expected to close in the first half of 2007 subject to regulatory approvals. Businesses sold generated approximately $2.7B of 2006 net sales; carrying amount of assets and liabilities in the sale estimated at approximately $2.6B; estimated tax expense of approximately $2.0B on the gain. Employee count affected not disclosed.
2006-12-31restructuringin_progress2007-12-31WorldwidePharmaceutical manufacturing; selected domestic and international commercial and R&D operationsUSD 210 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2006 restructuring charges of $210.3 million ($117.7M employee-related and other; $92.6M asset impairments) for plans approved during 2006; no employee headcount disclosed. An additional $70 million recorded in 2006, primarily accelerated depreciation. Accrued balance at December 31, 2006 was $193.3 million; up to $128 million of future charges expected, with realignments continuing into 2007 due to product re-registration timelines.
2006-12-31acquisition_additioncompleted2006-04-21United StatesVascular Productsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Guidant's vascular intervention and endovascular solutions businesses for approximately $4.1 billion cash, closed April 21, 2006; acquired headcount not disclosed.
2006-12-31acquisition_additioncompleted2006-12-13United StatesPharmaceutical Productsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Kos Pharmaceuticals Inc. for approximately $3.8 billion cash net of cash held, closed December 13, 2006; acquired headcount not disclosed.
2006-12-31divestiture_reductionannounced2007-01-182007-06-30WorldwideDiagnostic Products (core laboratory diagnostics and Point of Care)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Agreement to sell core laboratory diagnostics business, including Abbott Point of Care, to GE for $8.13 billion cash; expected to close in first half of 2007 subject to regulatory approvals. Businesses had approximately $2.7 billion of 2006 net sales; headcount to be transferred not disclosed.
2006-12-31restructuringin_progress2006-01-012007-12-31WorldwidePharmaceutical Manufacturing, Commercial, R&DUSD 210 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2006 pretax charges of $210.3 million for realignment of worldwide pharmaceutical manufacturing and selected domestic/international commercial and R&D operations. Includes employee severance and asset impairments. Manufacturing realignments expected to continue into 2007.
2006-12-31acquisition_additioncompleted2006-04-212006-04-21WorldwideVascular Productsbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of Guidant's vascular intervention and endovascular solutions businesses. Headcount not explicitly disclosed.
2006-12-31acquisition_additioncompleted2006-12-132006-12-13WorldwidePharmaceutical Productsbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of Kos Pharmaceuticals, Inc. Headcount not explicitly disclosed.
2006-12-31restructuringin_progress20062007WorldwidePharmaceutical manufacturing, commercial, and R&DUSD 210 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		2006 plan to realign worldwide pharmaceutical manufacturing and selected domestic/international commercial and R&D operations. Charges include asset impairments and employee severance. Manufacturing realignments expected to continue into 2007.
2006-12-31acquisition_additioncompleted2006-04-212006-04-21WorldwideVascular Productsbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Guidant's vascular intervention and endovascular solutions businesses. Headcount not explicitly disclosed.
2006-12-31acquisition_additioncompleted2006-12-132006-12-13WorldwidePharmaceutical Productsbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Kos Pharmaceuticals. Headcount not explicitly disclosed.
2006-12-31divestiture_reductionannounced2007-01-182007-06-30WorldwideDiagnostic Productssubsequent_events
f5-10k / Qwen3.6-27B-Q8_0		Agreement to sell core laboratory diagnostics business to GE. Sale expected to close in first half of 2007. Headcount not explicitly disclosed.
2006-09-30restructuringin_progress2005-01-01Global manufacturing operations and selected international commercial operationsUSD 256 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2005-approved program to realign global manufacturing and selected international commercial operations; charges of $191.7M employee-related and other, $63.8M asset impairments; accrued balance of $88.4M at September 30, 2006; an additional $39M recorded in first nine months 2006, primarily accelerated depreciation. No employee counts disclosed.
2006-09-30restructuringin_progress2005GlobalManufacturing operations and selected international commercial operationsUSD 39 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program approved in 2005 to realign global manufacturing and selected international commercial operations; no employee counts disclosed. Additional $39M recorded in first nine months of 2006, primarily accelerated depreciation. Accrued balance $88.4M at 2006-09-30 (2005 charges totaled $255.5M: $191.7M employee-related and other, $63.8M asset impairments).
2006-09-30acquisition_additionannounced2006-11-06United StatesPharmaceutical Productssubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Announced acquisition of Kos Pharmaceuticals Inc. for net cash of approximately $3.7 billion, subject to antitrust clearance and tender offer; to be debt-financed. No headcount associated with the transaction disclosed.
2006-09-30restructuringin_progress2005GlobalManufacturing and International Commercial OperationsUSD 39 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		2005 plan to realign global manufacturing and selected international commercial operations. Additional $39 million recorded in first nine months of 2006, primarily for accelerated depreciation. Employee-related accrual balance was $88.4 million at Sept 30, 2006.
2006-06-30restructuringin_progress2005-01-01Global manufacturing operations and selected international commercial operationsUSD 22 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2005-approved realignment program; additional $22 million recorded in first six months of 2006, primarily for accelerated depreciation. Accrued balance of $102.4 million at June 30, 2006, all employee-related and other; no employee counts disclosed.
2006-06-30acquisition_additioncompleted2006-04-21Vascular Products segmentUSD 4,128 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of Guidant's vascular intervention and endovascular solutions businesses for approximately $4.1 billion; no headcount figures disclosed.
2006-06-30restructuringin_progress2005GlobalManufacturing operations and selected international commercial operationsUSD 256 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2005-approved program to realign global manufacturing and selected international commercial operations; no employee counts disclosed. An additional $22 million recorded in first six months 2006, primarily accelerated depreciation; accrued balance $102.4 million at June 30, 2006.
2006-06-30acquisition_additioncompleted2006-04-212006-04-21GlobalVascular ProductsUSD 4,128 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Guidant's vascular intervention and endovascular solutions businesses for approximately $4.1 billion cash, closed April 21, 2006; headcount added not disclosed.
2006-06-30restructuringin_progress2005-01-01GlobalManufacturing and International Commercial OperationsUSD 22 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Additional $22 million recorded in first six months of 2006 relating to 2005 plans, primarily for accelerated depreciation. No employee count disclosed for this incremental charge.
2006-03-31restructuringin_progress2005-01-01Global manufacturing operations and selected international commercial operationsUSD 7 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2005-approved program to realign global manufacturing and selected international commercial operations; additional Q1 2006 charge primarily for accelerated depreciation. Accrued employee-related balance of $118.6 million at March 31, 2006; $36.2 million paid in the quarter. No employee counts disclosed.
2006-03-31restructuringin_progress2005-01-01GlobalGlobal manufacturing operations and selected international commercial operationsUSD 7 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2005-approved program; $7M additional charge in Q1 2006, primarily accelerated depreciation. Accrued balance $118.6M at 2006-03-31. No employee counts disclosed.
2006-03-31acquisition_additioncompleted2006-04-212006-04-21United StatesVascular intervention and endovascular solutions businesses (from Guidant)USD 4,100 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Post-quarter acquisition of Guidant vascular businesses for $4.1B cash; no headcount added disclosed. Also purchased $1.4B Boston Scientific stock and made a $900M loan.
2006-03-31restructuringin_progress2005-01-01GlobalManufacturing and International Commercial OperationsUSD 7 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Additional $7 million recorded in Q1 2006 relating to 2005 approved plans, primarily for accelerated depreciation. No employee count disclosed for this specific incremental charge.
2005-12-31restructuringin_progress20052007Global (multiple countries)Global pharmaceutical manufacturing operationsUSD 97 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		2005 charges comprised $44.1M employee-related and other plus $52.7M asset impairments; $43.8M accrual remained at year-end 2005. Program-wide, a further $14M (primarily accelerated depreciation) was recorded later in 2005. No employee count disclosed.
2005-12-31restructuringin_progress2005Domestic and internationalSelected domestic and international commercial operationsUSD 159 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		2005 charges comprised $147.6M employee-related and other plus $11.1M asset impairments; $111.0M accrual at year-end 2005. Filer expects up to an additional $150M of future charges. No employee count disclosed.
2005-12-31divestiture_reductionin_progress2004-04-122006Outside the United StatesResidual international hospital products operations (Hospira)discontinued_operations_footnote
f5-10k / GLM-5.3-flash-HTML		Legal transfer of remaining international operations and assets to Hospira, residual to the April 2004 spin-off, expected in the first half of 2006; related assets presented as held for sale at year-end 2005. No employee count disclosed.
2005-12-31acquisition_additionannounced2006-01-082006Vascular intervention and endovascular solutions businessessubsequent_events
f5-10k / GLM-5.3-flash-HTML		Agreement to acquire Guidant's vascular businesses from Boston Scientific for $4.1B plus up to $500M contingent milestone payments, contingent on Boston Scientific's closing of its Guidant acquisition; expected to complete in the first half of 2006. No employee count disclosed.
2005-12-31restructuringin_progress2005-01-012007-12-31GlobalPharmaceutical Products — global manufacturing operationsUSD 97 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2005 charges for global pharmaceutical manufacturing realignment ($44.1 employee-related, $52.7 asset impairments); accrual $43.8M at year-end. Realignment expected to continue into 2007 due to product re-registration timelines. Employees affected not disclosed.
2005-12-31restructuringin_progress2005-01-01Domestic and internationalSelected commercial operationsUSD 159 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		All other 2005 restructurings, individually not material ($147.6 employee-related, $11.1 asset impairments); accrual $111.0M at year-end. Employees affected not disclosed.
2005-12-31acquisition_additioncompletedMedical productsUSD 25 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2005 acquisitions of remaining interest in a small medical products company and a less-than-50% equity interest in another; aggregate cash purchase price ~$25M. Headcount added not disclosed.
2005-12-31acquisition_additionannounced2006-01-082006-06-30United StatesVascular intervention and endovascular solutions businessesUSD 4,100 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Post-year-end agreement to acquire Guidant's vascular businesses for $4.1B plus up to $500M milestones, contingent on Boston Scientific's acquisition of Guidant; target revenues ~$1B. Headcount not disclosed.
2005-12-31restructuringin_progress20052007GlobalManufacturing and Commercial OperationsUSD 256 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		In 2005, Abbott recorded pretax charges of approximately $256 million reflecting impairment of manufacturing facilities and other assets, employee severance and other related charges. Manufacturing related realignments are expected to continue into 2007.
2005-12-31restructuringin_progress2005GlobalGlobal Pharmaceutical ManufacturingUSD 97 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2005 restructuring charges for global pharmaceutical manufacturing operations totaled $96.8 million ($44.1 million employee-related, $52.7 million asset impairments). Accrued balance at Dec 31, 2005 was $43.8 million.
2005-12-31restructuringin_progress2005GlobalOther RestructuringsUSD 159 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2005 restructuring charges for all other restructurings totaled $158.7 million ($147.6 million employee-related, $11.1 million asset impairments). Accrued balance at Dec 31, 2005 was $111.0 million.
2005-12-31restructuringin_progress20052007-12-31GlobalManufacturing and Commercial OperationsUSD 256 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Pretax charges of approximately $256 million recorded in 2005 for impairment of manufacturing facilities, employee severance, and other related charges. Manufacturing realignments expected to continue into 2007.
2005-09-30restructuringin_progress2005-01-012007-12-31GlobalGlobal manufacturing operations and selected international commercial operationsUSD 229 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Pretax charges in Q2 and Q3 2005 for facility impairments, severance and related costs; ~$175 in cost of products sold, $5 in R&D, $49 in SG&A; realignment to continue into 2007 due to product re-registration timelines; up to an additional $190 expected in future periods.
2005-09-30restructuringin_progress2005-01-01GlobalGlobal pharmaceutical manufacturing operationsUSD 97 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2005 charges of $44.1 employee-related and other plus $52.7 asset impairments; accrued balance of $44.0 at September 30, 2005.
2005-09-30restructuringin_progress2005-01-01GlobalOther restructurings (individually not material)USD 132 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2005 charges of $121.2 employee-related and other plus $11.1 asset impairments; accrued balance of $105.7 at September 30, 2005.
2005-09-30divestiture_reductionin_progress2004-04-122006-06-30InternationalHospira spin-off — international hospital products operationsother
f5-10q / GLM-5.3-flash-fp4-HTML		Legal transfer of certain non-U.S. operations and assets to Hospira ongoing; 48 percent transferred as of September 30, 2005, remainder expected in first half of 2006; assets and liabilities presented as held for sale. No headcount figures disclosed.
2005-09-30restructuringin_progress2005-06-302007-12-31GlobalGlobal pharmaceutical manufacturing operations and selected international commercial operationsUSD 97 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Global pharmaceutical manufacturing restructuring component; charges recorded in Q2 and Q3 2005. Employee severance accrual of $44.0M outstanding at 2005-09-30. No employee count disclosed. Completion extends into 2007 due to product re-registration timelines.
2005-09-30restructuringin_progress2005-06-302007-12-31GlobalAll other restructurings (individually not material)USD 132 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Other restructuring component; employee-related accrual of $105.7M outstanding at 2005-09-30. No employee count disclosed. Combined 2005 pretax charges across both components approximately $229M, plus $2M accelerated depreciation in Q3.
2005-09-30divestiture_reductionin_progress2004-04-122006-06-30International (non-U.S.)Hospira international operations transferother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Legal transfer of certain non-U.S. operations and assets to Hospira; 48% transferred as of 2005-09-30, remainder expected in first half of 2006. Assets and liabilities presented as held for sale. No employee count disclosed.
2005-09-30acquisition_additioncompleted2005-09-302005-09-30Medical productsUSD 2 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q3 2005 acquisition of remaining interest in a small medical products company for ~$10M cash; $2M acquired in-process R&D charge. No headcount added disclosed.
2005-09-30acquisition_additioncompleted2005-09-302005-09-30Medical productsUSD 15 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q3 2005 acquisition of a less-than-50% equity interest in a small medical products company for ~$15M cash; $15M acquired in-process R&D charge. No headcount added disclosed.
2005-09-30restructuringin_progress2005-06-302007-12-31GlobalManufacturing and International CommercialUSD 229 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Pretax charges of approx $229M recorded in 2nd and 3rd quarters for impairment of manufacturing facilities, employee severance, and other related charges. Employee count not disclosed. Completion expected into 2007 due to product re-registration timelines.
2005-06-30restructuringannounced2005-07-012006-12-31GlobalGlobal manufacturing operations; selected international commercial operations across several business segmentsUSD 215 (millions)MD&A
f5-10q / GLM-5.3-flash-fp4-HTML		Announced July 2005: realignment of global manufacturing operations to reduce costs, involving staffing reductions in several business segments including selected international commercial operations. After-tax charges of approximately $215 million expected in second half of 2005, of which approximately $200 million projected in Q3 2005; approximately $60 million in after-tax charges expected in 2006 as the realignment continues due to product re-registration timelines under manufacturing regulations in a number of countries. No employee headcount figure disclosed.
2005-06-30divestiture_reductionin_progress2004-04-122006-06-30International (non-U.S. operations)Former Hospital products segment and portions of International segment (Hospira, Inc. spin-off)other
f5-10q / GLM-5.3-flash-fp4-HTML		Hospira spin-off completed April 30, 2004 (prior year); legal transfer of certain non-U.S. operations and assets (net of liabilities) to Hospira remains in progress, with approximately 20 percent transferred as of June 30, 2005, roughly half of the remainder expected in 2005 and the balance in the first half of 2006. Related assets and liabilities presented as held for sale. No employee headcount figure disclosed; included here because the ongoing transfer represents a continuing divestiture-related workforce separation in the current reporting period.
2005-06-30restructuringannounced2005-07-312006-06-30GlobalGlobal manufacturing operations; several business segments including selected international commercial operationsUSD 215 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		After-tax charges; approximately $200 million expected in Q3 2005 and approximately $60 million in 2006. No employee count disclosed. Announcement date is approximate (July 2005, day not specified).
2005-06-30restructuringannounced2005-072006-12-31GlobalManufacturing, International CommercialUSD 215 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Announced in July 2005. Plans to realign global manufacturing operations and reduce staffing in several business segments. After-tax charges of approx $215M expected in H2 2005, with approx $60M in 2006. Employee count not disclosed.
2004-12-31divestiture_reductioncompleted2004-04-122004-04-30Worldwide; U.S. hospital products operations plus portions of the International segmentHospital Products segment and portions of International segment (specialty injectable pharmaceuticals, medication delivery systems, critical care devices, injectable pharmaceutical contract manufacturing)USD 36 (millions)discontinued_operations_footnote
f5-10k / GLM-5.3-flash-HTML		Tax-free spin-off via special dividend distribution (one Hospira share per 10 Abbott shares) completed April 30, 2004; direct transaction costs of approximately $36 million recorded in discontinued operations in 2004; Hospira assumed $700 million of debt and received net assets of approximately $767 million; Hospira annual sales approximately $2.4 billion. Affected headcount not disclosed. Legal transfer of certain international operations to Hospira expected in 2005 and first half of 2006 (presented as held for sale at year-end); Abbott retained certain retiree benefit obligations and adjusted its benefit and stock option programs in connection with the spin-off.
2004-12-31acquisition_additioncompleted20042004Diagnostic Products — point-of-care blood analysisUSD 394 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		i-STAT Corporation acquired in the first quarter of 2004 for approximately $394 million in cash (consideration, not a severance charge); resulted in ~$60 million acquired in-process R&D charge, ~$263 million intangibles, ~$109 million goodwill. Acquired headcount not disclosed.
2004-12-31acquisition_additioncompleted20042004Diagnostic Products — Diabetes Care (blood glucose self-monitoring)USD 1,200 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		TheraSense, Inc. acquired in the second quarter of 2004 for approximately $1.2 billion in cash (consideration). Second-quarter acquisitions (TheraSense plus ~$352 million of other product technologies) generated a $164 million acquired in-process R&D charge, ~$912 million intangibles, ~$623 million goodwill. Acquired headcount not disclosed.
2004-12-31acquisition_additioncompleted20042004Ross Products — Adult NutritionalsUSD 320 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		EAS, a nutritional company with nationally recognized brands, acquired in the fourth quarter of 2004 for approximately $320 million in cash (consideration). Fourth-quarter acquisitions (EAS and Spine Next) generated a $47 million acquired in-process R&D charge, ~$152 million intangibles, ~$191 million goodwill. Acquired headcount not disclosed.
2004-12-31acquisition_additioncompleted20042004Spinal products (non-reportable segment) — orthopedic spinal implant devicesUSD 58 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Spine Next acquired in the fourth quarter of 2004 for approximately $58 million in cash plus up to $23 million in contingent milestone payments (consideration). Acquired headcount not disclosed.
2004-12-31divestiture_reductioncompleted2004-04-122004-04-30GlobalHospital Products segment and portions of International segmentdiscontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Spin-off distributed 1 Hospira share per 10 Abbott shares; assets/liabilities transferred disclosed but no employee headcount given. Direct spin-off transaction costs of approximately $36 million included in discontinued operations.
2004-12-31acquisition_additioncompletedUnited StatesDiagnostic Products (Diabetes Care)USD 1,200 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		TheraSense, Inc. acquired for approximately $1.2 billion cash in Q2 2004; headcount added not disclosed. Purchase price shown as associated charge value.
2004-12-31acquisition_additioncompletedUnited StatesDiagnostic Products (Point of Care)USD 394 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		i-STAT Corporation acquired for approximately $394 million cash in Q1 2004; headcount added not disclosed.
2004-12-31acquisition_additioncompletedUnited StatesRoss Products (Adult Nutritionals)USD 320 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		EAS acquired for approximately $320 million cash in Q4 2004; headcount added not disclosed.
2004-12-31acquisition_additioncompletedUnited StatesSpinal products (non-reportable segment)USD 58 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Spine Next acquired for approximately $58 million cash plus up to $23 million in milestone payments, Q4 2004; headcount added not disclosed.
2004-12-31acquisition_additioncompletedUnited StatesDiagnostic Products and other product technologiesUSD 352 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Certain other product technologies acquired for approximately $352 million in Q2 2004; headcount added not disclosed.
2004-09-30divestiture_reductioncompleted2004-04-122004-04-30Global (US and international operations)Hospital Products segment and portions of International segmentUSD 36 (millions)other
f5-10q / GLM-5.3-flash-fp4-HTML		Spin-off of Hospira completed April 30, 2004; hospital products business distributed to shareholders. Direct transaction costs of approximately $36 million in the nine months ended September 30, 2004. Headcount transferred not disclosed; net assets transferred were $767 million. Abbott retained certain tax, post-employment benefit, and pricing-practice liabilities.
2004-09-30divestiture_reductioncompleted2004-04-122004-04-30United States and internationalHospital Products segment and portions of the International segment (Hospira, Inc.)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Special dividend distribution of Hospira shares completed 2004-04-30; no employee counts disclosed. Direct spin-off transaction costs of approximately $36 million in the nine months ended 2004-09-30.
2004-09-30acquisition_additioncompleted2004-04-012004-04-30United StatesDiagnostic Products (Diabetes Care)USD 164 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		TheraSense, Inc. acquired for approximately $1.2 billion cash in April 2004; acquired in-process R&D charge of $164 million. No headcount added disclosed.
2004-09-30acquisition_additioncompleted2004-01-012004-01-31United StatesDiagnostic ProductsUSD 60 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		i-STAT Corporation acquired for approximately $394 million cash in January 2004; approximately $60 million in-process R&D charge. No headcount added disclosed.
2004-09-30acquisition_additionannounced2004-10-01United StatesRoss Products (nutrition)USD 320 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		October 2004 announcement of pending acquisition of Experimental & Applied Sciences for approximately $320 million cash; no headcount disclosed. Exact announcement day not stated.
2004-09-30acquisition_additionannounced2004-10-01InternationalVascular / spinal productsUSD 60 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		October 2004 announcement of pending acquisition of Spine Next, S.A. for approximately $60 million cash plus milestone payments; no headcount disclosed. Exact announcement day not stated.
2004-06-30divestiture_reductioncompleted2004-04-122004-04-30Global (US and international operations)Hospital Products segment and portions of International segmentUSD 36 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Spin-off of Hospira completed April 30, 2004; hospital products business distributed to shareholders tax-free. Direct transaction costs of approximately $36 million for six months 2004 recorded in discontinued operations. Net assets transferred of $767 million; $700 million of debt assumed by Hospira. Headcount transferred not disclosed.
2004-06-30acquisition_additioncompleted2004-04-01United StatesDiagnostics (Diabetes Care)USD 164 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquired TheraSense, blood glucose self-monitoring company, for approximately $1.2 billion cash plus $352 million for other product technologies. Resulted in $164 million acquired in-process R&D charge, $903 million intangibles, $708 million goodwill. Employee headcount added not disclosed.
2004-06-30acquisition_additioncompleted2004-01-01United StatesDiagnostics (point-of-care testing)USD 60 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquired i-STAT Corporation, point-of-care blood analysis diagnostics maker, for approximately $394 million cash in January 2004. Resulted in approximately $60 million acquired in-process R&D charge, $263 million intangibles, $126 million goodwill. Employee headcount added not disclosed.
2004-06-30divestiture_reductioncompleted2004-04-122004-04-30United States and international (Hospira international operations)Hospital Products segment and portions of International segmentother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Special dividend distribution of Hospira, Inc. shares (1 Hospira share per 10 Abbott shares); net assets transferred of $767 million. Direct spin-off transaction costs of approximately $36 million for the six months ended 2004-06-30. No employee headcount transferred or retained disclosed.
2004-06-30acquisition_additioncompleted2004-04United StatesDiagnostic Products (Diabetes Care)USD 164 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of TheraSense, Inc. for approximately $1.2 billion in cash, plus other product technologies for approximately $352 million; $164 million acquired in-process R&D charge. Headcount added not disclosed.
2004-06-30acquisition_additioncompleted2004-01United StatesDiagnostic ProductsUSD 60 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of i-STAT Corporation (point-of-care diagnostics) for approximately $394 million in cash; approximately $60 million acquired in-process R&D charge recorded in Q1 2004. Headcount added not disclosed.
2004-03-31acquisition_additioncompleted2004-01-31United StatesDiagnostic ProductsUSD 60 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of i-STAT Corporation for approximately $394 million cash; $60 million in-process R&D charge recorded. Headcount added not disclosed.
2004-03-31divestiture_reductionannounced2004-04-122004-04-30United StatesHospital Products (including portions of International segment)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Hospira spin-off; distribution of one Hospira share per 10 Abbott shares, record date 2004-04-22. Headcount removed not disclosed.
2004-03-31acquisition_additionannounced2004-04-30United StatesDiagnostic Products (Diabetes)USD 1,200 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Post-quarter acquisition of TheraSense, Inc. for approximately $1.2 billion cash; headcount added not disclosed. Charge value shown is purchase price, not a workforce charge.
2003-12-31restructuringin_progress2,1002002-10GlobalDiagnostic Products and International segments; global manufacturing operations (manufacturing, R&D, sales and administrative functions affected)USD 174 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Cumulative program figure: pretax charge of $174 recorded in 2002 ($83 cost of products sold, $5 R&D, $86 SG&A) covering facility impairments and severance; ~2,100 net positions eliminated. During FY2003 the only activity was $81 of payments/changes/translation, leaving a $23 severance reserve at Dec 31, 2003 payable over time under local law.
2003-12-31restructuringin_progress2,4002001Operations of acquired BASF pharmaceutical business (Knoll Pharmaceuticals); also closure of one Abbott manufacturing operation with production relocationUSD 207 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Cumulative multi-year program disclosed through this filing: $207 total charges in 2001 (of which $156 recorded as goodwill; expensed portion split $36 COGS, $2 R&D, $13 SG&A) plus $59 in 2002 recorded as goodwill. Costs include severance, relocation of former BASF employees, and outplacement. During FY2003 only payments occurred ($57), leaving an $11 severance reserve at Dec 31, 2003. The ~2,400 position elimination count is a cumulative program figure.
2003-12-31divestiture_reductionannounced2003-082004-06WorldwideCore hospital products business — most of Hospital Products segment and portions of International segment (Hospira, Inc. spin-off)other
f5-10k / GLM-5.3-flash-HTML		Tax-free pro rata spin-off of Hospira, Inc. announced August 2003; business has ~$2.4 billion annual sales. Expected completion in the first half of 2004 pending board approval. No employee headcount affected was disclosed. Reserve-relevant detail: Hospira will borrow/assume ~$750 million of debt retained by Abbott.
2003-12-31restructuringannounced2004-01Integration of TheraSense and i-STAT acquisitions (blood glucose self-monitoring and point-of-care diagnostics businesses)USD 115 (millions)subsequent_events
f5-10k / GLM-5.3-flash-HTML		Subsequent event: in January 2004 Abbott announced the $1.2 billion TheraSense acquisition and completed the ~$392 million i-STAT acquisition; in 2004 it expects to record ~$115 million of restructuring and integration costs (plus ~$171 million acquired IPR&D) related to these deals. No headcount impact was quantified.
2003-12-31restructuringin_progress2002-10GlobalDiagnostic Products and International segmentsrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Program announced October 2002 eliminated about 2,100 net positions in the prior year; FY2003 activity consisted of $81 million of payments, estimate changes and FX translation against the accrual, leaving a $23 million balance at year-end. No new positions or charges attributed to FY2003.
2003-12-31restructuringin_progress2001GlobalPharmaceutical Products (BASF/Knoll operations) and manufacturingrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Programs implemented in 2001-2002 for the acquired BASF/Knoll business eliminated about 2,400 positions in prior years; FY2003 activity was $57 million of payments and estimate changes, leaving an $11 million accrual at year-end. No FY2003 position eliminations or charges disclosed.
2003-12-31divestiture_reductionannounced2003-082004-06-30WorldwideHospital Products segment and portions of International segmentother
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Tax-free spin-off of Hospira, Inc. announced August 2003, expected in the first half of 2004 pending Board approval; annual sales of the spun-off business approximately $2.4 billion. Headcount to be transferred not disclosed; Hospira will borrow or assume about $750 million of debt.
2003-12-31acquisition_additioncompletedGlobalNutrition, vascular devices, spinal devices, coronary/peripheral interventionUSD 100 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Four 2003 acquisitions (ZonePerfect ~$160M, Integrated Vascular ~$65M, Spinal Concepts ~$166M plus up to $40M milestones, JOMED interventional assets ~$68M cash). Charge shown is the approximately $100 million acquired in-process R&D expense; headcount added not disclosed.
2003-12-31acquisition_additionannounced2004-012004-06-30GlobalDiagnostic Products — blood glucose self-monitoringsubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Subsequent event: agreement to acquire TheraSense, Inc. for $1.2 billion cash, announced January 2004, expected to close in Q2 2004 subject to shareholder and regulatory approvals. Headcount not disclosed; part of a combined expected 2004 charge of about $171 million for acquired in-process R&D and about $115 million for restructuring and integration.
2003-12-31acquisition_additioncompleted2004-01United StatesDiagnostic Products — point-of-care blood analysis systemssubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Subsequent event: January 2004 acquisition of the i-STAT Corporation shares not already owned for about $392 million cash. Headcount not disclosed; shares the combined expected 2004 charges noted for the TheraSense transaction.
2003-12-31restructuringcompleted2,1002002-10-01GlobalDiagnostic Products, InternationalUSD 174 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Announced in Oct 2002 to align global manufacturing. Eliminated approx 2,100 net positions. Pretax charge of $174M recorded in 2002. Accrued balance at Dec 31, 2003 was $23M.
2003-12-31restructuringcompleted2,4002001-01-01GlobalPharmaceutical Products (BASF Acquisition)USD 207 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Related to BASF acquisition and manufacturing closure. Eliminated approx 2,400 positions. Total charges of $207M in 2001 ($156M as goodwill, $51M expensed). Additional $59M charge in 2002 recorded as goodwill. Accrued balance at Dec 31, 2003 was $11M.
2003-12-31restructuringcompleted2,1002002-10-01GlobalDiagnostic Products, InternationalUSD 174 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		2002 restructuring plan to align global manufacturing operations. Eliminated approximately 2,100 net positions. Accrued balance at Dec 31, 2003 was $23 million.
2003-12-31restructuringcompleted2,4002001-01-01GlobalPharmaceutical Products (BASF acquisition)USD 207 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		2001 restructuring related to BASF acquisition and manufacturing closure. Eliminated approximately 2,400 positions. Accrued balance at Dec 31, 2003 was $11 million.
2003-09-30restructuringin_progress2002-10-01GlobalDiagnostics and International segmentsUSD 174 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program announced October 2002 to align global manufacturing with scientific focus; $174M charged in 2002 ($141M employee-related, $33M asset impairments); $28M accrued at 2003-09-30. No employee count disclosed.
2003-09-30restructuringin_progress2001-01-01GlobalAcquired BASF pharmaceutical businessUSD 266 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring related primarily to acquired BASF pharmaceutical operations; $207M charged in 2001 and $59M in 2002; $24M accrued at 2003-09-30. Announcement date approximate (year only). No employee count disclosed.
2003-09-30divestiture_reductionannounced2003-08-012004-06-30United States and InternationalHospital Products segment and portions of International segmentother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan announced August 2003 to create a separate publicly traded company for core hospital products business, expected spinoff in first half of 2004. No headcount associated with the spinoff disclosed. Announcement date approximate (month only).
2003-09-30restructuringin_progress2002-10GlobalDiagnostics and International segmentsUSD 174 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Announced Oct 2002 to align global manufacturing with scientific focus. Total charge $174M ($141M employee-related, $33M asset impairments). Accrued balance at Sept 30, 2003 was $28M.
2003-09-30restructuringin_progress2001GlobalAcquired pharmaceutical business of BASFUSD 266 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plans implemented in 2001 and 2002 related to BASF acquisition. Total charges $266M ($254M employee-related, $12M asset impairments). Accrued balance at Sept 30, 2003 was $24M.
2003-06-30restructuringin_progress2002-10-01Diagnostics and International segments; global manufacturing operationsUSD 174 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		October 2002 plan to align global manufacturing with scientific focus and improve operating efficiency. Accrued balance of $39 million at June 30, 2003 after $57 million of 2003 payments and an $8 million change in estimate; no employee counts disclosed.
2003-06-30restructuringin_progress2001-01-01Acquired pharmaceutical business of BASFUSD 207 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2001 restructuring charges of $195 million employee-related plus $12 million asset impairments, with additional $59 million of 2002 charges. Accrued balance of $32 million at June 30, 2003 after $36 million of 2003 payments; no employee counts disclosed.
2003-06-30restructuringin_progress2002-10-01GlobalDiagnostics and International segmentsUSD 174 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Announced Oct 2002 to align global manufacturing with scientific focus. Total charge $174M ($141M employee-related, $33M asset impairments). Accrued balance at June 30, 2003 was $39M. Employee count not disclosed.
2003-06-30restructuringin_progress2001-01-01GlobalPharmaceutical business of BASFUSD 207 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plans implemented in 2001 and 2002 related to acquired BASF pharmaceutical business. Total charge $207M ($195M employee-related, $12M asset impairments). Accrued balance at June 30, 2003 was $32M. Employee count not disclosed.
2003-03-31restructuringin_progress2002-10-01Diagnostics and International segments; global manufacturing operationsUSD 174 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		October 2002 plan to align global manufacturing with scientific focus and improve operating efficiency. Charges of $174M ($141M employee-related and other, $33M asset impairments); $70M paid/impairments in 2002; change in estimate of $(4)M and $32M payments in Q1 2003; accrued balance $68M at March 31, 2003. No employee counts disclosed.
2003-03-31restructuringin_progress2001-01-01Acquired pharmaceutical business of BASFUSD 207 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2001 restructuring charges of $207M ($195M employee-related and other, $12M asset impairments); additional $59M charges in 2002; $17M paid in Q1 2003; accrued balance $51M at March 31, 2003. No employee counts disclosed.
2003-03-31restructuringin_progress2002-10GlobalDiagnostics and International segmentsUSD 174 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program announced October 2002 to align global manufacturing with scientific focus; $174M charged in 2002 ($141M employee-related/other, $33M asset impairments). Accrued balance $104M at 2002-12-31, reduced by $4M change in estimate and $32M 2003 payments to $68M at 2003-03-31. No employee counts disclosed.
2003-03-31restructuringin_progressGlobalPharmaceutical (acquired BASF pharmaceutical business)USD 59 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring plans implemented in 2001 and 2002 for the acquired BASF pharmaceutical operations. 2002 charges of $59M (employee-related/other); accrued balance $68M at 2002-12-31, reduced by $17M of 2003 payments to $51M at 2003-03-31. Announcement date not specified in filing; no employee counts disclosed.
2003-03-31divestiture_reductioncompleted2003-03-31United StatesU.S. eye and ear care product linesother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of U.S. eye and ear care product lines completed in Q1 2003; proceeds recorded in net sales. No headcount impact disclosed.
2003-03-31restructuringin_progress2002-10-01GlobalDiagnostics and International segmentsUSD 32 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Payments made in Q1 2003 related to October 2002 restructuring plans to align global manufacturing operations.
2003-03-31restructuringin_progress2001-01-01United StatesPharmaceutical (BASF acquired business)USD 17 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Payments made in Q1 2003 related to 2001 and 2002 restructuring plans for the acquired pharmaceutical business of BASF.
2002-12-31restructuringin_progress2,6002002-10Diagnostics and International segments; global manufacturing operationsUSD 174 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Plans to realign global manufacturing with scientific focus and improve operating efficiency. Eliminates 2,600 positions, partly offset by 500 additions; approximately 1,400 employees had left by December 31, 2002. $174M pretax charge (facility impairments and severance) split $83M cost of products sold, $5M R&D, $86M SG&A; expected after-tax annual savings of $80M–$100M at full implementation. Also described in Item 1/MD&A; extracted once from the footnote.
2002-12-31restructuringin_progress2,4002001Operations of the acquired pharmaceutical business of BASF (Knoll Pharmaceuticals)USD 59 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Cumulative through fiscal year-end: approved plans cover approximately 2,400 employees, of whom about 2,000 had left by December 31, 2002. Current-year charge of $59M (2002) recorded as goodwill associated with the BASF acquisition; 2001 charges totaled $207M, of which $156M was recorded as goodwill. Employee-related costs primarily severance, relocation of former BASF employees, and outplacement services.
2002-12-31plant_closurein_progress2001Manufacturing operationsrestructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Announced in 2001 (prior fiscal year) and carried in this filing's restructuring summary: one of 32 manufacturing operations closed, with production relocated to other Abbott facilities. No separate headcount disclosed.
2002-12-31restructuringin_progress2,6002002-10GlobalDiagnostics and International segments; manufacturing, research and development, and sales and administrative-related functionsUSD 174 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Program eliminates 2,600 positions, partly offset by 500 additions; approximately 1,400 employees had left as of 2002-12-31. Charge comprises $83M cost of products sold, $5M R&D, $86M SG&A. Expected after-tax annual savings of $80–100M upon full implementation.
2002-12-31restructuringin_progress2,4002001-03-02GlobalPharmaceutical Products (acquired BASF/Knoll operations); manufacturing, research and development, and sales and administrative-related functionsUSD 59 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Multi-year program; counts are cumulative through fiscal year-end. Approximately 2,000 of 2,400 covered employees had left as of 2002-12-31. FY2002 charge of $59M was recorded as goodwill rather than expensed; FY2002 payments were $80M, leaving a $68M accrued balance at year-end.
2002-12-31restructuringin_progress2,6002002-10GlobalDiagnostics and International segments; manufacturing, R&D, sales and administrativeUSD 174 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Plans announced in October 2002 to align global manufacturing operations. Resulted in elimination of 2,600 positions offset by addition of 500 positions. Approximately 1,400 employees had left as of December 31, 2002. Pretax charge of $174 million recorded.
2002-12-31restructuringin_progress2,4002001GlobalAcquired pharmaceutical business of BASF; manufacturing, R&D, sales and administrativeUSD 59 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Restructuring plans related to operations of acquired BASF pharmaceutical business. Approved plans cover approximately 2,400 employees, of which approximately 2,000 had left as of December 31, 2002. $59 million charge recorded in 2002 as goodwill associated with acquisition.
2002-12-31restructuringin_progress2,6002002-10-01GlobalDiagnostics and International segments; manufacturing, R&D, sales and administrativeUSD 174 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Announced October 2002 to align global manufacturing with scientific focus. 2,600 positions eliminated offset by 500 additions. 1,400 employees left as of Dec 31, 2002. Pretax charge of $174 million.
2002-12-31restructuringin_progress2,4002001-01-01GlobalAcquired pharmaceutical business of BASF; manufacturing, R&D, sales and administrativeUSD 59 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Plans related to BASF acquisition approved in 2001 and 2002. 2002 charge of $59 million recorded as goodwill. 2,400 employees covered, 2,000 left as of Dec 31, 2002.
2002-09-30restructuringannounced2,0002002-10GlobalDiagnostics and International segments; manufacturing, sales and administrative-related functionsUSD 100 (millions)subsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		After-tax charge of $100-$125 million expected in Q4 2002 for facility impairments and severance; approximately 2,000 employees affected; expected after-tax annual savings of $80-$100 million upon full implementation. Charge range midpoint used for associated_charge_value.
2002-09-30restructuringin_progress2001Primarily operations of the acquired pharmaceutical business of BASFUSD 59 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Employee-related and other restructuring accrual: $88.8M at Dec 31, 2001; $59.3M charges recorded in Q1 2002 as goodwill related to BASF pharmaceutical acquisition; payments and other of $68.4M; accrued balance $79.7M at Sep 30, 2002. No employee count disclosed.
2002-09-30restructuringin_progressGlobalPharmaceutical Products (acquired BASF/Knoll pharmaceutical operations)USD 59 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program begun in 2001 tied to the BASF pharmaceutical acquisition; Q1 2002 charge of $59.3M recorded as goodwill. Accrued balance $79.7M at 2002-09-30 after $68.4M of payments. No employee count or completion date disclosed.
2002-09-30restructuringannounced2,0002002-10GlobalDiagnostics and International segments; manufacturing, sales and administrative-related functionsUSD 113 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Announced October 2002, after quarter end. Midpoint of disclosed after-tax charge range of $100–$125 million to be recorded in Q4 2002; covers impairment of manufacturing facilities and other assets plus employee severance. Expected after-tax annual savings of $80–$100 million upon full implementation. No completion date stated.
2002-09-30restructuringannounced2,0002002-10GlobalDiagnostics and International segments; manufacturing, sales and administrative-related functionsUSD 113 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		After-tax charge expected $100-$125 million; midpoint used for value. Includes impairment of facilities and severance.
2002-06-30restructuringin_progress2001-01-01Pharmaceutical (acquired BASF/Knoll business)USD 59 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Restructuring plans begun in 2001 related primarily to operations of the acquired BASF pharmaceutical business; charges recorded as goodwill. Accrued employee-related liability rose from $88.8M at Dec 31, 2001 to $97.5M at June 30, 2002 after $59.3M of charges and $50.6M of payments. No employee count disclosed.
2002-06-30restructuringin_progress2001Pharmaceutical (BASF/Knoll pharmaceutical business)USD 59 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring plans begun in 2001 primarily for the acquired BASF pharmaceutical operations; charges recorded as goodwill. Six-month 2002 charges $59.3M, payments $50.6M, accrual $97.5M at 2002-06-30. No employee counts or completion dates disclosed.
2002-06-30acquisition_additioncompletedUnited Kingdom and JapanCardiovascular stent business and pharmaceutical (Hokuriku Seiyaku)USD 108 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q2 2002 acquisitions: Biocompatibles stent business, Medtronic stent technology rights, and additional 28.8% of Hokuriku Seiyaku (to 95.5%); aggregate cash purchase price $586M. Associated $108M charge is acquired in-process R&D, not workforce-related. Headcount added not disclosed.
2002-06-30restructuringin_progressPharmaceutical (BASF acquisition)USD 59 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Restructuring charges recorded as goodwill associated with the acquisition of the pharmaceutical business of BASF. Accrued balance at June 30, 2002 was $97.5 million.
2002-03-31restructuringin_progressGlobalPharmaceutical Products (BASF/Knoll acquisition)USD 59 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring plans related primarily to the acquired BASF pharmaceutical business; $59.3M charge recorded as goodwill in Q1 2002. No employee count disclosed.
2002-03-31acquisition_additionannounced2002-03-182002-06-30GlobalCardiovascular stent business (Biocompatibles International plc)USD 235 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement to acquire Biocompatibles cardiovascular stent business for ~$235M cash; expected to close Q2 2002. No headcount disclosed.
2002-03-31restructuringin_progressPharmaceuticalUSD 59 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Restructuring plans related primarily to operations of acquired pharmaceutical business of BASF. Charges recorded as goodwill.
2002-03-31acquisition_additionannounced2002-03-182002-06-30CardiovascularUSD 235 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Agreement to acquire cardiovascular stent business of Biocompatibles International plc. Transaction expected to complete in Q2 2002.
2002-03-31acquisition_additionannounced2002-04-012002-05-30JapanPharmaceuticalUSD 292 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Tender offer announced to acquire remaining 33.3% of Hokuirku Seiyaku common shares.
2001-12-31restructuringin_progress2,3932001-03-02GlobalManufacturing, research and development, and sales and administrative-related functionsUSD 207 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Approved restructuring plans cover 2,393 employees, of which approximately 1,200 were severed by year end. Of the $207.0M total charges, $155.5M was recorded as goodwill related to the BASF pharmaceutical business acquisition; the remainder was expensed across cost of products sold, SG&A, and R&D. Includes closure of one manufacturing operation.
2001-12-31acquisition_additioncompleted2001-03-022001-03-02GlobalPharmaceutical Productsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of the pharmaceutical business of BASF (including Knoll Pharmaceuticals) for approximately $7.2 billion completed March 2, 2001. Headcount added through the acquisition is not separately disclosed.
2001-12-31acquisition_additioncompleted2001-11-012001-11-30United StatesDiagnosticsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Vysis, Inc. (genomic disease management company) for approximately $362 million in cash, completed November 2001. Headcount added is not separately disclosed.
2001-12-31restructuringin_progress2,3932001GlobalManufacturing, R&D, Sales and AdministrativeUSD 207 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Approved restructuring plans cover 2,393 employees, of which approximately 1,200 were severed by year end. Total charges of $207.0 million include $195.5 million employee-related and $11.5 million asset impairments. Related to BASF acquisition integration and manufacturing relocation.
2001-09-30restructuringin_progressOperations of acquired BASF pharmaceutical business; one Abbott manufacturing operation closing with production relocationUSD 167 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Charges of $155.9M employee/other related and $11.5M asset impairments; $118.4M recorded as goodwill; accrued balance $113.1M at 2001-09-30; no employee counts disclosed
2001-09-30restructuringin_progressGlobalPharmaceutical Products (acquired BASF/Knoll operations)USD 167 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring plans for acquired BASF pharmaceutical operations plus closure of one manufacturing site; $155.9M employee-related and $11.5M asset impairment charges; $118.4M recorded as goodwill; no employee count disclosed; $113.1M accrued at quarter-end
2001-09-30acquisition_additioncompleted2001-03-022001-03-02GlobalPharmaceutical ProductsUSD 7,133 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of BASF pharmaceutical business (Knoll Pharmaceuticals) for approximately $7.1 billion; headcount added not disclosed
2001-09-30acquisition_additionannounced2001-10-242001-12-31United StatesDiagnostics / GenomicsUSD 355 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Announced intention to acquire Vysis, Inc. for approximately $355 million; expected to close Q4 2001; headcount not disclosed
2001-09-30restructuringin_progress2001-06-30Pharmaceutical ProductsUSD 167 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Restructuring plans related to the acquired pharmaceutical business of BASF and closure of one manufacturing operation. Employee-related costs include severance pay, relocation, and outplacement services. Headcount affected is not disclosed.
2001-09-30plant_closurein_progress2001-06-30restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Announced in the second quarter 2001 that it was closing one of its manufacturing operations and relocating production to other Abbott facilities. Headcount affected is not disclosed.
2001-06-30restructuringin_progress2001-03-02Acquired pharmaceutical business of BASF (Knoll Pharmaceuticals)USD 89 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Restructuring plans related to operations of the acquired BASF pharmaceutical business; $77.0M employee-related (severance, relocation of former BASF employees, outplacement) and $11.5M asset impairments; $42.3M of the total recorded as goodwill; accrued balance of $56.7M at June 30, 2001; no employee headcount affected disclosed.
2001-06-30plant_closureannounced2001-04-01Manufacturing operationsrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Abbott announced in the second quarter 2001 that it was closing one of its manufacturing operations and relocating production to other Abbott facilities; no headcount affected disclosed.
2001-06-30acquisition_additioncompleted2001-03-02GlobalPharmaceutical ProductsUSD 1,187 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired BASF pharmaceutical business (Knoll Pharmaceuticals) for ~$7.0B; headcount added not disclosed.
2001-06-30restructuringin_progress2001-04-01GlobalPharmaceutical Products (acquired BASF operations)USD 89 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Employee-related $77.0M and asset impairments $11.5M; $42.3M capitalized to goodwill. Employee count not disclosed. Additional restructuring plans expected over 12 months post-acquisition.
2001-06-30plant_closureannounced2001-04-01United StatesManufacturingrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Abbott announced closing one manufacturing operation and relocating production to other Abbott facilities; employee count not disclosed.
2001-06-30restructuringin_progress2001-04-01Pharmaceutical ProductsUSD 89 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Restructuring plans related to the acquired pharmaceutical business of BASF and closing one manufacturing operation. Charges include $77.0M employee-related and $11.5M asset impairments. Employee count not disclosed.
2001-03-31acquisition_additioncompleted2001-03-02GlobalPharmaceutical ProductsUSD 1,015 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired BASF pharmaceutical business (Knoll) for ~$6.9B; no headcount disclosed. $1,015M in-process R&D charged to income.
2001-03-31restructuringannounced2001-03-312002-03-31GlobalPharmaceutical Products (Knoll)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Integration/restructuring plans for acquired Knoll operations to be finalized over 12 months post-acquisition; no employee count or charge quantified.
2001-03-31restructuringannounced2001-03-022002-03-02GlobalPharmaceutical Productsbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Abbott acquired BASF pharmaceutical business (Knoll) on March 2, 2001. Restructuring plans for specific business activities are being assessed and expected to be finalized throughout the 12 months following acquisition. Costs not yet reflected in acquisition cost allocation.
2000-12-31acquisition_additionannounced2000-12-15GlobalPharmaceutical Products (Knoll / BASF pharmaceutical business)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Definitive agreement to acquire BASF's pharmaceutical business, including Knoll global operations, for $6.9 billion; pending regulatory approval. Headcount of acquired workforce not disclosed. Estimated purchase accounting charges of ~$1.0 billion IPR&D and ~$5.0 billion goodwill/intangibles if completed.
2000-12-31divestiture_reductioncompleted2000-01Agricultural products businessUSD 139 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Sold agricultural products business to Sumitomo Chemical Co., Ltd. in January 2000; $139 million is a gain on sale of business (credit to income), not a severance charge. Employees transferred not disclosed; business generated ~$102 million in sales in 1999.
2000-12-31acquisition_additionannounced2000-12-15GlobalPharmaceutical ProductsUSD 6,900 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire BASF's pharmaceutical business (Knoll) for $6.9B; headcount not disclosed; pending regulatory approval.
2000-12-31divestiture_reductioncompleted2000-01-012000-01-31GlobalAgricultural ProductsMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sold agricultural products business to Sumitomo Chemical in January 2000; headcount not disclosed.
2000-12-31divestiture_reductioncompleted2000-01United StatesAgricultural ProductsMD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		In January 2000, Abbott sold its agricultural products business to Sumitomo Chemical Co., Ltd. Resulted in a $139 million gain. No specific employee count disclosed.
2000-12-31divestiture_reductioncompleted2000-012000-01GlobalAgricultural ProductsMD&A
f5-10k / Qwen3.6-27B-Q8_0		In January 2000, Abbott sold its agricultural products business to Sumitomo Chemical Co., Ltd. Sumitomo acquired R&D, sales, marketing, and support operations. Specific headcount affected is not disclosed.
2000-09-30voluntary_separationannounced12000-08-082001-01-31United StatesExecutive (Director and Officer; TAP Pharmaceutical Products Inc. director)USD 4,263,000 (units)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Executive retirement agreement filed with the 10-Q: resignation as Director/Officer effective 2000-09-01, employment through 2001-01-31, lump-sum payment of $4,263,000 (approx. two years base salary and bonus) plus a $1,089,000 bonus, contingent on a non-compete through 2002-07-31. Charge shown is the retirement payment amount, not a severance accrual.
2000-06-30divestiture_reductioncompleted2000-01-202000-01-20GlobalAgricultural products business (R&D, sales, marketing, support)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale to Sumitomo Chemical Co., Ltd.; transferred R&D, sales, marketing and support operations for biopesticides and plant growth regulators. No employee count disclosed; bulk active ingredient manufacturing retained by Abbott.
1999-12-31acquisition_additioncompleted1999-11-191999-11-19United StatesHospital ProductsUSD 16 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Perclose, Inc. merger accounted for as pooling-of-interests; ~15.1M Abbott shares issued; merger-related charges of $16.2M in SG&A; no employee headcount disclosed
1999-12-31acquisition_additioncompletedUnited StatesHospital ProductsUSD 217 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of certain assets of Glaxo Wellcome Inc.'s U.S. anesthesia business for ~$217M cash; no employee headcount disclosed
1999-12-31divestiture_reductioncompleted2000-01-202000-01-20United StatesOthersubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Agricultural products business sold to Sumitomo Chemical Co., Ltd. after fiscal year-end; ~$102M in 1999 sales from this business; no employee headcount disclosed
1999-06-30acquisition_additionannounced1999-06-211999-12-31United StatesPharmaceutical Productsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement for Abbott to acquire ALZA Corporation; to be accounted for as a pooling of interests. No headcount impact disclosed; expected completion by year end.
1999-06-30acquisition_additionannounced1999-07-081999-12-31United StatesHospital Productssubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement for Abbott to acquire Perclose, Inc. (arterial closure devices); pooling-of-interests accounting expected. No headcount impact disclosed; announced after quarter end.
1997-12-31acquisition_additioncompleted1997Hospital and Laboratory Productsbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired certain Sanofi Pharmaceuticals parenteral products businesses, completed in the second quarter of 1997, for approximately $200 million purchase price; number of employees added through the acquisition was not disclosed.
1997-06-30acquisition_additioncompleted1997-04-29United StatesHospital and Laboratory Products (parenteral products)USD 200 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of certain parenteral products businesses of Sanofi Pharmaceuticals for approximately $200 million; filing discloses no employee headcount added.
1997-03-31acquisition_additionannounced1997-04-29Parenteral products businessesUSD 200 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement signed to acquire certain Sanofi parenteral products businesses for approximately $200 million; no headcount disclosed. Company stated the acquisition would not have significantly changed reported sales or net income had it occurred January 1, 1996.
1996-12-31acquisition_additioncompletedUnited StatesHospital and Laboratory ProductsUSD 867 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquisition of MediSense Inc., a blood glucose self-testing products manufacturer, completed during the second and third quarters of 1996; number of employees added was not disclosed. Value shown is the approximate cash purchase price (of which $37 million was charged to earnings for in-process research and development), not a severance or workforce charge.
1996-12-31acquisition_additioncompleted1996-06-30United StatesHospital and Laboratory ProductsUSD 867 (millions)Item 1. Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Company acquired all outstanding shares of MediSense, Inc. in second and third quarters of 1996 for cash. Specific headcount added not disclosed.
1996-06-30acquisition_additioncompleted1996-05-31Hospital and Laboratory Products (blood glucose self-testing)USD 35 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		May 1996 cash acquisition of substantially all MediSense, Inc. shares; no headcount added disclosed. $35.2M charged to earnings for in-process R&D; purchase price allocation still being finalized.